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ABBREVIATIONS 
SAN = sino-atrial node 
If = f-current 
DD = diastolic depolarization 
cAMP = cyclic adenosine monophosphate 
HCN = Hyperpolarization-activated and Cyclic Nucleotide-gated 
CNBD = cyclic nucleotide-binding domain 
AC = adenylyl cyclase 
CNS = central nervous system 
DRG = dorsal root ganglion 
MDR = multidrug resistance 
SHR = spontaneously-hypertensive rats 
HEK293 = Human Embryonic Kidney 293 cells 
ER = eudismic ratio 
e.e. = enantiomeric excess (%) 
TOS = target-oriented synthesis 
DOS = diversity-oriented synthesis 
b/c/p = build/couple/pair 
CMLD = chemical methodology and library development 
RCM = ring-closing metathesis 
OTIPS = triisopropylsiloxane 
HG-II = Hoveyda-Grubbs 2nd generation catalyst 
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The autonomous beating of the heart is initiated by specialized pacemaker cells in the 
sino-atrial node (SAN), which generate spontaneous, rhythmic electrical stimuli in the 
absence of any external input. Different region of the brain are also able to generate 
rhythmic oscillations that are implicated in the modulation of vital physiological 
functions1. In fact, spontaneous action potentials in cells isolated from these natural 
pacemaker regions demonstrate a slow membrane depolarization phase, which is a 
typical characteristic in the time course of action potentials. 
The so-called “pacemaker” current, with the description of the main part of 
conductance underlying the pacemaker activity, was first reported in the late 1970s2. 
When this current was discovered, its properties were deemed unique, in particular its 
characteristically slow activation in response to hyperpolarization. For this reason the 
current has been termed Ih (h for hyperpolarization activated), If (f for funny) or Iq (q 
for queer). 
 
1.1 If and Ih 
The “funny” current has unusual characteristics3. A first unusual feature is its voltage 
dependence: If is indeed activated by hyperpolarization with a threshold of 
approximately -40/-50 mV in the SAN. The fully activated current/voltage relation 
reverses near -10/-20 mV in physiological solutions as a consequence of the channel 
mixed permeability to Na+ and K+, which is a second unusual feature of If4. These two 
properties are critical with respect to the role of If in the generation of diastolic 
depolarization (DD) and hence of spontaneous activity. Thus, “f channel” is opened by 
hyperpolarization in the pacemaker range voltages and carries the inward current, 
which generates the DD, eventually leading to the threshold for Ca2+ channel activation 
and action potential firing. 
Moreover, If is directly modulated by cAMP and regulated also by neurotransmitter 
receptors coupled to cyclic nucleotide second messengers. These important properties 
will be deeply discussed later. 
A similar current to If was found in other tissues, as for example in neurons, where is 
termed Ih. 
 
Despite these currents were known since 1970s, only in 1997 the molecular basis of If/h 
were revealed. In fact, a “mouse brain cyclic nucleotide-gated channel” (mBCNG) was 
cloned5, and it was proven that this particular channel was compatible with the 
pacemaker functions. 
  8 
This channel belongs to a family of channels activated by hyperpolarization (HAC) and 
comprises four different subtypes. In 1998, further studies confirmed that pacemaking 
channels of mammals SAN belong to HAC channel6 and finally, in 1999, it was 
proposed the nomenclature as HCN channels (Hyperpolarization-activated and Cyclic 
Nucleotide-gated)7. 
 
1.2 HCN channels 
1.2.1 Structure 
HCN channels form, together with cyclic nucleotide-gated (CNG) channels and Eag-
like K+ channel, the subgroup of cyclic nucleotide-regulated cation channels within the 
large superfamily of the poor-loop cation channels8-10. Their core unit consists of four 
subunits that are arranged around the centrally located pore (figure 1). In mammals, 
four homologous HCN channel subunits (HCN1-4) 
exist, which form four different homotetramers with 
distinct biophysical properties. There is evidence that 
the number of potential HCN channel types is increased 
in vivo by the formation of homotetramers1,11. Each 
HCN channel subunit consists of two major structural 
modules, the transmembrane core and the cytosolic C-
terminal domain. The first one harbours the gating 
machinery and the ion conducting pore, the latter one 
confers modulation by cyclic nucleotides. 
Figure 1. Structure of HCN channels.Top: HCN channels are 
tetramers. One monomer is composed of six transmembrane 
segments including the voltage sensor (S4), the selectivity filter 
and the pore region between S5 and S6.The C-terminal channel 
domain contains the cyclic nucleotide-binding domain (CNBD; 
middle).Bottom: the C-terminal channel domain is composed of 
two domains. The C-linker domain consists of six α-helical 
segments, designated A’ to F’. The CNBD follows the C-linker 
domain and consists of ahelices A–C with a β-roll between the A- 
and B-helices (arrow). 
Both modules allosterically cooperate with each other during channel activation. As for 
the K+ voltage-dependent channel, the transmembrane channel core of HCN channels 
consists of six α-helical segments (S1–S6) and an ion conducting pore loop between S5 
and S6. A highly conserved asparagine residue in the extracellular loop between S5 and 
the pore loop is glycosylated. It was shown that this post-translational channel 
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modification is crucial for normal cell surface expression12. The voltage sensor of HCN 
channels is formed by a charged S4-helix carrying nine arginine or lysine residues 
regularly spaced at every third position11,13. Positively charged S4 segments are found 
in all voltage-dependent members of the pore-loop cation channel superfamily14. 
Moreover, inward movement of S4 charges through the plane of the cell membrane 
leads to the opening of HCN channels and triggers the closure of depolarization-
activated channels. The molecular determinants underlying the different polarity of the 
gating mechanism of HCN and depolarization-gated channels remain to be determined. 
However, there is initial evidence that the loop connecting the S4 with the S5 segment 
plays a crucial role in conferring the differential response to voltage15-21. 
A further structural analogy between the K+ selective channel and HCN channel is the 
presence of a glycine-tyrosine-glycine (GYG) motif between S5 and S6 loops. This 
motif is particularly important in the K+ selective channel because it forms the 
selectivity filter for K+ ions. HCN channels conduct Na+ and K+ with permeability 
ratios of about 1:4, and also seem to display a small permeability for Ca2+.22,23 
Despite this preference for K+ conductance, HCN channels carry an inward Na+ current 
under physiological conditions; a possible explanation could be that in the tetrameric 
HCN channel complex, the GYG motif is coordinated in a less rigid fashion than in K+ 
channels, allowing the entrance of cations of different size. 
 
1.2.2 Role of cyclic nucleotides 
The sensitivity of HCN channels to cAMP is mediated by the proximal portion of the 
cytosolic C-terminus23. This part of the channel contains a cyclic nucleotide-binding 
domain composed of about 120 amino acids (CNBD) and an 80 amino acids long C-
linker region that connects the CNBD with the S6 segment of the channel core. cAMP 
binding to CNBD speeds up channel opening and shifts the voltage-dependence of 
activation to more positive voltages (figure 2)23. Thus, at a given voltage the current 
flowing through HCN channels is larger in the presence than in the absence of cAMP. 
 
Figure 2. Left: sinoatrial Ih activates faster in the 
presence of cAMP (grey) than in the absence 
(black) of cAMP at maximal activation voltage (–
140 mV). Right: activation curve of Ih in the 
absence (black) and the presence (grey) of cAMP. 
The activation curve of Ih is shifted to the right in 
the presence of cAMP. 
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The determination of the crystal structure of the C-linker-CNBD of HCN223 has 
revealed that the CNBD shows a highly conserved fold, consisting of an initial α-helix 
(A-helix), followed by an eight-stranded antiparallel β-roll, a short B-helix and a long 
C-helix (figure 1). The C-linker consists of six a-helices (A’–F’). Most of the subunit-
subunit interactions in the tetramer are mediated by amino acid residues in the C-linker. 
 
Figure 3. Representation of a single protomer of HCN2 with cAMP.23 
 
The binding pocket for cAMP (figure 3) is formed by a number of residues at the 
interface between the β-roll and the C-helix: three of these residues are located in the 
β-roll and four in the C-helix and, among them, only one key residue contributes to the 
higher selectivity of the channel toward cAMP respect of cGMP. In fact, both 
nucleotides enhance channel opening but the interaction is more selective for cAMP24. 
 
Figure 4. cAMP and cGMP bind to the same site with different stereochemistry. Stereoview of the 
cAMP-binding site, showing hydrogen bonds and salt bridges (brokenlines)23. 
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However, it is not clear how these residues generate cAMP selectivity (figure 4). It was 
suggested that cAMP selectivity is, at least partially, not due to its preferential contacts 
with the protein, but rather reflects the greater hydration energy of cGMP relative to 
cAMP. This could result in a greater energetic cost for cGMP binding to the 
channel15,23-25. 
In 200323, a study from HCN2 crystal structure shed light on the dynamics of the 
allosteric process that couples cAMP binding with channel opening. According to this 
recent model, in the absence of cAMP the C-linker is thought to be in a “compact” 
conformation that produces an inhibitory effect on channel opening. In turn, cAMP 
binding induces a conformational change in the CNBD involving the C-helix. The 
conformational change in the C-helix is then coupled to the C-linker that occupies a 
more “loose” conformation leading to an alteration of the intersubunit interface 
between helices of neighboring subunits. The resulting change in the quaternary 
conformation removes the inhibition of the C-terminus and destabilizes the closed 
state, thus promoting the opening of the channel. 
1.2.3 Biophysical properties of HCN channel types. 
Although all the four different HCN channel types display the principal biophysical 
properties of native If/h, they differ from each other with respect to their voltage 
dependence, activation time constant and activation by cAMP. 
- voltage-dependent activation: there are some differences between the HCN channel 
subtypes. In table 1 are reported values for the midpoint of activation (V0.5)16,26,27. 
These values can be altered significantly by several conditions, as reported by many 
studies20. 
 
 
 
 
 
  Table 1. 
 
HCN channel subtypes midpoint of activation (V0.5) 
HCN1 -70 mV 
HCN2 -95 mV 
HCN3 -77 to -95 mV 
 HCN4 -100 mV 
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- activation kinetics: they also differ between the HCN channel subtypes (figure 5). 
HCN1 is the fastest channel (25-300 ms, depending on the voltage) whereas HCN4 is 
the slowest channel with values between a few hundred milli-seconds (at strongly 
hyperpolarized voltages) up to several seconds (normal resting potential). HCN2 and 
HCN3 activate with kinetics between the previous two20,26-32. 
 
 
 
 
 
Figure 5. Different activation kinetics curves of 
the HCN channel subtypes respect of DRG 
(dorsal root ganglion)33. 
 
- modulation by cAMP: all the four HCN channel subtypes are modulated in a different 
way by cAMP even if they carry a highly conserved C-linker-CNBD portion. In fact, 
cAMP shifts the activation curves of HCN2 and HCN4 by about +10 to 25 mV and so 
it speeds up the opening kinetics whereas it weakly affect HCN1 and HCN321,23,26,30,33-
37. Interestingly, when the CNBD of HCN4 is replaced by the corresponding domain of 
HCN3, cAMP sensitivity is fully maintained, suggesting that the CNBD of HCN3 is 
mainly able to bind cAMP and to mediate cAMP-dependent gating29. Thus, within the 
HCN3 channel, the CNBD may be functionally silenced by a structural change in 
channel domains that relate cAMP binding with channel gating27,38,39. 
1.2.4 Dual channel activation. 
The dual activation of HCN channels by voltage and by cyclic nucleotides has been 
described by a cyclic allosteric model40-42. Each of the four subunits of the tetrameric 
channel are independently gated by voltage. Every time a voltage sensor switches to the 
activated state the probability for channel opening increases. The opening/closing 
reactions occur allosterically and involve concerted transitions of all four subunits. This 
transition occurs if the channel is unliganded, partially liganded or fully liganded and is 
energetically stabilized by a constant amount for each cAMP bound. The model further 
assumes that cAMP has a higher binding affinity to open rather than to closed channels 
(figure 6). 
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Figure 6. Cartoon of an unliganded 
closed channel (left) and a liganded 
open channel (right)23. 
 
 
1.2.5 HCN channels regulation. 
HCN channels are tightly regulated by interacting proteins and by low molecular 
factors located in the cytosol and in the extracellular space. 
- G-Protein coupled receptors (GPCRs): binding with cAMP is certainly the most 
important factor for the HCN channel modulation and it also explains the many effects 
on If/h mediated by GPCRs. Modulation is dependent on the type of G-protein coupled 
with a particular receptor (Gi, G0, Gs), followed by activation/inhibition of adenylyl 
cyclase (AC) responsible of cAMP level. An example of this is given by adrenergic and 
cholinergic receptors: they are coupled to Gs and Gi proteins, respectively, which 
activate and deactivate AC, causing an increment or a decrement of If/h. This is the 
reason that explains the opposite effects on the heart of acetylcholine (inhibition) and 
catecholamine as adrenaline (activation) as represented in figure 7. 
 
 
 
 
Figure 7. Regulation of HCN channel by up or 
down-regulation of cAMP25. 
 
Also morphine, an analgesic and a full agonist of opioid receptor coupled to Gi/G0, 
decreases sensibly Ih by decreasing of cAMP production. On the other hand, addiction 
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to morphine is given by an increasing of Ih due to a rebound effect of cAMP 
production43,44. Other GPCRs can modulate If/h as shown in figure 8. 
 
Figure 8. Schematic representation of the main signaling pathway involved in the regulation of If in a 
SAN cell. β, adrenergic receptor; A1, adenosine receptor; AC, adenylyl cyclase; ACH, acetylcholine; 
AMP, adenosine monophosphate; ATP, adenosine triphosphate; cAMP, cyclic adenosine 
monophosphate; cGMP, cyclic guanosine monophosphate; GC, guanylyl cyclase; GTP, guanosine 
triphosphate; M, muscarinic receptor; NAD, nicotinamide adenine dinucleotide; NO, nitric oxide; NPY, 
neuropeptide Y; PDE, phosphodiesterase; R, NPY or VIP receptor; T3, triiodothyronine; T3-R, 
triiodothyronine receptor; VIP, vasoactive intestinal peptide. Ivabradine is taken as an example for a 
heart rate slowing agent. 
 
- phosphatidylinositol-4,5-bisphosphate (PIP2): voltage-dependent gating of HCN 
channel is allosterically regulated by membrane lipids, which shift of the voltage 
toward positive potentials without interaction with cyclic nucleotides. Perhaps, this 
HCN channel activation is due to an electrostatic interaction between the negatively 
charged head groups of lipids and the channel protein. 
- pH: the activity of HCN channels depends on both intracellular45,46 and extracellular47 
concentration of protons. An increase of the intracellular protons shifts the voltage-
dependence of channel activation to more negative (hyperpolarized) potentials and 
slow down the speed of channel opening. On the other hand, increasing intracellular pH 
gives the opposite result with increasing If/h. Intracellular pH sensitivity has been 
conferred to a protonable histidine residue (His321), localized at the boundary between 
the voltage-sensing S4-helix and the cytoplasmic S4-S5 linker45. 
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- chloride ion: the steady-state conductance of Ih is regulated by extracellular chloride 
and this effect is more pronounced for HCN2 and HCN4 while being rather weak for 
HCN148. This regulation could be relevant for heart physiology where hypochloremia 
could be involved in the reduction of the amplitude of sinoatrial Ih with consequent 
arrhythmias11. As for pH, also for chloride ion a single amino acid residue was 
identified as the molecular determinant of extracellular Cl- sensitivity: HCN2 and 
HCN4 channels (high Cl- sensitivity) carry an arginine residue (R405 in HCN2, R483 
in HCN4) while HCN1 carries an alanine (A352)48. Chloride ion can regulate HCN 
channel function also from the intracellular site, although the physiological relevance 
of this regulation remains to be determined48,49. 
- tyrosine phosphorylation: tyrosine kinase c-Src constitutively binds to the C-linker-
CNBD and, as a result of this phosphorylation, the activation kinetic of the channel is 
enhanced50. The residue that confers this particular modulation is located in the B’-
helix of the C-linker and is conserved in all the HCN channel isoforms11. 
- p38-MAP (mitogen-activated protein)-kinase: it significantly shifts the voltage-
dependent activation towards more positive potentials, and this regulation could be 
important to modulate neuronal excitability51. 
- interacting protein: there is a growing evidence that ion channels usually are 
macromolecular protein complexes that, in addition to the principal pore-forming 
subunits, contain auxiliary proteins that are required for the fine-tuning of 
electrophysiological properties. Also HCN channels are subjected to this rule (figure 
9), as in the case of the MinK-related protein MiRP152,53, which reacts with different 
HCN channel types. In fact, MiRP1 belongs to a family of a single transmembrane-
spanning proteins and is considered as an auxiliary subunit of HCN channels. In 
200854, another transmembrane protein KCR1 was reported to interact with HCN2. 
Owing to its capacity to reduce the current density of native Ih, KCR1 could be an 
inhibitory auxiliary subunit of HCN channels and could be a regulator of cardiac 
automaticity. Finally, other proteins (TRIP8b, tamalin, filaminA), mainly found in 
neurons, are able to interact with the C-terminus of HCN channels. 
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Figure 9. Regulation of HCN channels by interacting proteins. Only two C-termini of the tetrameric 
channel complex are shown. Proteins interacting with HCN channels are indicated. KCR1, MiRP1, 
Filamin A, TRIP8b, S-SCAM, Tamalin, Mint2 and c-Src interact with different channel portions as 
indicated. 
 
1.3 Tissue expression and distribution of HCN channels 
Quantitative rt-PCR studies showed that the different isoforms of HCN channels are 
mainly expressed in the nervous system and the heart (figure 10), but they are widely 
expressed also in other excitable or non-excitable tissues55-57. HCN channels are also 
located in perception and sense transmission tissues, such as retina, auditory neurons, 
lingual taste buds, and olfactory pathways47,58-60. 
 
Figure 10. Relative expression of HCN subtypes in large DRG neurons versus SAN cells, as determined 
by rtPCR33. 
 
HCN1: it is expressed in many regions of the brain, in the spinal cord and in the 
peripheral nervous system where it is the most abundant isoform55,61. 
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HCN2: it is distributed nearly ubiquitous throughout most brain regions and also in the 
heart31,62. 
HCN3: it is sparsely distributed at very low levels in the central nervous system, heart 
and in the olfactory bulbs62. 
HCN4: it is the major isoform expressed in SAN, accounting for about 80% of Ih63,64. 
It is important to underlie that expression levels of HCN channels are low in normal 
heart muscle compared to cells of the conduction system. However, during heart 
disease65-68, upregulation of HCN channels may occur, as for example in cardiac 
hypertrophy and heart failure, where HCN2 and HCN4 are up-regulated in the atrial 
and ventricular myocardium65-71. Thus, Ih overexpression could well be an important 
trigger of arrhythmogenic activity in the hypertrophied heart65-68,70,71. 
1.4 Functional properties of HCN channels on different tissues 
There are many different functional properties of If/h75-77, depending on the different 
location of HCN channels. The functionality of different isoforms was made possible 
utilizing knockout phenotype technique. 
1.4.1 Heart 
Heart beating regulation is surely the most widely studied and important effect of If/h. 
In fact, this current generates a special kind of action potential (called “pacemaker”) in 
SAN, which is characterized by the presence of a progressive DD in the -65 to -45 mV 
range. Consequently, after the repolarization phase, the DD drives the membrane 
potential back to the threshold of calcium channel activation, thereby maintaining 
firing; in this way, the repetitive rhythm of action potential is generated. 
If/h plays also an important role in the heart rate regulation by the autonomic nervous 
system. In fact, stimulation of sympathetic or parasympathetic systems can activate or 
inhibit respectively If/h through the modulation of cAMP level. 
With the exception of HCN3, all HCN isoforms are significantly expressed in the adult 
heart and, among them, the dominant isoform is HCN4, accounting for almost the total 
HCN message78, so HCN4 has been considered to be crucial for the generation of heart 
beating. Concerning HCN2, it contributes for about 20% of If/h expressed in SAN and 
may serve as a complementary channel to HCN474. These data are confirmed by the 
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knockout phenotype technique: when a global- or heart-specific disruption of the 
HCN4 gene occurred, mice died in utero within 10 - 11.5 days, showing before day 10 
an about 40% reduction of the beating frequency without any response to the β-
adrenergic stimulation72. Surprisingly, the same experiments conducted on adult mice 
displayed a rather mild cardiac phenotype73. In conclusion, these experiments showed 
how this channel is absolutely crucial for autonomous heart rate regulation72 and for 
maintaining a stable cardiac rhythm but it is not needed for principal pacemaking. 
The analysis of human HCN4 channel reveals that patients suffering from these 
mutations display bradycardia. Bradycardic agents (e.g. Zatebradine, Ivabradine and 
Cilobradine) act blocking heart HCN channel and, as a consequence, a decrease of 
intensity of If/h occurred, followed by reduction of firing frequency in SAN cells. 
1.4.2 Brain 
All four HCN channel isoforms are expressed throughout the brain6,31,55,79,80, where 
they play a role in the setting of membrane potential, dendritic summation, action 
potential threshold and firing frequency79. The exact role (both excitatory and 
inhibitory) of HCN channels depends on where they are located and expressed. 
The importance of this channel in CNS function was revealed by HCN knockout mice. 
Deletion of HCN1 impairs motor learning but enhances spatial learning and memory, 
whereas deletion of HCN2 results in absence epilepsy and tremor74,81,82. Moreover, 
expression and/or function in the CNS can vary depending on prevailing levels/patterns 
of normal and pathological activity; thus, HCN channel expression either increases or 
decreases following changes in network activities83-86.  
1.4.3 Spinal Cord 
HCN1, HCN2 and HCN4 are found in the dorsal and ventral horn of the spinal cord. In 
200387, it was reported that, when spinal intathecal is treated with ZD7288 (HCN 
channel blocker), no effect occurred on allodynia thresholds, suggesting that spinal Ih 
did not contribute substantially to the nerve injury pain state. 
1.4.4 Sensory Nerves 
Ih and HCN channel isoforms are highly expressed in primary afferent neurons 
(sensory), where they may function to control neuronal excitability and transmitter 
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release. Their presence was demonstrated in a variety of peripheral sensory nerve 
preparations, such as rat dorsal root ganglion (DRG)87-95. A consistent result from these 
studies is that Ih appears more prominent in large diameter Aβ neurons compared to 
small or medium diameter cells. 
The subcellular localization of HCN channels depends on different factors, such as cell 
type, function and recent history. Using in-situ hybridization, the most abundant 
isoform found in DRG cells was HCN1 followed by HCN2, with the highest 
expression level in large diameter neurons64. HCN2 and HCN3 mRNAs are still 
undetectable. 
As a complementary approach to the identification of the key isoforms responsible for 
Ih in sensory neurons, different attempts were made in order to correlate the properties 
of Ih in sensory nerves with those of heterologously expressed recombinant HCN 
channels. In large and medium sensory neurons, their activation rates are fast and 
comparable to those measured for HCN1 and/or HCN2, whereas activation appears to 
be slower in small cells. 
Moreover, HCN isoforms also differ for the different sensitivity to cAMP, which 
increases HCN-based current by shifting the voltage-dependence of activation in a 
depolarizing direction, meaning that there is a greater open probability at physiological 
potential. Anyway, it is important to underlie how cAMP has only modest effects on Ih 
in sensory neurons33. 
All these data suggest that HCN1 channel gives a significant contribution to Ih in large 
diameter, mechanosensitive fibers. However, since most cells express more than one 
HCN isoform and because of the different biophysical properties of Ih among the four 
different HCN sub-types, also HCN2, HCN3 and HCN4 isoforms (either as homo- or 
heterotetrameric channels) may also contribute to Ih in many sensory neurons. 
1.4.5 Retina 
HCN channels are also expressed in the retina, where Ih plays a role in the shaping of 
retinal responses to light, including limitation of the retinal hyperpolarization that 
encodes brightness96,97. 
Apart from expected effects on heart rate, one of the most commonly described side 
effects of treatment with an HCN channel inhibitor in humans is visual disturbance. 
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These disturbances consist of photopsia (light flashes) or phosphenes (visual 
perceptions evoked by stimuli other than changes in light), particularly with abrupt 
changes in illumination98-101. 
1.5 Known HCN channels antagonists 
Heart rate modulation forms part of standard angina-prevention strategies. Although β-
adrenergic blocking drugs decrease heart rate and thus prevent angina, side effects that 
may be associated with therapy have stimulated the search for selective heart rate 
lowering agents, specifically targeting HCN channels. 
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Nowadays, most of HCN channel blockers are specific bradycardic agents, which 
modulate If because of its relevant physiological activity in SAN cells. These drugs, 
however, have low selectivity among the different isoforms of HCN channels with an 
increase of the side effects. Achievement of selectivity is a stimulating challenge to 
medicinal chemists to develop new molecules that are able to discriminate for a 
specific isoform, HCN4 in the case of heart. A molecule that is able to selectively 
target isoform HCN1 would lead to block Ih in neurons and would represent a possible 
therapeutic option for the treatment of neuropatic pain and epilepsy24. 
The structures of the known HCN modulators are summarized in figure 11. They will 
be briefly discussed according to their mechanisms of action. 
1.5.1 Pore Blockers 
Monovalent cations, such as cesium (Cs+), rubidium (Rb+), thallium (Tl+) and 
ammonium (NH4+), enter the permeation pathway, binding tightly enough to prevent 
sodium or potassium flowing102. Channel block and washout are nearly instantaneous, 
and block does not appear to be use-dependent. However a drawback of these cations is 
that they inhibit numerous other ion channels in a similar concentration range, which 
limits their use as therapeutic agents. Only Cs+ (at 1 mM concentration) is commonly 
used as a diagnostic for HCN currents. 
1.5.2 Inner Pore Antagonists 
Most of these antagonists (falipamil, zatebradine, ivabradine, cilobradine) are 
analogues of the L-type calcium channel inhibitor verapamil. They all exhibit slow use-
dependent block of If, requiring channel activation to reach the binding site. When the 
channel is activated the gate is opened so these molecule can enter the pore from the 
intacellular side103. Channel block occurs without shifting activation potential and can 
be relieved by strong hyperpolarization of the membrane104. 
Zatebradine is not a specific blocker of If since it has been shown to have inhibitory 
effects on cardiac potassium channel105. As a result, its application not only decreases 
the firing rate of autorythmic tissues but also prolongs action potentials recorded from 
these tissues106-108, behaving like the III class antiarrythmic drugs105. Despite a 
significant reduction in heart rate, it did not improve exercise tolerance in angina 
patients109,110. Finally, due to the concomitant inhibition of hyperpolarization-activated 
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channels in neuronal tissues, Zatebradine presented undesired effects on vision, leading 
to its consequent withdrawal from clinical trials109. 
Falipamil, as zatebradine, was hampered by lack of selectivity. Although efficacious 
against angina111, it showed anticholinergic effects112 and a relatively short-life in 
human113. 
Cilobradine is structurally related to zatebradine but with less conformational freedom. 
Its structure bears a stereogenic center and the (+)-S enantiomer is a more potent HCN 
channel blocker than the (-)-R enantiomer. As Zatebradine, it reduces the maximal 
conductance in a use- and frequency-dependent manner114,115. More precisely, it 
induces a concentration- and voltage-dependent inhibition of If in Pukinje fibers and in 
isolated rabbit SAN cells114,116,117, which results in a decrease in the spontaneous firing 
rate. In comparison to zatebradine, the inhibitory effect is faster and with higher 
intensity perhaps because of the higher drug-target association rates118. Moreover, it 
has not side effects on retina so it has a safer profile than zatebradine. The (+)-S 
enantiomer is patented for cardiac insufficiency whereas the other enantiomer is 
patented for the neuropathic pain treatment. 
Ivabradine is also related to zatebradine structure. It is a new therapeutic agent 
(Procoralan®) recomended in the treatment of stable angina pectoris119. Ivabradine has 
been shown to induce heart rate slowing by acting specifically on If120-122. The cardiac 
effects are specific to the SAN with no effect on the myocardial contractility, 
relaxation, intra-ventricular conduction, or repolarization. The blockade of the channel 
is more efficient when the current is outward (i.e. during the deactivation of the 
pacemaker current). Ivabradine is an open channel blocker that produces a “current-
dependent” channel blockade. The dependence of blockade upon current flow was 
limited to HCN4 and is not significant for HCN1123. This last property distinguishes 
ivabradine from the other heart-rate reducing agents that reduce If in a voltage-
dependent manner independently of the electrochemical gradient. 
ZD7288 appears to have a mechanism of blockade similar to verapamil analogues. It 
reduces the spontaneous beating rate without affecting the contractile force124. ZD7288, 
like alanidine (see 1.5.3 chapter) but unlike zatebradine, depresses If in a use- and 
frequency-independent way, suggesting that it interacts with its channel binding site 
independently from the channel gating configuration125. Moreover, this bradycardic 
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agent has also the capacity to selectively block Ih in central neurons125-128. Finally, it 
has been proposed that ZD7288, when applied externally, may behave as a ‘lipophilic’ 
quaternary cation, capable of passing into the cell interior to block pacemaker channel 
activity126; for this reason it could be used as a tool in place of Cs+ for studying the 
properties and significance of the pacemaker current in controlling heart and/or 
neuronal function. 
1.5.3 Activation Modulators 
Several compounds have been identified as HCN channel antagonists, whose 
mechanism of action involves a shift in activation potential. It has been shown that 
these compounds alter the stability of the closed state relative to the open state. 
Generally they do not show use-dependence, but instead they demonstrate strongly 
voltage-dependent modulation of the current. 
Alinidine is structurally related to clonidine, an adrenergic α2-agonist. It induces 
bradycardia with no observable effects on action potential shape or inotropy129. 
Perhaps, due to its structure, alinidine has also an interesting analgesic effect acting on 
α-adrenergic receptors129,130. Alinidine directly inhibits HCN current by shifting the 
activation potential toward more negative potential, stabilizing the closed state131. 
Drawbacks of this molecule are the numerous side effects, including sedation, dry 
mouth, hypotension and vision132 due to the blocking of HCN channel in retina, which 
would compromise its therapeutic use. 
Recently89,133, also clonidine has been shown to directly inhibit HCN channel; its 
affinity (1-10 nM) for adrenergic receptors is two orders of magnitude higher than the 
IC50 for HCN channels blockade. 
Propofol, an intravenous general anesthetic acting via GABAA receptors, was shown to 
inhibit HCN channels in neurons at relevant concentration134. It slows activation and 
speeds deactivation of HCN gating with no apparent effect on the fully activated 
conductance135,136. It seems that it has no effect on HCN2 at concentrations at which it 
inhibits HCN1137. 
Loperamide is an opioid agonist that directly modulates HCN channels by slowing 
inactivation and shifting activation toward hypepolarized potential138. It is active in the 
micromolar range against HCN currents whereas it requires nanomolar concentration to 
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inhibit the opiate receptors, so it is unlikely that HCN inhibition contributes to the 
clinical properties of this drug. 
1.5.4 Positive Allosteric Agents 
Lamotrigine, an anticonvulsivant thought to operate primarily as a use-dependent 
antagonist of voltage-gated Na+ and Ca2+ channels, was recently shown to enhance 
HCN currents in rat hyppocampal pyramidal cells; its mechanism is still unclear but it 
seems to involve a shift in activation toward more depolarized potentials. 
1.5.5 Unclassified Mechanisms and other antagonists 
Bupivacaine, lidocaine and mepivacaine, local anesthetics, inhibit HCN currents in 
DRG neurons139. Their potencies at HCN are similar to those at Na+ channels, 
suggesting that HCN inhibition occurs at clinically relevant concentrations in vivo. As 
for the sodium channels, HCN channel blockade appears to be from the inside of the 
cell, so it could be interesting to see if the binding site is intracellulary located in the 
pore as with Na+ channels. 
Genistein, a tyrosine kinase and a DNA topoisomerase inhibitor140, blocks f-current at 
concentrations similar to its potency on the enzymes141. This compound acts from the 
intracellular face of the channel and is not use-dependent. It behaves like a pore 
blocker, since antagonism occurs via reduction in open-channel conductance with no 
alteration of gating kinetics or voltage dependence. 
W7 is a calcium-calmodulin inhibitor but it also directly blocks HCN currents. Its 
mechanism is unclear with both a reduction in fully-open conductance and a shift in 
activation toward more hyperpolarized potentials. 
CP-339,818 is a voltage-gated K+ channel inhibitor, but it blocks HCN currents with an 
unclear mechanism. It seems to have voltage-dependent blockade and to have a slight 
preference for HCN1 isoform relative to the others. 
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In summary, the activation of HCN1 channels, the most abundant isoform in brain and 
peripheral nervous system, produces Ih, which is the prominent current in many 
peripheral sensory nerves. Consequently, HCN1 channels may represent a valid target 
for the treatment of spontaneous pain and allodynia associated with nerve injury. In 
contrast, HCN4 channels are the predominant isoform in heart, especially in SAN cells, 
so they could be an ideal target in treating diseases associated with heart failures as 
angina and arrhythmia. 
Antagonists that are selective for a specific HCN isoform are of paramount importance 
to eliminate, or at least minimize, adverse side effects. 
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2. BACKGROUND AND AIM OF THE WORK 
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In a series of papers produced over the past fifteen years, Prof. Gualtieri and coworkers 
have shown that modifications of the structure of the well-known calcium antagonist 
and multidrug resistance (MDR) modulator verapamil can change its cardiovascular 
and MDR-modulating pharmacological profile142-148. In particular, by suitably 
modifying the substituent on the nitrogen atom and the conformational freedom of the 
molecule, some dissociation between negative chronotropic and inotropic or 
vasorelaxant activity were obtained. Moreover, a clear-cut dissociation of calcium 
antagonism and MDR inhibitory activities was also achieved. Taking advantage of the 
experience acquired in that research, a similar modulation was performed on the 
molecule of zatebradine, which is structurally related to verapamil. As a consequence, 
several derivatives of zatebradine were designed where the N-methyl-homoveratryl 
group has been replaced by different amines or the conformational freedom of the 
molecule has been reduced by introducing double and triple bonds. Moreover, since it 
is known that the dehydro- and the desmethyl- analogues of zatebradine show potency 
similar to that of the parent compound155,156, some of the previously-mentioned 
modifications were applied also to these series.  
The aim of the work was to find substances able to reduce cardiac If through a direct 
blockade of the channel. However, before testing the substances on If, a screening test 
was necessary in order to avoid expensive and time-consuming electrophysiological 
experiments on inactive substances. Therefore, all the synthesized compounds were 
tested first for their negative chronotropic activity on guinea pig spontaneously-beating 
isolated atria; the absence of bradycardic activity could reasonably rule out a possible 
interaction with cardiac HCN channels. Then, the activity on If of the most interesting 
compounds was tested on ventricular cardiomyocytes of old spontaneously-
hypertensive rats (SHR): these myocytes re-express If, whose biophysical and 
pharmacological properties closely resemble those reported for the sinoatrial node f-
current65,66. This research, published in 2005, disclosed a structural analog of 
zatebradine, (1, EC4, chart 1) which was able to reduce heart rate in guinea-pig 
spontaneously-beating right atria and to block the If current with a potency comparable 
to the lead144.  
As a continuation of this research, the cis-isomer of 1, 2 (EC32) and another reduced-
flexibility analogue of zatebradine, 3 (EC18)151, were prepared; they were found to 
possess good negative chronotropic activity in guinea-pig isolated atria152, but their 
activity was not published. In fact, since the old spontaneously-hypertensive rats is an 
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expensive and time-consuming model, we decided to test the If-blocking activity on 
more accessible biological preparations. In 2006, HEK293 cells stably expressing 
HCN1, HCN2 and HCN4 isoforms were made available to us by the group of Prof. M. 
Biel from Munich; with this experimental model the compounds can be tested on 
different isoforms, and structure-activity relationships can be derived to optimize 
potency and selectivity. 
The aim of the present work is to find isoform-selective HCN blockers, to be used as 
pharmacological tools to study the role of these channels in physiological processes 
and/or in pathological conditions, or to understand the stoichometry of the channels in 
native tissues. Moreover, isoform-selective substances can be useful to design safe 
drugs for different pathologies involving HCN channels. To date, no selective 
substance has been reported in the literature and this may be due to several reasons. 
First, electrophysiological studies are needed to characterize HCN blockers, but this 
kind of tests require time and skill, and therefore they are not easily accessible. Second, 
cloned isoforms stably expressed in host cells have been available only in recent times. 
Third, the interest in HCN blockers has been strengthened only after the 
commercialization of Ivabradine (2005): in fact, the intensive efforts on the synthesis 
of specific bradycardic agents, produced by industries between ‘80s and ‘90s153-157, 
were hampered by the disappointing result of zatebradine, the first HCN blocker to 
enter clinical trials158,159. Actually, only for a few compounds the activity on If has been 
reported, while the majority of the synthesized compounds have been characterized 
only for their negative chronotropic activity in vitro or in vivo: since the bradycardic 
effect can be due to several mechanisms, no information can be obtained on the activity 
of the compounds on cardiac HCN channels. 
We decided to test EC4, EC32 and EC18 on the three HCN isoforms available to us, 
to see if the reduction of conformational flexibility could introduce some selectivity. 
After the promising preliminary results (see pharmacological section) we decided to 
continue this research in two directions: A) to optimize the synthetic pathway leading 
to EC18, trying to obtain also its trans isomer, in order to study the effect of 
geometrical and optical isomerism on the potency and selectivity of this cyclohexane 
derivative; B) to make some additional structural manipulations on the easily-
accessible linear compounds. Therefore, a chiral center was placed on the phenethyl 
moiety of EC4 and EC32, and/or the size of the molecule was increased by introducing 
on the basic nitrogen a second (7,8-dimethoxybenzazepin-3-yl)butenyl moiety or other 
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alkyl groups. During this research, the results of the enantioselectivity study prompted 
us also to hybridize the structure of ivabradine with that of EC4 and EC32. 
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“People should continue to work hard at organic synthesis; it is hard, frustrating, but 
always fascinating. Synthesis can create whole new worlds” 
S. Danishfesky 
 
 
 
 
 
 
 
 
3. CHEMISTRY 
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3.1 Synthesis of EC18 (cis-3) 
The first synthesis of 3 is reported in Scheme 1. The cyclohexane ring was built 
through Diels-Alder reaction of sulpholene with methyl acrylate to give methyl 3-
cyclohexene carboxylate 4, which was brominated in the allylic position with 
NBS/AIBN160 and reacted with 6,7-dimethoxy-1,3-dihydro-(2H)-3-benzazepin-2-one 
14149 to give, after catalytic hydrogenation and chromatographic separation, the 
intermediate cis-7; this compound was hydrolyzed to cis-8 under basic conditions and 
transformed into carbamate cis-9 by Curtius rearrangement following a one-pot 
procedure reported in the literature161. Acid hydrolysis gave cis-10, which was treated 
with 3,4-dimethoxyphenylethyl bromide and methylated with formaldehyde and formic 
acid to give the desired compound cis-3 (EC18).  
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Scheme 1. a) 120 °C. b) NBS, AIBN. c) t-BuOK, 14. d) H2, Pd/C. e) chromatographic separation. f) 
NaOH. g) t-BuOH, DPPA. h) HCl. i) 3,4-dimethoxyphenethyl bromide. j) CH2O, HCOOH. 
This pathway allowed us to obtain a small amount of EC18 for the preliminary test on 
spontaneously-beating guinea-pig right atria, but was not suitable for a large scale 
synthesis. In fact, while compound 14 could be easily prepared as reported in the 
literature (Scheme 2)149, several steps of the reaction sequence gave very poor yields. 
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Scheme 2. a) SOCl2. b) NH2CH2CH(OCH3)2, NEt3. c) HCl, CH3COOH. 
 
In order to obtain suitable amounts of EC18, a different approach was attempted, 
starting from cis 1,3-diaminocyclohexane. Since this compound is expensive, attempts 
to get the monoprotected diamine were carried out on the cheaper 1,4-
diaminocyclohexane. Several methods are reported in the literature for the 
monoprotection of a diamine162, but unfortunately, none of these was really successful 
(scheme 3): in fact, in all instances the diprotected compound was the most abundant, 
while the monoprotected one was obtained in poor yields, and only after 
chromatographic separation.  
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Scheme 3. a) (Boc)2O 0.5eq, CHCl3 (diluted condition), 0 °C. b) AcCl, MeOH. c) Ph3CCl, NEt3, 
dryTHF. d) BrCH2CH(OEt)2, NEt3, CH3CN. e) BrCH2CH(OEt)2, K2CO3, dryDMF, Δ. f) 9-BBN in 
hexane, dryTHF; benzoyl chloride. g) Benzyl bromide, CHCl3, Δ. h) Phthalic anhydride, CHCl3, Δ. i) 
Benzaldheyde, MgSO4, DCM, Δ. j) Benzyl chloroformiate 0.5eq, CHCl3 (diluted condition), Δ. 
 
Anyway, we decided to try also on 1,3-diaminocyclohexane, using the BOC as 
protecting group, following the pathway reported in Scheme 4. Therefore, the diamine 
was treated with di-t-butyldicarbonate, obtaining the monoprotected derivative 15 in 
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20% yield, along with the diprotected analogue and some unreacted starting material. 
After chromatographic separation, the synthesis was continued by sequentially treating 
15 with iodoacetaldehyde diethyl acetal175 and then with compound 12, obtaining 17, 
which was treated with conc. HCl in AcOH to give 18. Unfortunately, this pathway 
gave only a small amount of the desired compound 18, owing to the low yields of the 
last reaction (10%). In order to try again the cyclization step, we attempted the 
synthesis of the monoprotected diamine following a different strategy. 
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Scheme 4. a) Di-tert-butyl dicarbonate. b) 1,1-diethoxy-2-iodoethane. c) 2-(3,4-dimethoxyphenyl)acetyl 
chloride, NEt3. d) HCl, CH3COOH. 
Previous work163 had explored the use of 1,3-cyclohexanedione (Scheme 5): when this 
compound was treated with commercially-available N-methyl-homoveratrylamine in 
toluene, the enaminone was obtained, which was hydrogenated over PtO2, but 
subsequent reaction with aminoacetaldehyde dimethylacetal was not successful. 
Therefore, we decided to explore the use of 2-cyclohexen-1-one (Scheme 6). 
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Scheme 5163. 
The aza-Michael addition with urethane gave compound 19. The ketone was first 
reacted with 2,2-dimethoxyethanamine and titanium tetraisopropoxide164, and then 
reduced to amine 20 by sodium cyanoborohydride. Due to the different reactivity of the 
two nitrogen atoms, the nucleophilic amine was treated with 2-(3,4-
dimethoxyphenyl)acetyl chloride 12 to yield 21, which underwent cyclization under 
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strong acidic condition. The latter one was again the limiting step of this pathway, due 
to the very poor yields. The cyclization and the formation of the benzazepinone moiety 
seemed to be crucial and difficult to obtain. For this reason, we tried a direct 
attachment of compound 14 to cyclohexenone under several experimental 
conditions165, but without success. Therefore, we decided to switch back to the old 
synthesis, and optimize it. 
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Scheme 6. a) Urethane, TMSCl, PPh3. b) 2,2-dimethoxyethanamine, Ti(iOPr)4, NaCNBH3. c) 12, NEt3. 
d) HCl, CH3COOH. e) 14 and DABCO, or FeCl3/TMSCl, or PPh3/TMSCl, or t-BuOK, or PPh3/DEAD. 
The problematic steps of the old synthesis were analyzed in details. The bromination of 
methyl 3-cyclohexane carboxylate (scheme 1; step b) gave a mixture of products; GC-
MS analysis showed that at least four different products with the same desired 
molecular weight (219) were present. We reckoned that bromination could occur at 
both allylic positions (on C2 and C5) obtaining isomers with different reactivity, since 
the subsequent reaction with 14 gives only the desired compound 6. A possible way to 
limit bromination at C2 could be the increase of steric bulkiness of the ester group; 
therefore, bromination was accomplished on the t-butyl ester but the subsequent 
treatment with 14 failed to give the desired compound: apparently, the large increase in 
steric bulkiness stopped the reactivity of the molecule. 
Catalytic hydrogenation of 6 gave a cis/trans mixture of esters 7 in approximately 3 to 
2 ratio; chromatographic separation afforded cis-7 in good yields, but only a small 
amount of trans-7, together with mixed fractions. Basic hydrolysis of cis-7 gave cis-8 
in quantitative yields, but previous work had shown that when the same reaction 
conditions were applied to trans-7, isomerization occurred, giving a cis/trans mixture 
of acids163.  
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Treatment of cis-7 with diphenylphosphorylazide (DPPA) and triethylamine in t-
butanol gave cis-9 in low yields: chromatographic separation of the complex reaction 
mixture showed the presence of at least two major by-products, which were later 
identified as the cis-carbamoyl azide 9a and the urea 9b. In addition, when the same 
reaction conditions were applied to trans-8, only a small amount of compound cis-9 
could be isolated from the reaction mixture151. 
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Therefore, we decided to repeat the reaction sequence reported in scheme 1 on ethyl 3-
cyclohexanecarboxylate, changing the conditions of the Curtius rearrangement 
(scheme 7). Compound 22 was obtained by esterification of the now commercially 
available 3-cyclohexene carboxylic acid, and transformed into 25 as reported for 6. We 
found that a small difference in the ester group could lead us to a different ratio of 
diastereisomers: in fact, on the methyl ester 6, after catalytic hydrogenation the 
cis/trans ratio of the ester mixture was approximately 3 to 2, whereas on the ethyl ester 
25, the ratio changed in 8 to 1. Therefore, the ethyl ester 25 was the ideal intermediate 
to get higher amount of EC18 (cis isomer), while the methyl ester was a more suitable 
compound to obtain some amount of the trans isomer (trans-3). The cis ester 25 was 
separated from the trans isomer by column chromatography and the synthesis 
continued on the single diastereoisomer. Despite many attempts, column 
chromatography was not efficient to obtain substantial amount of pure trans-25; in 
addition, to avoid isomerization due to basic conditions, we tried to use acid hydrolysis, 
but the reaction was so much slower and, above all, it never got completion. For this 
reason the synthesis of trans-3 continued on the diastereoisomeric mixture of the esters. 
Compound cis-25 underwent basic hydrolysis; cis-8 was transformed into the acylazide 
26 by treatment first with SOCl2 and then with NaN3 in acetone-water, and heating in 
toluene afforded isocyanate 27: these reactions were followed by IR spectroscopy and 
the two compounds were not fully characterized. Careful workup of 26 is needed: 
removal of acetone must be done at room T, in order to avoid the rearrangement of 
acylazide in presence of traces of water, which can lead to the formation of 
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carbamoylazide 9a and urea 9b. Finally, the amine cis-10 was obtained by hydrolysis 
of the isocyanate under acidic condition. 
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Scheme 7. a) EtOH, H2SO4. b) NBS, AIBN. c) 14, t-BuOK, DMSO. d) H2, Pd/C, 90psi, EtOH-EtOAc. e) 
Chromatographic separation. f) NaOH, MeOH. g) SOCl2, NaN3. h) Toluene, Δ. i) HCl 2N, THF. j) 3,4-
dimethoxyphenethyl bromide, dryDMF, NEt3. k) HCOOH, HCHO, MeOH. THB = 6,7-dimethoxy-
1,3,4,5-tetrahydro-2H-3-benzazepin-2-one. 
The same reaction sequence was performed on the cis/trans mixture of esters, and a 
cis/trans mixture of amine 10 was obtained, from which trans-10 (the first eluting 
isomer) was isolated by column chromatography. Compounds (±)-cis-11 and (±)-trans-
11 were prepared by treatment of the corresponding amines with 3,4-
dimethoxyphenetyl bromide and NaI. Finally, methylation with formic acid and 
formaldehyde occurred to yield the desired compounds (±)-cis-3 and (±)-trans-3. These 
compounds proved to be unstable if stored as free bases, and must be transformed into 
their stable hydrochloride salts. 
Due to the promising biological activity of cis-3, we thought it important to study 
enantioselectivity. At the moment, the synthesis of higher amount of derivatives is 
ongoing; at the same time, the separation of a small amount of enantiomers is being 
attempted by chiral HPLC.  
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3.2 Synthesis of linear compounds 
The synthesis of 2 (EC32) is reported in scheme 8. 
aNH
MeO
MeO
O
14
N
MeO
MeO
O
Cl
N
MeO
MeO
O
N
Me
OMe
OMe
N
MeO
MeO
O
N
MeO
OMe
O
cis-28 29
2
b
+
 Scheme 8. a) t-BuOK, cis-1,4-dichlorobutene. b) N-methyl-homoveratrylamine. 
 
N-alkylation of 14 with commercially-available cis 1,4-dichlorobutene gave Z-3-(4-
chlorobut-2-enyl)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one cis-28; the low yield 
of the reaction can be accounted for the competition with the double addition of 14 to 
the cis dichlorobutene, yielding 3,3'-((Z)-but-2-ene-1,4-diyl)bis(7,8-dimethoxy-1H-
benzo[d]azepin-2(3H)-one) 29. Changes in the ratio between reactants, or reverse 
addition of the anion to the halogen derivative did not stop the formation of the by-
product. The formation of the dimeric product had not been observed when the reaction 
was carried out on trans 1,4-dichlorobutene144. Reaction of cis-28 with commercially 
available N-methyl-homoveratrylamine gave 2 in good yields.  
In a similar way (scheme 9), nucleophilic displacement of the chlorine of cis-28 by 
amines 29-33 gave compounds 34-39. Reaction of primary amine 33 with cis-28 in 1:1 
ratio gave a mixture of products resulting from mono- and double alkylation 
(compounds 38 and 39, respectively), which were separated by column 
chromatography. The secondary amine 38 was transformed into 40 by methylation 
under standard conditions.  
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 Scheme 9. a) NEt3, MeCN, Δ. b) HCOOH, HCHO, MeOH. 
Amines 30-33 were synthesized following the procedures reported in schemes 10-13, 
while 29 (6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline) was commercially available. 
Secondary amine 30 was synthesized as shown in scheme 10166. Commercially 
available 5,6-dimethoxy indan-1-one was treated with diethyl carbonate and sodium 
hydride to give 41, which was reduced and hydrolyzed to acid 42. The carboxylic 
group was first converted into amide (43) and finally reduced to the desired compound. 
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Scheme 10. a) diethyl carbonate, NaH, dryTHF. b) Zn, HgCl2; NaOH 1N. c) CDI, NH2CH3, DCM. d) 
LiAlH4, dryTHF. 
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The synthesis of secondary amines (R)-31 and (S)-31, reported in Scheme 11, started 
from D-Alanine and L-Alanine, respectively. The aminoacid was N-protected as 
trifluoroacetate (44), then the acid was activated by ossalyl chloride (45) and treated 
with veratrol and AlCl3, to yield compound 46. Carbonyl reduction afforded 47, which 
was hydrolyzed to 48, transformed into the N-formyl derivative 49 and finally reduced 
to the desired secondary amine 31. 
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Scheme 11. a) Ethyltrifluoroacetate, NEt3. b) Oxalyl chloride, pyridine. c) Veratrol, AlCl3. d) Et3SiH, 
CF3COOH. e) K2CO3. f) HCOOEt. g) LiAlH4. 
 
Amines (R)/(S)-32 were synthesized as reported in scheme 12. 3,4-
Dimethoxycinnamic acid was hydrogenated to give 50167, which was first brominated 
to 51168 and then transformed into the amide 52. Dehydration with phosphoryl chloride 
gave nitrile 53. Formation of compound 54169 was the key step of the whole synthesis: 
treating compound 53 with sodium amide in liquid ammonia gave both deprotonation 
in position α to the nitrile, and dehydrobromination with formation of the arine; the 
reactive intermediate rapidly undergoes cyclization176. Reduction of 54 with borane170 
yielded the primary amine 55. Resolution of the racemic mixture by fractional 
crystallization first with N-acetyl-L-glutamic acid171 and then with N-acetyl-D-glutamic 
acid afforded respectively (S)-55 and (R)-55 as pure enantiomers, which were treated 
with ethyl formate and then reduced to N-methyl amines (S)-32 and (R)-32. 
  40 
MeO
MeO
COOH MeO
MeO
COOH MeO
MeO
COOH
Br50 51
a b
MeO
MeO
CONH2
Br 52
c MeO
MeO
CN
Br
MeO
MeO
CN
MeO
MeO
NH2
53 54
55
d e
f
g
h (R)-32
MeO
MeO
(S)
NH2
MeO
MeO
(R)
NH2
MeO
MeO
(S)
N
H
MeO
MeO
(R)
N
H
Me
Me
(S)-32(S)-55
(R)-55
i
i
 
Scheme 12. a) H2, Pd/C, 60psi, THF. b) Br2, AcOH. c) SOCl2; NH3. d) POCl3 e) liq NH3, NaNH2, -33 C. 
f) BH3.THF. g) N-acetyl-L-glutamic acid, EtOH. h) N-acetyl-D-glutamic acid, EtOH. i) HCOOEt; 
LiAlH4. 
 
The enantiomers of amines 33 were synthesized from the commercially available 3,4-
dimethoxyphenylacetic acid according to a literature procedure, with slight 
modifications (scheme 13)172. First, α-alkylation was performed with lithium 
diisopropylamide and ethyl iodide to give 57, which was converted into the acyl 
chloride and then treated with (S)-α-methylbenzylamine to give 58. Reduction with 
borane afforded the intermediate 59 as mixture of diastereoisomers that were separated 
by column chromatography yielding (R,S)-59 and (S,S)-59. Primary amines (R)-33 and 
(S)-33 were obtained through hydrogenation in a PARR apparatus utilizing the 
Pearlman’s catalyst in methanol. In order to obtain N-methylated secondary amines, 
(R,S)-59 and (S,S)-59 were first reacted with  formic acid and formaldehyde obtaining 
(R,S)-60 and (S,S)-60, which were hydrogenated to the desired compounds (R)-61 and 
(S)-61173,174. 
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Scheme 13. a) LDA, CH3I, dryTHF. b) SOCl2, (S)-α-methylbenzylamine, benzene, pyr. c) 1M BH3.THF, 
HCl, CH3OH. d) Chromatographic separation of diastereisomers. e) HCOOH, HCHO. f) H2, Pd(OH)2, 
60psi, CH3OH. 
 
In order to compare the activity of cis and trans isomers, the enantiomers of amines 31, 
32 and 61 were reacted with E-3-(4-chlorobut-2-enyl)-7,8-dimethoxy-1H-
benzo[d]azepin-2(3H)-one trans-28, prepared from 14 and E-1,4-dichlorobutene as 
previously reported144. The enantiomers of compounds 62-64 were then obtained 
(scheme 14). 
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Scheme 14. a) t-BuOK, trans-1,4-dichlorobutene. b) NEt3, MeCN, Δ. 
 
To prepare the trans analogue of 39, in order to optimize yields, amine (R)/(S)-33 was 
reacted with trans-28 in a 1:2 ratio obtaining 65 (scheme 15). In the same way, the 
achiral compound 66 was also synthesized.  
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Scheme 15. a) NEt3, (R)/(S)-33. b) NEt3, MeCN, homoveratrylamine. 
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The promising activity of compound (R)-39 (see results) prompted us to make some 
modification in its structure. In fact, this compound has a high molecular weight, and 
low water solubility even as hydrochloride salt. In order to reduce its size, one of the 
(7,8-dimethoxybenzazepin-3-yl)butenyl moiety was replaced by smaller alkyl groups 
bearing unsaturation (benzyl, crotyl and allyl). These modifications were made only on 
the cis-derivative and only in the R-configuration. Amines 71-73 were therefore 
prepared from (R)-33, which was treated with di-t-butyldicarbonate to give 67, 
deprotonated with NaH and treated with allyl, benzyl and crotyl bromide to give 
carbamates 68-70. Deprotection with trifluoroacetic acid gave amines 71-73 that were 
reacted with cis-28 in 1:1 ratio, obtaining compounds 74-76 (scheme 16). 
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Scheme 16. a) Di-tert-butyl dicarbonate, dryTHF. b) NaH, allyl or benzyl or crotyl bromide, dryDMF. c) 
Trifluoroacetic acid, DCM. d) cis-28, NEt3, MeCN. 
 
Finally, in order to include Ivabradine in the study of enantioselectivity, its R-
enantiomer was synthesized. At the same time, we thought it interesting to see the 
effect of placing a stereogenic center on the phenylethyl moiety of Zatebradine, 
maintaining the conformational flexibility on this part of the molecule. Therefore we 
synthesized the saturated derivatives reported in scheme 17. 
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Scheme 17. a) i: t-BuOK, Cl(CH2)3Br. ii: NaI. b) NEt3, MeCN, (R)/(S)-32. c) NEt3, MeCN, (R)/(S)-31. 
d) H2, Pd/C. 
Compound 77, prepared by reaction of 14 with 1-bromo-3-chloropropane utilizing 
potassium tert-butoxide as a base, followed by the displacement of chlorine with iodine 
to increase the reactivity of the leaving group150, was reacted with (R)/(S)-32 and 
(R)/(S)-31, obtaining compounds 78-79. Compound (R)-78 was finally hydrogenated to 
(R)-80 (R-Ivabradine) using palladium on carbon as catalyst. 
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“Il prodotto e’ un condensato di sudore chimico” 
G. Appendino 
 
 
 
 
 
 
 
 
 
 
4. EXPERIMENTAL SECTION 
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Material and Methods: 
All melting points were taken on a Büchi apparatus and are uncorrected. Infrared 
spectra were recorded with a Perkin-Elmer Spectrum RX I FT-IR spectrophotometer in 
Nujol mull for solids and neat for liquids. NMR spectra were recorded on a Bruker 
Avance 400 spectrometer. Chromatographic separations were performed on a silica gel 
column by gravity chromatography (Kieselgel 40, 0.063-0.200 mm; Merck) or flash 
chromatography (Kieselgel 40, 0.040-0.063 mm; Merck). Yields are given after 
purification, unless otherwise stated. Where analyses are indicated by symbols, the 
analytical results are within ±0.4% of the theoretical values. We have chosen to 
perform and report only the combustion analyses of final compounds. The identity and 
purity of the intermediates was ascertained through IR, NMR and TLC 
chromatography. Compounds were named following IUPAC rules as applied by 
Beilstein-Institut AutoNom 2000 (4.01.305) or CA Index Name. When reactions were 
performed in anhydrous conditions, the mixtures were maintained under nitrogen. 
 
 
Ethyl 3-oxocyclohexylcarbamate; 19 
In a two-necked flask, urethane (0.0062 mol; 0.56 g) and 2-cyclohexen-
1-one (0.0052 mol; 0.5 mL) were added under nitrogen to a solution of 
PPh3 (0.0052 mol; 0.14 g) in dichloromethane (5 mL). After 5 minutes 
trimethylchlorosilane (0.0057 mol; 0.73 mL) was slowly added to the solution and the 
resulting mixture was stirred for 24 hours at room temperature. The reaction was 
quenched with a saturated aqueous solution of sodium bicarbonate and extracted with 
dichloromethane (3 × 15 mL). The organic layers were collected, dried (Na2SO4) and 
evaporated under vacuum. The residue was purified by flash chromatography (eluent: 
petroleum ether-ethyl acetate, 1:1) to give 19 as a clear oil: 0.33 g; 34%; ESI-MS [M + 
1]+ m/z 186, [M + Na]+ m/z 208; 1H NMR (CDCl3) δ 1.22-1.26 (m, 3H),1.71-1.88 (m, 
3H), 1.97-2.09 (m, 1H), 2.10-2.12 (m, 1H), 2.23-2.31 (m, 2H), 2.35-2.41 (m, 1H), 2.68-
2.73 (m, 1H), 3.97 (bs, 1H), 4.08-4.14 (m, 2H), 4.71 (bs, 1H). 
 
 
N-(2,2-dimethoxyethyl)-2-(3,4-dimethoxyphenyl)acetamide; 13 
Thionyl chloride (0.158 mol; 11 mL) was added dropwise to a 
suspension of 3,4-dimethoxyphenylacetic acid (0.051 mol; 10 g) 
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in chloroform (50 mL). The mixture was heated at 61 °C for 3 hours under nitrogen. 
The reaction was monitored by TLC (eluent: cyclohexane-ethyl acetate, 1:1). The 
solvent was removed under vacuum and the residue washed with cyclohexane (2 × 30 
mL, removed under vacuum). The obtained dark red oil (12) was dissolved in 
chloroform (50 mL) yielding a solution that was added dropwise to a solution at 0 °C 
of amino acetaldehyde dimethyl acetal (0.05 mol; 7.5 mL) and anhydrous triethylamine 
(7 mL) in chloroform (50 mL). The mixture was stirred for 1 hour at room temperature 
and then was quenched with water and extracted with chloroform. Removal of the dried 
solvent (Na2SO4) under vacuum afforded 13 as a yellow oil: 13.95 g; 98%; 1H NMR 
(CDCl3, δ): 3.36 (s, 6H), 3.37 (t, J=5.5 Hz, 2H), 3.52 (s, 2H), 3.89 (s, 6H), 4.33 (t, 
J=5.5 Hz, 1H), 5.67 (bs, 1H), 6.79-6.86 (br, 3H). 
 
 
7,8-Dimethoxy-1H-benzo[d]azepin-2(3H)-one; 14 
A solution of 13 (0.049 mol; 13.9 g) in glacial acetic acid (1.14 mol, 70 
mL) and 37% HCl (70 mL) was stirred for 1 day at room temperature. 
The reaction was monitored by TLC (eluent: cyclohexane-ethyl acetate, 3:7). Ice was 
then added to the mixture to give a white precipitate that was filtered off under vacuum, 
washed with water, and dried for 2 hours at 70 °C affording 25: 7.2 g; 66.7%; mp 240-
244 °C; 1H NMR (DMSO) δ 3.29 (s, 2H), 3.74 (s, 3H), 3.77 (s, 3H), 6.15-6.25 (m, 2H), 
6.85 (s, 1H), 6.89 (s, 1H). IR (Nujol, cm-1) ν 3174 (NH), 1606, 1631, 1664 (C=O). 
 
 
Ethyl cyclohex-3-enecarboxylate; 22 
Concentrated sulfuric acid (0.35 mL) was added to a solution of 3-
cyclohexene-1-carboxylic acid (0.039 mol; 5 g) in absolute ethanol (35 
mL). The mixture was heated at reflux for 1 day and monitored by TLC (eluent: 
cyclohexane-ethyl acetate, 1:1). The solvent was removed under vacuum to give a 
residue that was treated with sodium bicarbonate and extracted with dichloromethane. 
Removal of the dried (Na2SO4) solvent under vacuum afforded 22 as a pale yellow oil: 
5.22 g; 0.034 mol; 87%; 1H NMR (CDCl3) δ 1.20 (t, J=7.2 Hz, 3H), 1.57-1.67 (m, 1H), 
1.92-1.97 (m, 1H), 2.02-2.06 (m, 2H), 2.18-2.20 (m, 2H), 2.45-2.52 (m, 1H), 4.09 (q, 
J=7.2 Hz, 2H) 5.65 (s, 2H). 
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Ethyl 5-bromocyclohex-3-enecarboxylate; 23 
N-bromosuccinimmide (0.034 mol; 6.03 g) and a catalytic amount of 
AIBN were added to a solution of 22 (0.034 mol; 5.22 g) in CCl4 (10 
mL). The mixture was heated at reflux for 3 hours and monitored by TLC (eluent: 
cyclohexane-ethyl acetate, 9:1). During the reaction a white precipitate (succinimide) 
was formed that was filtered off once the reaction was finished. The filtrate was 
collected and the solvent was removed under vacuum to afford 23 as a cis/trans 
mixture (7.75 g; yellow oil), which was used in the next reaction without further 
purification. 
 
 
Ethyl-5-(7,8-dimethoxy-2-oxo-1H-benzo[d]azepin-3(2H)-yl)cyclohex-3-
enecarboxylate; 29 
Potassium terbutoxyde (5.15 mmol; 0.22 g) was added under 
nitrogen to a milky brown suspension of 14 (1.29 mmol; 0.75 
g) in anhydrous DMSO. The complete formation of the anion was observed because of 
the formation of a dark red solution. Then, 23 (1.29 mmol; 0.30 g) was added dropwise 
to the solution. After stirring overnight at room temperature, DMSO was partially 
distillated under reduced pressure. Ice was then added to the mixture and a formation of 
a milky brown precipitate (14 not reacted) was observed. The aqueous layer was 
extracted with chloroform (3 × 30 mL). The organic layers were collected, dried on 
Na2SO4 and evaporated under vacuum to give a residue that was purified by flash 
chromatography. Eluting with cyclohexane-ethyl acetate (6:4) afforded 24 (clear oil) as 
a mixture of cis/trans isomers: 0.20 g; 0.54 mmol; 42%; 1H NMR (CDCl3) δ 1.22 (t, 
J=7.20 Hz, 3H), 1.54-1.60 (m, 1H), 2.1-2.2 (m, 1H), 2.25-2.38 (m, 2H), 2.68-2.80 (m, 
1H), 3.3-3.4 (m, 1H), 3.5-3.6 (m, 1H), 3.88 (s, 3H), 3.89 (s, 3H), 4.10 (q, J=7.20 Hz, 
2H), 5.21-5.69 (m, 2H), 5.92-6.12 (m, 1H), 6.18-6.40 (m, 2H), 6.73 (s, 1H), 6.79 (s, 
1H). 
 
 
(±)-cis-Ethyl-3-(7,8-dimethoxy-2-oxo-4,5-dihydro-1H-benzo[d]azepin-3(2H)-
yl)cyclohexanecarboxylate; (±)-cis-25 
Pd/C (10% p/p) was added to a solution of 24 (8.63 mmol; 
3.2 g) in absolute ethanol (50 mL). The mixture was placed 
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in a Parr apparatus at 90 Psi and allowed to react for 4 days at room temperature. The 
reaction was monitored by TLC (eluent: dichloromethane-methanol, 96:4). The mixture 
was filtered and the solvent removed under vacuum to give 2.42 g of a white solid that 
was purified by gravity column chromatography. Eluting with dichloromethane-
methanol (98:2) afforded (±)-cis-25 as a clear oil: 2.11 mmol; 0.79 g; 25%; 1H NMR 
(CDCl3) δ 1.24 (t, J=7.20 Hz, 3H), 1.27-1.50 (m, 3H), 1.59 (q, J=12.4 Hz, 1H), 1.77 (d, 
J=9.6 Hz, 1H), 1.90-1.99 (m, 3H), 2.43-2.51 (m, 1H), 3.01-3.04 (m, 2H), 3.72 (t, J=5.6 
Hz, 2H), 3.84-3.86 (m, 8H), 4.11 (q, J=7.20 Hz, 2H), 4.50-4.56 (m, 1H), 6.53 (s, 1H), 
6.60 (s, 1H). 
 
 
(±)-cis-3-(7,8-Dimethoxy-2-oxo-4,5-dihydro-1H-benzo[d]azepin-3(2H)-
yl)cyclohexanecarboxylic acid; (±)-cis-8 
A solution of (±)-cis-25 (2.11 mmol; 0.79 g) in NaOH 2.5M 
(2.53 mmol; 1.01 mL) and methanol (15 mL) was stirred for 
24 hours at room temperature. The reaction was monitored by 
TLC (eluent: dichloromethane-methanol, 9:1). The solvent was evaporated under 
vacuum and the residue was taken up in water and extracted with ethyl acetate. The 
water layer was collected, acidified (pH 1) with 2N HCl, and extracted with 
dichloromethane. Removal of the dried (Na2SO4) solvent under vacuum gave (±)-cis-8 
as a gummy white solid: 0.76 g; quantitative yield; 1H NMR (CDCl3,) δ 1.29-1.50 (m, 
3H), 1.59 (q, J=12.3 Hz, 1H), 1.77 (d, J=10 Hz, 1H), 1.92 (d, J=11.7 Hz, 1H), 2.04 (d, 
J=12.1 Hz, 2H), 2.53 (t, J=11.5 Hz, 1H), 3.04 (m, 2H), 3.72 (m, 2H), 3.84 (s, 2H), 3.86 
(s, 6H), 4.55 (t, J=11.2 Hz, J=10.6 Hz, 1H), 6.54 (s, 1H), 6.62 (s, 1H). 
 
 
(±)-cis-3-(3-Aminocyclohexyl)-7,8-dimethoxy-4,5-dihydro-1H-benzo[d]azepin-2(3H)-
one; (±)-cis-10 
In a two-necked flask under nitrogen atmosphere, thionyl 
chloride (5.54 mmol; 0.4 mL) was added dropwise to a 
solution of (±)-cis-8 (0.58 mmol; 0.2 g) in chloroform (50 mL). The mixture was 
heated at 61 °C for 3 hours and monitored by TLC (eluent: dichloromethane-methanol, 
96:4). The solvent was removed under vacuum to give a residue that was washed with 
cyclohexane (2 × 30 mL) and dried under vacuum. Anhydrous acetone (10 mL) was 
poured into the flask followed by a saturated aqueous solution of NaN3 (2 mL). After 
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stirring for 10 minutes, a small excess of water was added to the solution. Acetone was 
evaporated under vacuum and the aqueous layer was extracted with dichloromethane (3 
× 15 mL). The organic layers were collected, dried (Na2SO4) and evaporated under 
vacuum to give (±)-cis-26 as a gummy yellow solid (0.18 g; 87%) that was used in the 
next step without further purification. The formation of acylazide was detected by IR 
spectroscopy (ν= 2100 cm-1; CON3). 
A solution of (±)-cis-26 (1.29 mmol; 0.48 g) in toluene was heated at reflux overnight 
to allow the formation of isocyanate. The reaction was monitored by IR spectroscopy 
and continued until the peak of acylazide (ν 2100 cm-1) disappeared because of the 
formation of isocyanate (±)-cis-27 (ν 2250 cm-1). The toluene was removed under 
vacuum to give a residue that was dissolved in THF (3 mL) and 2N HCl (3 mL). The 
resulting solution was stirred at room temperature overnight and monitored by TLC 
(dichloromethane-methanol-ammonia, 90:10:0.5). Organic solvents were evaporated 
under vacuum and the aqueous layer was washed with diethyl ether, basified with 2.5M 
NaOH and extracted with dichloromethane. The organic layers were collected, dried on 
Na2SO4 and removed under vacuum. (±)-cis-10 was obtained as a gummy yellow solid 
(0.41 g). 
It is important to notice that a careful workup of 26 is required; in fact, acetone must be 
removed at room temperature in order to avoid the rearrangement of the acylazide in 
presence of traces of water, which can lead to the formation of side products such as 
carbamoylazide (9a) and urea (9b). 
(±)-cis-10: 1H NMR (CDCl3) δ 1.01 (qd, J=12.3 Hz, J=3.7 Hz, 1H), 1.24-1.47 (m, 3H), 
1.70 (d, J=11.9 Hz, 1H), 1.80-1.91 (m, 5H), 2.86 (tt, J=11.0 Hz, J=3.8 Hz, 1H), 3.02 
(dd, J=6.3 Hz, J=5.6 Hz, 2H), 3.69 (t, J=6.1 Hz, 2H), 3.81 (s, 2H), 3.83 (s, 3H), 3.85 (s, 
3H), 4.51 (tt, J=12.1 Hz, J=3.5 Hz, 1H), 6.53 (s, 1H), 6.61 (s, 1H); 13C NMR (CDCl3, 
APT) δ 23.20, 29.66, 33.95, 35.32, 40.36, 40.83, 43.03, 49.74, 50.91, 55.93, 113.28, 
114.13, 123.49, 127.22, 147.18, 147.95, 172.05. 
9a: 1H NMR (CDCl3) δ 1.10-2.10 (m, 8H), 3.01-3.02 (m, 2H), 3.66-3.69 (m, 3H), 3.83-
3.85 (m, 8H), 4.45-4.51 (m, 1H), 5.06 (bs, 1H), 6.52 (s, 1H), 
6.60 (s, 1H); 13C NMR (CDCl3) δ 22.93, 29.43, 31.94, 
33.79, 36.98, 40.99, 42.78, 49.68, 51.39, 55.90, 113.20, 114.07, 123.17, 126.90, 
128.07, 128.48, 147.22, 147.96, 155.35, 172.15; IR (Nujol, cm-1) ν 2141; LC-MS [M + 
1]+ m/z 388. 
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9b: 1H NMR (CDCl3) δ 1.20-2.17 (m, 16H), 2.99-3.01 (m, 4H), 3.50-3.51 (m, 2H), 
3.66-3.70 (m, 4H), 3.77-3.80 (m, 16H), 
4.37-4.40 (m, 2H), 4.71 (bs, 2H), 6.53 (s, 
2H), 6.58 (s, 2H); IR (Nujol, cm-1) ν 1636 
(CO); LC-MS [M + 1]+ m/z 663. 
 
 
(±)-cis-3-(3-(3,4-Dimethoxyphenethylamino)cyclohexyl)-7,8-dimethoxy-4,5-dihydro-
1H-benzo[d]azepin-2(3H)-one; (±)-cis-11 
A solution of (±)-cis-10 (0.63 mmol; 0.20 g), 
anhydrous triethylamine (0.94 mmol; 0.13 mL) and 
3,4-dimethoxyphenethyl bromide (0.94 mmol; 0.23 g) 
in dry DMF (2 mL) was heated at 60 °C overnight 
under anhydrous conditions. The reaction was 
monitored by TLC in dichloromethane-methanol (96:4). The mixture was cooled to 
room temperature and then the solvent was evaporated under vacuum to give a residue 
that was treated with 2N HCl (3 mL) and washed with diethyl ether (2 × 15 mL). The 
acidic aqueous layer was basified with a sodium carbonate saturated aqueous solution 
and extracted with dichloromethane (3 × 15 mL). The organic layers were collected, 
dried (Na2SO4) and evaporated under vacuum to afford a residue that was purified with 
gravity column chromatography. Eluting with dichloromethane-methanol-ammonia 
(90:10:0.5) gave (±)-cis-11 as a clear oil: 0.15 g; 0.31 mmol; 49%; 1H NMR (CDCl3) δ 
1.05 (q, J=11.9 Hz, 1H), 1.32-1.46 (m, 3H), 1.72 (d, J=10.1 Hz, 1H), 1.78-2.05 (m, 
4H), 2.65 (t, J=10.9 Hz, 1H), 2.77 (t, J=7 Hz, 2H), 2.92 (t, J=6.4 Hz, 2H), 3.00 (d, 
J=5.8 Hz, 2H), 3.67 (t, J=6.0 Hz, 2H), 3.82 (d, J=4.5 Hz, 2H), 3.83 (s, 3H), 3.85 (s, 
3H), 3.86 (s, 3H), 3.87 (s, 3H), 4.50-4.56 (m, 1H), 6.53 (s, 1H), 6.60 (s, 1H), 6.74 (d, 
J=7.1 Hz, 2H), 6.81 (d, J=8.5 Hz, 1H); 13C NMR (CDCl3, APT) δ 23.09, 30.07, 32.40, 
33.96, 35.71, 37.54, 40.31, 43.01, 48.22, 50.79, 55.89, 55.94, 56.08, 56.66, 111.50, 
112.05, 113.31, 114.13, 120.54, 123.43, 127.21, 132.15, 147.21, 147.60, 147.94, 
149.04, 172.05. 
 
 
(±)-cis-3-(3-((3,4-Dimethoxyphenethyl)(methyl)amino)cyclohexyl)-7,8-dimethoxy-4,5-
dihydro-1H-benzo[d]azepin-2(3H)-one; (±)-cis-3 (EC18) 
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A solution of (±)-cis-11 (0.31 mmol; 0.147 g), formic 
acid (5.12 mmol; 0.196 mL) and 37% aqueous 
formaldehyde (1.52 mmol; 0.115 mL) in absolute 
ethanol (2 mL) was heated at reflux for 15 hours. The 
reaction was monitored by TLC (eluent: 
dichloromethane-methanol, 85:15). The solvent was then removed under vacuum and 
the residue (yellow solid) treated with NaHCO3 (saturated solution) and extracted with 
dichloromethane (3 × 15 mL). The organic layers were collected, dried (Na2SO4) and 
removed under vacuum to give a brown oil that was purified by gravity column 
chromatography. Eluting with dichloromethane-methanol-ammonia (95:5:0.5) afforded 
(±)-cis-3 as a clear oil: 0.10 g; 0.20 mmol; 65.9%; 1H NMR (CDCl3) δ 1.17-1.44 (m, 
4H), 1.72 (d, J=12 Hz, 1H), 1.85-1.92 (m, 3H), 2.38 (s, 3H), 2.62-2.75 (m, 5H), 3.01 (t, 
J=5.6 Hz, 2H), 3.69 (t, J=5.8 Hz, 2H), 3.82 (s, 2H), 3.84 (s, 3H), 3.85 (s, 3H), 3.86 (s, 
3H), 3.88 (s, 3H), 4.51 (t, J=12 Hz, 1H), 6.54 (s, 1H), 6.61 (s, 1H), 6.74-6.80 (m, 3H); 
13C NMR (CDCl3, APT) δ 23.48, 28.39, 30.29, 32.24, 34.02, 37.82, 40.49, 43.05, 
51.68, 55.89, 55.92, 55.95, 56.10, 61.44, 111.31, 112.14, 113.21, 114.05, 120.55, 
123.41, 127.15, 132.98, 147.16, 147.38, 147.91, 148.86, 172.01. 
 
 
(±)-trans-3-(3-Aminocyclohexyl)-7,8-dimethoxy-4,5-dihydro-1H-benzo[d]azepin-
2(3H)-one; (±)-trans-10 
It was synthesized following the procedure described for (±)-cis-
10, starting from a cis/trans mixture of 26 (0.80 g, 0.0021 mol). 
After the workup, the crude was purified by flash chromatography (eluent: 
dichloromethane-methanol-ammonia, 90:10:0.5). (±)-trans-10 was eluted first (clear 
yellowish oil; 50 mg) and then a mixture of the cis/trans amines. 1H NMR (CDCl3) δ 
1.43-1.45 (m, 2H), 1.58-1.67 (m, 4H), 1.71-1.77 (m, 2H), 2.04 (bs, 2H), 2.96-2.99 (m, 
2H), 3.41-3.42 (m, 1H), 3.63-3.66 (m, 2H), 3.78 (s, 2H), 3.80 (s, 3H), 3.81 (s, 3H), 
4.79-4.82 (m, 1H), 6.50 (s, 1H), 6.58 (s, 1H). 13C NMR (CDCl3, APT) δ 19.40, 30.65, 
31.61, 33.84, 37.41, 40.31, 42.98, 46.58, 47.12, 55.80, 55.92, 113.08, 113.95, 123.38, 
127.06, 147.00, 147.76, 172.04. 
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(±)-trans-3-(3-(3,4-Dimethoxyphenethylamino)cyclohexyl)-7,8-dimethoxy-4,5-dihydro-
1H-benzo[d]azepin-2(3H)-one; (±)-trans-11 
It was synthesized following the procedure described 
for (±)-cis-11, starting from (±)-trans-10 (0.267 
mmol; 85 mg), anhydrous triethylamine (0.267 mmol; 
0.037 mL) and 3,4-dimethoxyphenethyl bromide 
(0.267 mmol; 65 mg) in dry acetonitrile. After workup, the crude was purified by flash 
chromatography (eluent: dichloromethane-methanol, 85:15) to give (±)-trans-11 
obtained as a clear oil: 25 mg; 19%; 1H NMR (CDCl3) δ 1.40-1.46 (m, 2H), 1.55-1.63 
(m, 2H), 1.72-1.88 (m, 4H), 2.82-2.87 (m, 4H), 2.92-2.93 (m, 2H), 3.21-3.22 (m, 1H), 
3.65-3.68 (m, 2H), 3.81-3.88 (m, 14H), 4.78-4.84 (m, 1H), 6.51 (s, 1H), 6.64 (s, 1H), 
6.73-6.77 (m, 3H); 13C NMR (CDCl3, APT) δ 19.73, 28.75, 30.41, 33.86, 40.57, 43.05, 
47.65, 48.59, 53.40, 55.86, 55.93, 111.26, 112.05, 113.13, 114.08, 120.52, 123.33, 
127.03, 147.12, 147.42, 172.24. 
 
 
(±)-trans-3-(3-((3,4-Dimethoxyphenethyl)(methyl)amino)cyclohexyl)-7,8-dimethoxy-
4,5-dihydro-1H-benzo[d]azepin-2(3H)-one; (±)-trans-3 
It was synthesized following the procedure described 
for (±)-cis-3, starting from (±)-trans-11 (0.052 mmol; 
25 mg), formic acid (0.881 mmol; 0.033 mL) and 
37% aqueous formaldehyde (0.259 mmol; 0.019 mL) in absolute ethanol (1 mL). After 
workup, the crude was purified by gravity column chromatography (eluent: 
dichloromethane-methanol-ammonia, 95:5:0.5) to give (±)-trans-3 as a clear oil: 20 
mg; 78%; 1H NMR (CDCl3) δ 1.38-2.00 (m, 8H), 2.35 (s, 3H), 2.62-2.63 (m, 1H), 
2.70-2.71 (m, 4H), 2.99-3.02 (m, 2H), 3.66-3.69 (m, 2H), 3.81 (s, 2H), 3.84 (s, 3H), 
3.85 (s, 3H), 3.86 (s, 3H), 3.88 (s, 3H), 4.82-4.88 (m, 1H), 6.54 (s, 1H), 6.60 (s, 1H), 
6.70-6.78 (m, 3H). 
 
 
(Z)-3-(4-chlorobut-2-enyl)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one; cis-28 
(EC30) 
Potassium terbutoxyde (1.7 mmol; 0.2 g) was added to a 
suspension of 14 (1.1 mmol; 0.25 g) in dry DMSO (4 mL) 
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under nitrogen. The resulting solution was added dropwise to a solution of cis-
1,4.dichlorobut-2-ene (2.3 mmol; 250 µL) in dry DMSO (4 mL), and the mixture was 
stirred for 1 hour at room temperature. Ice was then poured into the reaction mixture 
that was extracted with diethyl ether. The organic layers were collected, dried (Na2SO4) 
and removed under vacuum. The residue was purified by flash chromatography (eluent: 
cyclohexane-ethyle acetate, 5:5) to give cis-28 as a yellow oil (30%) and the double 
addition’s product 29 (6%). 
28: 1H NMR (CDCl3) δ 3.46 (s, 2H), 3.89 (s, 3H), 3.91 (s, 3H), 4.17 (d, J=7.9 Hz, 2H), 
4.28 (d, J=7.1 Hz, 2H), 5.54 (dt, J=10.7 Hz, J=7.1 Hz, 1H), 5.81 (dt, J=10.6 Hz, J=7.9 
Hz, 1H), 6.21 (d, J=9.1 Hz, 1H), 6.39 (d, J=9.1 Hz, 1H), 6.75 (s, 1H), 6.79 (s, 1H); 13C 
NMR (CDCl3, APT) δ 38.64, 43.09, 43.90, 55.99, 109.54, 111.21, 117.64, 124.59, 
126.26, 127.41, 128.86, 129.15, 148.05, 149.95, 167.65. 
 
29: 1H NMR (CDCl3) δ 3.46 (s, 4H), 3.89 (s, 6H), 
3.91 (s, 6H), 4.29 (d, J=4.4 Hz, 4H), 5.45 (t, J=4.4 
Hz, 2H), 6.24 (d, J=9.2 Hz, 2H), 6.35 (d, J=9.2 Hz, 2H), 6.73 (s, 2H), 6.80 (s, 2H). 
 
 
(Z)-3-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)but-2-enyl)-7,8-dimethoxy-
1H-benzo[d]azepin-2(3H)-one; 34 
In a two-necked flask under nitrogen, 6,7-dimethoxy-
1,2,3,4-tetrahydroisoquinoline hydrochloride 
(commercially available; 0.65 mmol; 0.15 g) was 
added to a solution of cis-28 (0.32 mmol; 0.1 g) in dry triethylamine (5 mL). The 
mixture was stirred for 5 hours at 60 °C. The solvent was removed under vacuum and 
the residue was taken up with water and extracted with dichloromethane (3 × 15 mL). 
The organic layers were collected, dried (Na2SO4) and evaporated under vacuum. The 
residue was purified by flash chromatography (eluent: dichloromethane-methanol, 9:1) 
to give 34 as a yellow oil: 80 mg; 53%; 1H NMR (CDCl3) δ 2.74-2.77 (m, 2H), 2.83-
2.86 (m, 2H), 3.30 (d, J=6.8 Hz, 2H), 3.45 (s, 2H), 3.60 (s, 2H), 3.83-3.88 (m, 14H), 
4.27 (d, J=6.8 Hz, 2H), 5.52-5.58 (m, 1H), 5.76-5.82 (m, 1H), 6.22 (d, J=9.2 Hz, 1H), 
6.36 (d, J=9.2 Hz, 1H), 6.50 (s, 1H), 6.59 (s, 1H), 6.73 (s, 1H), 6.78 (s, 1H); 13C NMR 
(CDCl3, APT) δ 28.26, 43.26, 44.75, 50.61, 54.45, 55.32, 56.00, 56.09, 109.56, 109.69, 
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111.35, 111.47, 117.48, 124.74, 125.56, 125.73, 126.46, 127.77, 128.40, 129.63, 
147.47, 147.85, 148.19, 150.08, 167.62. 
 
 
(Z)-3-(4-(((5,6-Dimethoxy-2,3-dihydro-1H-inden-2-yl)methyl)(methyl)amino)but-2-
enyl)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one; 35 
In a two-necked flask under nitrogen, 30 (0.36 
mmol; 80 mg) was added to a solution of cis-28 
(0.24 mmol; 74 mg) in chloroform (3 mL) and 
anhydrous triethylamine (3 mL). The mixture was stirred for 5 hours at 60 °C. The 
reaction was monitored by TLC (eluent: dichloromethane-methanol-ammonia, 
99:1:0.5). The solvent was removed under vacuum and the residue was dissolved in 
water and extracted with dichloromethane (3 × 15 mL). The organic layers were 
collected, dried (Na2SO4) and evaporated under vacuum. The residue was purified by 
flash chromatography (eluent: dichloromethane-methanol, 9:1) to give 35 as a clear oil: 
0.04 mmol; 18 mg; 15%; 1H NMR (CDCl3) δ 2.27 (s, 3H), 2.39 (d, J=7.2 Hz, 2H), 
2.60-2.73 (m, 3H), 3.00 (dd, J=7.2 Hz, J=14.4 Hz, 2H), 3.10-3.12 (m, 2H), 3.45 (s, 2H), 
3.85 (s, 6H), 3.87 (s, 3H), 3.90 (s, 3H), 4.25 (d, J=6.8 Hz, 2H), 5.43-5.49 (m, 1H), 
5.66-5.72 (m, 1H), 6.18 (d, J=9.2 Hz, 1H), 6.33 (d, J=8.8 Hz, 1H), 6.72-6.74 (m, 3H), 
6.79 (s, 1H); 13C NMR (CDCl3, δ, APT): 37.57, 37.65, 42.47, 43.15, 44.41, 54.57, 
55.94, 56.00, 62.84, 107.87, 109.42, 111.15, 117.21, 124.61, 126.32, 127.59, 134.37, 
147.84, 147.98, 149.84, 167.47. 
 
 
(S,Z)-3-(4-((1-(3,4-Dimethoxyphenyl)propan-2-yl)(methyl)amino)but-2-enyl)-7,8-
dimethoxy-1H-benzo[d]azepin-2(3H)-one; (S)-36 
It was synthesized following the procedure 
described for (S)-62, starting from (S)-31 (0.0005 
mol; 0.10 g), cis-28 (0.15 g; 0.0005 mol), dry 
triethylamine (0.07 mL; 0.0005 mol) and dry CH3CN (5 mL). (S)-36 was obtained as a 
whitish solid: 0.13 g; 55%; mp 75 °C; [α]20D = +11.4° (c=1; CHCl3); 1H NMR (CDCl3) 
δ 0.93 (d, J=6.8 Hz, 3H), 2.25 (s, 1H), 2.37 (dd, J=12.8 Hz, J=9.2 Hz, 1H), 2.84-2.95 
(m, 2H), 3.17 (d, J=6.4 Hz, 2H), 3.45 (s, 2H), 3.85 (s, 3H), 3.86 (s, 3H), 3.87 (s, 3H), 
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3.89 (s, 3H), 4.24 (d, J=14 Hz, 2H), 5.41-5.47 (m, 1H), 5.62-5.67 (m, 1H), 6.19 (d, 
J=9.0 Hz, 1H), 6.34 (d, J=9.0 Hz, 1H), 6.69-6.72 (m, 3H), 6.7-6.79 (m, 2H). 
 
 
(R,Z)-3-(4-((1-(3,4-Dimethoxyphenyl)propan-2-yl)(methyl)amino)but-2-enyl)-7,8-
dimethoxy-1H-benzo[d]azepin-2(3H)-one; (R)-36 
It was synthesized following the procedure 
described for (S)-62, starting from (R)-31 (0.0005 
mol; 0.10 g), cis-28 (0.15 g; 0.0005 mol), dry 
triethylamine (0.07 mL; 0.0005 mol) and dry CH3CN (7 mL). (R)-36 was obtained as a 
whitish solid: 52%; mp 70 °C; [α]20D = -11.4° (c=1; CHCl3). The 1H NMR spectrum 
was identical to that of (S)-35. 13C NMR (CDCl3, APT) δ 13.82, 36.86, 39.23, 43.35, 
44.64, 50.31, 56.02, 56.06, 56.13, 60.15, 109.78, 111.39, 111.45, 112.71, 117.33, 
121.25, 124.87, 126.57, 126.97, 127.82, 132.07, 133.20, 147.46, 148.25, 148.94, 
150.12, 167.65. 
 
 
(S,Z)-3-(4-(((4,5-Dimethoxy-1,2-dihydrocyclobutabenzen-1-yl)methyl)(methyl) 
amino)but-2-enyl)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one; (S)-37 
It was synthesized following the procedure 
described for (S)-63, starting from cis-28 (0.10 g; 
0.0005 mol), dry triethylamine (0.07 mL; 0.0005 
mol) and (S)-32 (0.15 g; 0.0005 mol). (S)-37 was obtained as a pale yellow solid: 26%; 
mp 61-63 0C; [α]20D = +13.8° (c=1; CHCl3); 1H NMR (CDCl3) δ 2.31 (s, 3H), 2.58 (dd, 
J=12.8 Hz, J=8.8 Hz, 1H), 2.71-2.79 (m, 2H), 3.17 (d, J=6.4 Hz, 2H), 3.27 (dd, J=12.8 
Hz, J=5.2 Hz, 1H), 3.43 (s, 2H), 3.55-3.62 (m, 1H), 3.83 (s, 6H), 3.86 (s, 3H), 3.87 (s, 
3H), 4.18-4.29 (m, 2H), 5.42-5.52 (m, 1H), 5.65-5.75 (m, 1H), 6.17 (d, J=9.2 Hz, 1H), 
6.32 (d, J=9.2 Hz, 1H), 6.67 (s, 1H), 6.70 (s, 1H), 6.71 (s, 1H), 6.76 (s, 1H). 13C NMR 
(CDCl3, APT) δ 35.25, 40.62, 42.49, 43.17, 44.53, 54.63, 55.98, 56.25, 56.33, 61.55, 
106.78, 107.46, 109.52, 111.21, 117.32, 124.63, 126.35, 127.63, 129.21, 130.44, 
134.96, 138.63, 148.05, 149.36, 149.92, 167.51. 
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(R,Z)-3-(4-(((4,5-Dimethoxy-1,2-dihydrocyclobutabenzen-1-yl)methyl)(methyl) 
amino)but-2-enyl)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one; (R)-37 
It was synthesized following the procedure 
described for (S)-63, starting from cis-28 (0.09 g; 
0.0003 mol), dry triethylamine (0.04 mL; 0.0003 
mol) and (R)-32 (0.06 g; 0.0003 mol). (R)-37 was obtained as a pale yellow solid: 
31%; mp 63-66 0C; [α]20D = -11.3° (c=0.75; CHCl3). The 1H NMR spectrum was 
identical to that of (S)-37. 
 
 
(R,Z)-3-(4-((2-(3,4-Dimethoxyphenyl)propyl)(methyl)amino)but-2-enyl)-7,8-dimethoxy-
1H-benzo[d]azepin-2(3H)-one; (R)-38 
3,3'-(2Z,2'Z)-4,4'-((R)-2-(3,4-Dimethoxyphenyl)propylazanediyl)bis(but-2-ene-4,1-
diyl)bis(7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one); (R)-39 
Dry triethylamine (0.11 mL; 0.001 mol) and (R)-33 (0.16 g; 0.01 mol) were added, 
under nitrogen, to a solution of cis-28 (0.18 g; 0.001 mol) in dry CH3CN (10 mL). The 
reaction mixture was stirred overnight at room temperature and monitored by TLC 
(eluent: dichloromethane-methanol-ammonia, 95:5:0.5). Removal of the solvent gave a 
residue that was dissolved in dichloromethane and washed with 2M NaOH (3 × 15 
mL). The organic layers were collected, dried (Na2SO4) and evaporated under vacuum 
to give a residue that was purified by flash chromatography (eluent: dichloromethane-
methanol-ammonia, 95:5:0.5). (R)-39 was eluted first (Rf=0.71; 0.095 mmol; 70 mg; 
12%; yellow solid; mp 97-98 °C), followed by (R)-38 (Rf=0.42; yellow oil, 0.06 mmol; 
30 mg; 8%). 
(R)-39 (hydrochloride): [α]20D = -22.25° (c=0.5; CH3OH); 1H NMR (CDCl3) δ 1.21 (d, 
J=6.8 Hz, 3H), 2.43-2.48 (m, 1H), 2.54-2.59 
(m, 1H), 2.83.2.89 (m, 1H), 3.11-3.15 (m, 
4H), 3.44 (s, 4H), 3.83 (s, 3H), 3.84 (s, 3H), 
3.86 (s, 6H), 3.88 (s, 6H), 4.12-4.24 (m, 4H), 
5.39-5.45 (m, 2H), 5.56-5.62 (m, 2H), 6.13 (d, 
J=9.2 Hz, 2H), 6.31 (d, J=9.2 Hz, 2H), 6.70-
6.72 (m, 4H), 6.77-6.79 (m, 3H); 13C NMR (CDCl3, APT) δ 20.38, 37.87, 43.14, 44.53, 
51.00, 55.80, 55.82, 55.92, 61.70, 109.50, 110.58, 111.09, 111.17, 117.10, 119.00, 
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124.61, 126.34, 127.27, 127.63, 131.01, 138.71, 147.26, 147.99, 148.71, 149.84, 
167.41. 
 
(R)-38 (free base): [α]20D = -1.70° (c=1; CHCl3); 1H NMR (CDCl3) δ 1.25 (d, J=6.8 
Hz, 
3H), 2.73-2.75 (m, 2H), 2.86-2.89 (m, 1H), 3.29 (d, 
J=6.8 Hz, 2H), 3.43 (s, 2H), 3.86 (s, 3H), 3.88 (s, 
6H), 3.89 (s, 3H), 4.18 (d. J=6.8 Hz, 2H), 5.36-5.39 
(m, 1H), 5.58-5.61 (m, 1H), 6.13 (d, J=9.2 Hz, 1H), 6.31 (d, J=9.2 Hz, 1H), 6.72-6.76 
(m, 4H), 6.78-6.82 (m, 1H); 13C NMR (CDCl3, APT) δ 20.29, 39.64, 43.15, 44.39, 
46.11, 55.84, 55.89, 55.96, 56.73, 109.48, 110.44, 111.20, 111.36, 117.22, 118.89, 
124.63, 126.26, 126.32, 127.54, 131.92, 137.72, 147.52, 148.01, 148.98, 149.89, 
167.46. 
 
 
(S,Z)-3-(4-((2-(3,4-Dimethoxyphenyl)propyl)(methyl)amino)but-2-enyl)-7,8-dimethoxy-
1H-benzo[d]azepin-2(3H)-one; (S)-38 
3,3'-(2Z,2'Z)-4,4'-((S)-2-(3,4-dimethoxyphenyl)propylazanediyl)bis(but-2-ene-4,1-
diyl)bis(7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one); (S)-39 
 
 
 
 
 
 
They were synthesized following the procedure described for (S)-39 and (S)-38, 
starting from (S)-33: 0.61 mmol; 0.12 g. 
(S)-38: 0.13 mmol; 60 mg; yellow oil; 21%); [α]20D = +1.58° (c=1; CHCl3. 
(S)-39: 0.122 mmol; 90 mg; 20%; yellow solid; mp 98-102 °C; (S)-39 (hydrochloride): 
[α]20D = +25.13° (c=0.5; CH3OH). 
Their NMR spectra were identical to those of their enantiomers. 
 
 
  59 
(R,Z)-3-(4-((2-(3,4-Dimethoxyphenyl)propyl)(methyl)amino)but-2-enyl)-7,8-dimethoxy-
1H-benzo[d]azepin-2(3H)-one; (R)-40  
A solution of (R)-38 (0.06 mmol; 30 mg), formic 
acid (17 eq), 37% aqueous formaldehyde (5 eq) in 
absolute ethanol (4 mL) was heated at reflux for 4 
hours. The reaction was monitored by TLC in dichloromethane-methanol (96:4). The 
solvent was then removed by rotary evaporation and the residue was treated with 
NaHCO3 (saturated solution) and extracted with dichloromethane (3 × 15 mL). The 
organic layers were collected, dried ( Na2SO4) and the solvent was removed under 
vacuum to give a residue that was purified by flash chromatography: Eluting with 
dichloromethane-methanol (96:4) afforded (R)-40 as a clear oil: 0.06 mmol; 28.5 mg; 
92%; [α]20D = -8.84° (c=1; CHCl3); 1H NMR (CDCl3) δ 1.24 (d, J=7.2 Hz, 3H), 2.22 (s, 
3H), 2.40-2.53 (m, 2H), 2.86-2.91 (m, 1H), 3.02-3.12 (m, 2H), 3.44 (s, 2H), 3.85 (s, 
3H), 3.87 (s, 3H), 3.88 (s, 3H), 3.89 (s, 3H), 4.15-4.26 (m, 2H), 5.30-5.47 (m, 1H), 
5.60-5.66 (m, 1H), 6.15 (d, J=9.2 Hz, 1H), 6.31 (d, J=9.2 Hz, 1H), 6.72-6.80 (m, 5H); 
13C NMR (CDCl3, APT) δ 20.41, 37.66, 42.64, 43.16, 44.48, 54.64, 55.81, 55.84, 
55.95, 65.07, 109.49, 110.49, 111.19, 117.08, 118.88, 124.65, 126.37, 127.18, 127.66, 
131.03, 138.79, 147.29, 148.00, 148.79, 149.86, 167.46. 
 
 
(S,Z)-3-(4-((2-(3,4-Dimethoxyphenyl)propyl)(methyl)amino)but-2-enyl)-7,8-dimethoxy-
1H-benzo[d]azepin-2(3H)-one; (S)-40 
It was synthesized following the procedure 
described for (R)-40, starting from (S)-38 (0.13 
mmol; 60 mg). (S)-40 was obtained as a clear oil: 
21 mg; 0.04 mmol; 34%. The 1H NMR spectrum was identical to that of (R)-40. 
(S)-40 (free base): [α]20D = +8.00° (c=1; CHCl3). 
Ethyl 5,6-dimethoxy-1-oxo-2,3-dihydro-1H-indene-2-carboxylate; 41 
Diethyl carbonate (0.0052 mol; 0.63 mL) was added under 
anhydrous condition to a suspension of NaH (60% in hexane; 0.0104 
mol; 0.42 g) in dry THF (15 mL). The mixture was stirred and 
heated at reflux under nitrogen. After 1 hour, 5,6-dimethoxy indan-1-one (0.0026 mol; 
0.5 g) was added to the milky suspension, which turned into an orange-brown color. 
The mixture was heated at reflux for 3 hours and monitored by TLC (eluent: ethyl 
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acetate-cyclohexane, 1:1). The residue was diluted with water, neutralized with acetic 
acid and extracted with ethyl acetate (3 × 15 mL). The organic layers were collected, 
dried (Na2SO4) and evaporated under vacuum to give 41 as an orange oil: 0.0025 mol; 
0.65 g; 95%; 1H NMR (CDCl3) δ 1.31 (t, J=6.8 Hz, 3H; CH3), 3.27 (dd; J=8.0 Hz, 
J=17.2 Hz, 1H; HB), 3.45 (dd, J=3.6 Hz, J=17.2 Hz, 1H; HA), 3.71 (dd, J=3.6 Hz, J=8.0 
Hz, 1H; HC), 3.91 (s, 3H; OCH3), 3.98 (s, 3H; OCH3), 4.25 (q, J=7.2 Hz, 2H; OCH2), 
6.91 (s, 1H; H aromatic), 7.18 (s, 1H; H aromatic). 
 
 
5,6-Dimethoxy-2,3-dihydro-1H-indene-2-carboxylic acid; 42 
Water (2 mL), hydrochloric acid (3.75 mL), Zn (1.125 g) and HgCl2 
(0.1125 g) were added to a suspension of 41 (1.89 mmol; 0.5 g) in 
toluene (10 mL). The resulting mixture was heated at reflux (112 °C) for 4 hours and 
stirred overnight at room temperature. The reaction was monitored by TLC (eluent: 
ethyl acetate-cyclohexane, 1:1). The two layers were separated and the organic phase 
was extracted with 10% NaOH (3 × 15 mL). The separator funnel was shaken 
vigorously for allowing the complete hydrolysis. The basic aqueous layer was acidified 
with 2N HCl and extracted with ethyl acetate (3 × 15 mL). The organic layers were 
collected, dried (Na2SO4) and removed under vacuum to give 42: 0.23 g; 1.04 mmol; 
55%. 
Ethyl 5,6-dimethoxy-indan-2-carboxylate was recovered as secondary product from the 
toluene’s layer after evaporation of the solvent and converted into 42 after hydrolysis 
with absolute ethanol (10 mL) and 1N NaOH (10 mL). 1H NMR (CDCl3) δ 3.16-3.28 
(m, 4H), 3.37-3.42 (m, 1H), 3.86 (s, 6H), 6.76 (s, 2H). 
 
 
5,6-Dimethoxy-N-methyl-2,3-dihydro-1H-indene-2-carboxamide; 43 
In a round bottom flask, carbonyl diimidazole (2.39 mmol; 0.39 g) 
was slowly added to a solution of 42 (2.39 mmol; 0.53 g) in 
dichloromethane (10 mL). The mixture was stirred for 2 hours at 
room temperature. The reaction was monitored by TLC (eluent: ethyl acetate-
cyclohexane, 1:1) and, once the starting material was disappeared, methylamine (2M 
solution in THF; 23.9 mmol; 11.9 mL) was added. The resulting mixture was stirred for 
additional 2 hours at room temperature, then it was poured into a separator funnel and 
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the organic layer was washed with 10% NaOH (3 × 15 mL). The organic phase was 
then dried (Na2SO4) and evaporated under vacuum to give 43 that was crystallized 
from absolute ethanol: 1.28 mmol; 0.30 g; 53.5%; 1H NMR (CDCl3) δ 2.83 (d, J=4.8 
Hz, 3H), 3.05-3.19 (m, 5H), 3.84 (s, 6H), 5.73 (bs, 1H), 6.73 (s, 2H). 
 
 
1-(5,6-dimethoxy-2,3-dihydro-1H-inden-2-yl)-N-methylmethanamine; 30 
Under anhydrous condition, a solution of 43 (1.70 mmol; 0.40 g) in 
anhydrous THF (10 mL) was added to a suspension of LiAlH4 (1.70 
mmol; 0.065 g) in anhydrous THF (2 mL). The mixture was heated at reflux for 1 day 
under nitrogen. The reaction was monitored by TLC (ethyl acetate-cyclohexane, 1:1) 
until the starting material disappeared, then water (5 mL) and 10% NaOH (1 mL) were 
added to the mixture. The white precipitate was filtered off and the solvent was 
removed under vacuum to give a residue that was dissolved in ethyl acetate and washed 
with water (3 × 15 mL). The organic layer was dried (Na2SO4) and the solvent 
evaporated under vacuum yielding a residue that was purified by flash chromatography 
(eluent: dichloromethane-methanol-ammonia, 95:5:0.5) to give 30: 1.45 mmol; 0.32 g; 
85%; 1H NMR (CDCl3) δ 1.59 (bs, 1H), 2.47 (s, 3H), 2.59-2.60 (m, 1H), 2.64-2.68 (m, 
4H), 3.00-3.03 (m, 2H), 3.84 (s, 6H), 6.73 (s, 2H). 
 
 
(S)-2-(2,2,2-Trifluoroacetamido)propanoic acid; (S)-44 
Under anhydrous condition, dry triethylamine (0.056 mol; 7.82 mL) 
and ethyltrifluoroacetate (0.066 mol; 8.35 mL) were added to L-
Alanine (0.056 mol; 5.00 g) in dry methanol (30 mL). The suspension was stirred for 
26 hours at room temperature until it became a clear solution. The solvent was removed 
under vacuum and the residue was dissolved in water, which was acidified to pH 3 with 
2N HCl. The acidic aqueous layer was extracted three times with ethyl acetate. The 
organic layers were collected, dried (Na2SO4) and evaporated under vacuum to afford 
(S)-44 as a white solid: 9.42 g; 91%; mp 54 °C. The free base was converted into the 
HCl salt: [α]20D = +11.5° (c=1; CHCl3); 1H NMR (CDCl3) δ 1.55 (d, J=7.2Hz, 3H), 
4.60-4.67 (m, 1H), 7.22 (bs, 1H), 9.19 (bs, 1H). 
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(R)-2-(2,2,2-Trifluoroacetamido)propanoic acid; (R)-44 
It was obtained following the procedure described for (S)-44, starting 
from D-Alanine (0.056 mol; 5.00 g), dry triethylamine (0.056 mol; 7.82 
mL) and ethyltrifluoroacetate (0.066 mol; 8.35 mL), as a white solid (9.22 g; 89%; mp 
55 °C). The free base was converted into the HCl salt: [α]20D = -12.9° (c=1; CHCl3). 
The 1H NMR spectrum was identical to that of (S)-44. 
 
 
(S)-N-(1-(3,4-Dimethoxyphenyl)-1-oxopropan-2-yl)-2,2,2-trifluoroacetamide; (S)-46 
Under anhydrous condition, dry pyridine (2 drops) and oxalyl 
chloride (0.0172 mol; 1.46 mL) were added to a solution (0 °C) of 
(S)-44 (0.0015 mol; 1.50 g) in dry dichloromethane (30 mL). The 
mixture was stirred for 1 day at room temperature, then the solvent was removed to 
afford crude (S)-45 that was dissolved in dry dichloromethane (15 mL) under nitrogen. 
The flask was placed into an ice-bath and AlCl3 (0.0089 mol; 1.19 g) and veratrol 
(0.0089 mol; 1.13 mL) were added to the reaction mixture, which was stirred for 48 
hours at room temperature and then poured into a separator funnel where the organic 
layer was washed with 1N HCl, aqueous NaHCO3 (saturated solution) and brine. The 
organic phase was then dried (Na2SO4) and evaporated under vacuum to give a residue, 
which was purified by flash chromatography (eluent: cyclohexane-ethyl acetate, 7:3) 
yielding (S)-46 as a white solid: 0.686 g; 35%; mp 87 °C. The free base was converted 
into the HCl salt: [α]20D = -8.8° (c=1; CHCl3). 1H NMR (CDCl3) δ 1.53 (d, J=6.8 Hz, 
3H), 3.96 (s, 3H), 3.98 (s, 3H), 5.46-5.53 (m, 1H), 6.92 (d, J=8.6 Hz, 1H), 7.51 (d, 
J=1.4 Hz, 1H), 7.61 (dd, J=8.6 Hz, J=1.4 Hz, 1H). 
 
 
(R)-N-(1-(3,4-Dimethoxyphenyl)-1-oxopropan-2-yl)-2,2,2-trifluoroacetamide; (R)-46 
It was obtained following the procedure described for (S)-46, 
starting from (R)-44 (0.052 mol; 9.71 g) in dichloromethane (105 
ml) and utilizing AlCl3 (0.058 mol; 7.7 g) and veratrol (0.058 mol; 7.36 ml). (R)-46 
was obtained as a white solid (29%; mp 85 °C). The free base was converted into the 
HCl salt: [α]20D = +8.8° (c=1; CHCl3).The 1H NMR spectrum was identical to that of 
(S)-46. 
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(S)-N-(1-(3,4-Dimethoxyphenyl)propan-2-yl)-2,2,2-trifluoroacetamide; (S)-47 
Under a nitrogen atmosphere, Et3SiH (1.23 ml; 0.0077 mol) was 
added to a red solution of (S)-46 (0.0026 mol; 0.69 g) in 
CF3COOH (0.010 mol; 4 mL). The resulting discolored mixture was stirred first for 2 
hours at 72 °C and then for 15 hours at room temperature. The solution was basified 
with NaHCO3 and extracted with ethyl acetate. The organic layers were collected, dried 
(Na2SO4) and evaporated under vacuum to give (S)-47, which was used in the next step 
without further purification. 
 
 
(R)-N-(1-(3,4-Dimethoxyphenyl)propan-2-yl)-2,2,2-trifluoroacetamide; (R)-47 
It was synthesized following the procedure described for (S)-47, 
starting from (R)-46 (0.015 mol; 4.58 g), CF3COOH (0.058 mol; 
26.70 mL) and Et3SiH (8.18 ml; 0.058 moli). Crude (R)-47 was used in the next step 
without further purification. 
 
 
(S)-1-(3,4-Dimethoxyphenyl)propan-2-amine; (S)-48 
K2CO3 (2.50 g) was added to a solution of (S)-47 (0.0093 mol; 1.81 g) 
in methanol (49.5 mL) and water (2.5 mL). The mixture was stirred 
for 24 hours at 64 °C. The pricipitate was filtered off and the filtrate was diluted with 
water and extracted with dichloromethane (3 × 25 mL). The organic layers were 
collected, dried (Na2SO4) and evaporated to afford a residue that was purified by flash 
chromatography (dichloromethane-methanol, 95:5) yielding (S)-48 as a yellow oil 
(0.0032 mol; 0.62 g; 34%). The free base was converted into the HCl salt: [α]20D = 
+24.6° (c=1; CHCl3); e.e.=91% (determined by chiral HPLC); 1H NMR (CDCl3) δ 1.14 
(d, J=6.4 Hz, 3H), 2.31 (bs, 2H), 2.51 (dd, J=13.4 Hz, J=8.0 Hz, 1H), 2.67 (dd, J=13.4 
Hz, J=5.6 Hz, 1H), 3.15-3.20 (m, 1H), 3.82 (s, 3H), 3.86 (s, 3H), 6.71-6.73 (m, 2H), 
6.80 (d, J=8.0 Hz, 1H). 
 
 
(R)-1-(3,4-Dimethoxyphenyl)propan-2-amine; (R)-48 
It was synthesized following the procedure described for (S)-48, 
starting from (R)-47 (0.015 mol; 4.37 g), K2CO3 (0.0457 mol; 6.30 g), 
methanol (125 ml) and water (6 ml). (R)-48 was obtained as a yellow oil (20%). The 
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free base was converted into the HCl salt: [α]20D = -29° (c=1; CHCl3); e.e.=98.6% 
(determined by chiral HPLC). The 1H NMR spectrum was identical to that of (S)-48. 
 
 
(S)-N-(1-(3,4-Dimethoxyphenyl)propan-2-yl)formamide; (S)-49 
Under a nitrogen atmosphere, a solution of (S)-48 (0.0029 mol; 0.59 
g) in HCOOEt (0.036 mol; 2.88 mL) was stirred for 96 hours at 45 
°C to give, after removal of volatiles, (S)-49 that was used in the next step without any 
purification. 
 
 
(R)-N-(1-(3,4-Dimethoxyphenyl)propan-2-yl)formamide; (R)-49 
Under a nitrogen atmosphere, a solution of (R)-48 (0.0031 mol; 
0.60 g) in HCOOEt (0.018 mol; 1.49 mL) was stirred for 96 hours at 
45 °C to give, after removal of volatiles, (S)-49 that was used in the next step without 
any purification. 
 
 
(S)-1-(3,4-Dimethoxyphenyl)-N-methylpropan-2-amine; (S)-31 
Under anhydrous condition and nitrogen, a solution of the above (S)-
49 in dry THF (12.5 mL) was slowly added to a suspension of 
LiAlH4 (0.0036 mol; 0.14 g) in dry THF (25 mL) at 0 °C. The 
mixture was stirred at reflux for 15 hours and then the flask was placed into an ice-bath 
and water and 10% NaOH (1.5 mL) were slowly added to the mixture. The precipitate 
was filtered off and the filtrate was evaporated yielding a residue that was dissolved in 
ethyl acetate and washed with water. The organic layer was collected, dried (Na2SO4) 
and evaporated to afford a crude that was purified by flash chromatography (eluent: 
dichloromethane-methanol-ammonia, 95:5:0.5) giving (S)-31 as a yellow oil (0.0006 
mol; 0.13 g; 21%). The free base was converted into the HCl salt: [α]20D = +6.6° (c=1; 
CHCl3); 1H NMR (CDCl3) δ 1.07 (d, J=6.4 Hz, 3H), 1.53 (bs, 1H), 2.40 (s, 3H), 2.59 
(dd, J=13.6 Hz, J=6.4 Hz, 1H), 2.64 (dd, J=13.6 Hz, J=7.0 Hz, 1H), 2.72-2.80 (m, 1H), 
3.86 (s, 3H), 3.87 (s, 3H), 6.7-6.74 (m, 1H), 6.8 (d, J=8.0 Hz, 1H). 
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(R)-1-(3,4-Dimethoxyphenyl)-N-methylpropan-2-amine; (R)-31 
It was obtained following the procedure described for (S)-31, starting 
from (R)-49 (0.0009 mol; 0.20 g), LiAlH4 (0.0012 mol; 46 mg) and 
dry THF (30 ml). (R)-31 was obtained as a yellow oil (45%). The 
free base was converted into the HCl salt: [α]20D = -8.8° (c=1; CHCl3). The 1H NMR 
spectrum was identical to that of (S)-31. 
 
 
3-(3,4-Dimethoxyphenyl)propanoic acid; 50 
Palladium on charcoal (10% p/p) was added to a solution of 3,4-
dimethoxy cinnamic acid (0.024 mol; 5 g.) in THF (50 mL). The 
mixture was placed in a Parr apparatus at 60 Psi and allowed to react at room 
temperature for 2 days. The catalyst was filtered off and the solvent was removed under 
vacuum, giving 50 as a white solid: 0.023 mol; 98%; mp 96-98 °C; 1H NMR (CDCl3) δ 
2.68 (t, J=7.6 Hz, 2H), 2.92 (t, J=7.2 Hz, 2H), 3.87 (s, 3H), 3.88 (s, 3H), 6.75-6.77 (m, 
2H), 6.80-6.82 (m, 1H). 
 
 
3-(2-Bromo-4,5-dimethoxyphenyl)propanoic acid; 51 
Bromine (0.023 mol, 1.22 mL) was slowly added to a solution of 50 
(0.023 mol; 4.98 g) in glacial acetic acid (25 mL) at 0 °C (ice-water 
bath). The mixture was stirred for 3 hours at room temperature and monitored by TLC 
(eluent: hexane-ethyl acetate, 1:1). The mixture was poured into ice with formation of a 
precipitate, which was filtered off, washed with water and dried under vacuum to give 
51: 5.94 g; 0.020 mol; 87%; mp 126-128 °C; 1H NMR (CDCl3) δ 2.69 (t, J=7.8 Hz, 
2H), 3.01 (t, J=7.6 Hz, 2H), 3.86 (s, 6H), 6.79 (s, 1H), 7.01 (s, 1H). 
 
 
3-(2-Bromo-4,5-dimethoxyphenyl)propanamide; 52 
In a two-necked flask under nitrogen atmosphere, thionyl chloride 
(0.041 mol; 2.99 mL) was added dropwise to a solution of 51 (0.020 
mol; 5.94 g) in chloroform (50 mL). The mixture was heated at 61 °C for 3 hours 
monitoring the progress of the reaction by TLC (eluent: hexane-ethyl acetate, 1:1). The 
solvent was removed under vacuum and the residue was washed with cyclohexane (2 × 
30 mL, removed under vacuum) and dissolved in ammonia (33% in water). After 
  66 
stirring overnight at room temperature, the solvent was removed under vacuum. The 
residue was dissolved in dichloromethane and washed twice with aqueous Na2CO3 
solution. The organic layers were collected, dried (Na2SO4) and removed under 
vacuum. The residue was purified by flash chromatography (eluent: dichloromethane-
methanol-ammonia, 95:5:0.5) yielding 52 as a pale yellow gummy solid: 0.017 mol; 5 
g; 84%; 1H NMR (CDCl3) δ 2.47 (t, J=8 Hz, 2H), 2.96 (t, J=7.2 Hz, 2H), 3.80 (s, 6H), 
5.69 (bs, 1H), 6.07 (bs, 1H), 6.76 (s, 1H), 6.95 (s, 1H). 13C NMR (CDCl3, APT) δ 
31.48, 35.88, 55.91, 56.00, 113.14, 113.66, 115.37, 131.76, 147.97, 148.25, 174.56. IR 
(Nujol, cm-1) ν 1662 (CONH2). 
 
 
3-(2-Bromo-4,5-dimethoxyphenyl)propanenitrile; 53 
In a two-necked flask under nitrogen atmosphere, phosphoryl chloride 
(0.035 mol; 3.18 mL) was added dropwise to a solution of 52 (0.017 
mol; 5 g) in chloroform (50 mL). The mixture was heated at 61 °C for 5 hours 
monitoring the reaction by TLC (eluent: dichloromethane-methanol-ammonia, 
95:5:0.5). The mixture was poured into ice and then extracted with chloroform (3 × 25 
mL). The organic layers were collected, dried (Na2SO4) and evaporated under vacuum. 
The residue was purified by flash chromatography (eluent: dichloromethane) yielding 
53 as a white solid: 0.016 mol; 4.41 g; 96%; mp 77-80 °C; 1H NMR (CDCl3) δ 2.65 (t, 
J=7.2 Hz, 2H), 3.01 (t, J=7.2 Hz, 2H), 3.86 (s, 3H), 3.88 (s, 3H), 6.81 (s, 1H), 7.02 (s, 
1H); IR (Nujol, cm-1) ν 2245 (CN). 
 
 
4,5-Dimethoxy-1,2-dihydrocyclobutabenzene-1-carbonitrile; (R)/(S)-54 
A 100 mL three-necked flask was thoroughly dried and fitted with a 
large condenser, a nitrogen inlet and a thermometer. The flask was 
dipped into a liquid nitrogen-ethanol bath (-33 °C) and ammonia was allowed to 
condense (50 mL). Then commercial sodium amide (0.06 mol; 2.34 g) was rapidly 
added; the temperature went down so the suspension was stirred until the temperature 
reached –33 °C. Then 53 (0.015 mol; 4.05 g) was rapidly added to the suspension. The 
dark green reaction mixture was stirred for 1 hour and monitored by TLC (eluent: 
cyclohexane-ethyl acetate, 1:1). The mixture was then treated with solid ammonium 
chloride (0.06 mol; 3.21 g) allowing ammonia to evaporate. The residue was taken up 
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in dichloromethane (50 mL) and washed twice with 2N HCl (2 × 25 mL) and once with 
aqueous saturated solution of ammonium chloride (1 × 25 mL). The organic layer was 
collected, dried (Na2SO4) and evaporated under vacuum. The yellow-brown oil was 
purified by flash chromatography (eluent: cyclohexane-ethyl acetate, 1:1) to give 
(R)/(S)-54 as a pale yellow solid: 0.0106 mol; 2 g; 71%; mp 85-89 °C; 1H NMR 
(CDCl3) δ 3.44 (dd, J=13.6 Hz, J=2.2 Hz, 1H), 3.57 (dd, J=13.6 Hz, J=5.2 Hz, 1H), 
3.84 (s, 6H), 4.15 (dd, J=5.2 Hz, J=2.2 Hz, 1H), 6.69 (s, 1H), 6.77 (s, 1H). 13C NMR 
(CDCl3, APT) δ 28.00, 35.47, 56.16, 56.20, 106.17, 106.99, 119.84, 129.72, 134.18, 
150.45, 151.39. 
 
 
(4,5-Dimethoxy-1,2-dihydrocyclobutabenzen-1-yl)methanamine; (R)/(S)-55 
(R)/(S)-54 (0.0095 mol; 1.8 g) was dissolved in dry THF (50 mL) 
under nitrogen flow in a flame-dried flask. Then BH3.THF (1M; 0.019 
mol; 19 mL) was added at room temperature and the mixture was stirred for 6 hours at 
reflux. Once the mixture was cooled to room temperature, 9.5 mL of 1N methanolic 
HCl was carefully added, and the mixture was heated at 40 °C for 30 minutes to 
hydrolyze the intermediate boramine complex. The solvent was removed under vacuum 
and the residue was taken up in 1N NaOH (25 mL) and extracted with dichloromethane 
(3 × 25 mL). The organic layers were collected, dried (Na2SO4) and evaporated under 
vacuum. The residue (yellow oil) was purified with flash chromatography (eluent: 
dichloromethane-methanol-ammonia, 95:10:1) to give (R)/(S)-55 as a pale yellow oil: 
0.0078 mol; 1.50 g; 82%; 1H NMR (CDCl3) δ 1.67 (bs, 2H), 2.73 (d, J=13.6 Hz, 1H), 
2.98 (d, J=6.8 Hz, 2H), 3.20 (dd, J=13.6 Hz, J= 5.2 Hz, 1H), 3.43-3.51 (m, 1H), 3.84 (s, 
6H), 6.70 (s, 1H), 6.73 (s, 1H); 13C NMR (CDCl3, APT) δ 33.00, 45.27, 45.90, 56.19, 
56.25, 106.57, 107.58, 135.02, 138.33, 149.32, 149.84. 
 
 
Resolution of (R)/(S)-55 by fractional crystallization 
N-acetyl-L-glutamic acid dissolved in absolute ethanol (10 mL) was added to a solution 
of (R)/(S)-55 in absolute ethanol (10 mL). The mixture was kept at room temperature 
until there was the formation of a precipitate. The solid was filtered off, dried under 
vacuum and then it was crystallized more times to reach constant values for melting 
point and [α], following the procedure shown in scheme A. 
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Scheme A. 
 
The solid product obtained from the last crystallization was treated with 10% NaOH 
and extracted with dichloromethane. Removal of the solvent afforded (S)-55 as a clear 
oil (0.44 g): [α]20D = -11.7° (c=0.75; CHCl3). 
The solvents of previous crystallizations were collected and evaporated. The residue 
was treated with 10% NaOH and extracted with dichloromethane. Removal of the 
solvent afforded an unbalanced racemic mixture of (R)/(S)-55, which was dissolved in 
absolute ethanol (5 mL) and poured into a solution of N-acetyl-D-glutamic acid in 
absolute ethanol (5 mL). The mixture was kept at room temperature until there was the 
formation of a precipitate. The solid was filtered off and dried under vacuum and then 
it was crystallized more times to reach constant values for melting point and 
[α],following the procedure shown in scheme B. 
Scheme B. 
 
 
Number of 
crystallization 
Volume of 
Ethanol used 
Precipitate 
mass 
[α]20D 
(c=1; MeOH) 
Melting 
point (0C) 
1 20 mL 2.25 g +12.10 100-105 
2 20 mL 1.31 g +16.80 130-133 
3 15 mL 1.04 g +18.50 136-137 
4 10 mL 0.92 g +19.00 136-137 
Number of 
crystallization 
Volume of 
Ethanol used 
Precipitate 
mass 
[α]20D 
(c=1; 
MeOH) 
Melting point 
(0C) 
1 10 mL 1.70 g -10.10 110-130 
2 10 mL 1.00 g -13.00 120-130 
3 5 mL 0.819 g -14.80 120-130 
4 5 mL 0.702 g -16.20 122-134 
5 4 mL 0.600 g -18.10 131-133 
6 4 mL 0.515 g -19.20 135-136 
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The solid product obtained from the last crystallization was treated with 10% NaOH 
and extracted with dichloromethane. Removal of the solvent afforded (R)-55 as a clear 
oil: 0.25 g; [α]20D = +11.9° (c=0.75; CHCl3). 
 
 
(S)-1-(4,5-Dimethoxy-1,2-dihydrocyclobutabenzen-1-yl)-N-methylmethanamine; (S)-32 
Under anhydrous condition, ethyl formiate (0.010 mol; 0.81 mL) was 
slowly added to (S)-55 (0.002 mol; 0.32 g) and the mixture was 
stirred for 24 hours at room temperature. After removal of the 
solvent, the residue was dissolved in dry THF (4 mL) and poured into a suspension of 
LiAlH4 (0.003 mol; 0.10 g) in dry THF under nitrogen atmosphere. The reaction 
mixture was stirred and heated at reflux for 4 hours. Then ice was added and the 
formed precipitate was filtered off and washed with THF. The filtrate was evaporated 
and the residue was taken up in ethyl acetate and washed with water. The organic 
layers were collected, dried (Na2SO4) and evaporated to give a residue that was purified 
by flash chromatography (eluent: dichloromethane-methanol-ammonia, 95:5:0.5) 
affording (S)-32 as a red oil: 55%; [α]20D = -8.7° (c=1; CHCl3); 1H NMR (CDCl3) δ 
1.80 (bs, 1H), 2.48 (s, 3H), 2.75 (dd, J=13.6 Hz, J=1.8 Hz, 1H), 2.83 (dd, J=11.8 Hz, 
J=7.6 Hz, 1H), 2.90 (dd, J=11.8 Hz, J=6.8 Hz, 1H), 3.22 (dd, J=13.6 Hz, J=4.8 Hz, 
1H), 3.53-3.59 (m, 1H), 3.83 (s, 3H), 3.84 (s, 3H), 6.67 (s, 1H), 6.70 (s, 1H). 
 
 
(R)-1-(4,5-Dimethoxy-1,2-dihydrocyclobutabenzen-1-yl)-N-methylmethanamine; (R)-
32 
It was obtained following the procedure described for (S)-32, starting 
from (R)-55 (0.001 mol; 0.25 g), ethyl formiate (0.008 mol; 0.63 ml) 
and LiAlH4 (0.002 mol; 0.08 g). (R)-32 was obtained as a red oil: 92%; [α]20D = +8.0° 
(c=1; CHCl3). The 1H NMR spectrum was identical to that of (S)-32. 
 
 
2-(3,4-Dimethoxyphenyl)propanoic acid; 57 
In a two-necked flask, butyl lithium (1.6M in hexane; 0.0204 mol; 
12.74 mL) was added under nitrogen to a cooled (-50 °C, ethanol-
liquid nitrogen bath) solution of diisopropylamine (0.0204 mol; 2.86 
mL) in dry THF (90 mL). The mixture was then allowed to warm to -20 °C and stirred 
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for 20 minutes. A solution of 3,4-dimethoxyphenylacetic acid (0.0102 mol; 2 g) in 
anhydrous THF (10 mL) was then added and the resulting mixture was stirred at 25 °C. 
After 1 hour, methyl iodide (0.0102 mol; 0.63 mL) was added to the reaction mixture 
that was stirred overnight at room temperature and then diluted with water (100 mL). 
THF was removed under vacuum and the aqueous solution was washed with diethyl 
ether (3 × 50 mL) and acidified to pH=1 with 6N HCl and extracted with diethyl ether 
(3 × 50 mL). The organic layers were collected, dried (Na2SO4) and the solvent was 
removed under vacuum to give a residue that was crystallized from ethyl 
acetate/hexane yielding 57: 1.40 g; 70%; mp 62-64 °C; 1H NMR (CDCl3) δ 1.51 (d, 
J=27.2 Hz, 3H), 3.70 (q, J=7.2 Hz, 1H), 3.86 (s, 3H), 3.87 (s, 3H), 6.81-6.87 (m, 3H). 
 
 
(S)-2-(3,4-Dimethoxyphenyl)-N-(1-phenylethyl)propanamide; 58 
Thionyl chloride (11.9 mmol; 0.86 mL) was added dropwise to a 
solution of 57 (4.76 mmol; 1 g) in chloroform (50 mL). The 
mixture was stirred and heated at reflux for 2 hours. The solvent was removed under 
vacuum to give a residue that was dissolved in benzene (10 mL) and added to a 
solution of (S)-α-methylbenzylamine (6.18 mmol; 0.80 mL) in benzene (10 mL) and 
pyridine (1 mL). The reaction mixture was stirred for 15 minutes at room temperature 
and then washed with water (25 mL), 1N HCl (25 mL) and 5% Na2CO3 (25 mL). The 
organic layers were collected, dried (Na2SO4) and the solvent was removed under 
vacuum. 
The residue was purified by flash chromatography (eluent: hexane-ethyl acetate, 1:1), 
giving 58 as a yellow solid: 83%; 3.96 mmol; 1.24 g; mp 101-103 °C; 1H NMR 
(CDCl3) δ 1.36-1.41 (m, 3H), 1.50 (t, J=7.2 Hz, 3H), 3.47-3.56 (m, 1H), 3.79-3.89 (m, 
6H), 5.10-5.14 (m, 1H), 5.54-5.56 (m, 1H), 6.72-6.87 (m, 3H), 7.11-7.23 (m, 5H). 
 
 
(S)-2-(3,4-Dimethoxyphenyl)-N-(1-phenylethyl)propan-1-amine; 59 
In a two-necked flask, BH3.THF was added (1M; 6.90 mmol; 6.9 
mL) to a solution of 58 (1.72 mmol; 0.54 g) in dry THF (20 mL). 
The reaction mixture was stirred for 24 hours at room 
temperature. THF was removed under vacuum affording a residue that was treated with 
methanol (20 mL) and concentrated HCl (1 mL). The resulting mixture was stirred at 
reflux for 2 hours. After cooling, the solvents were removed under vacuum to give a 
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residue  that was dissolved in 2N HCl and washed with diethyl ether (3 × 15 mL). The 
aqueous layer was basified to pH=10 with 10% NaOH and then extracted with 
dichloromethane (3 × 15 mL). The organic layers were collected, dried (Na2SO4) and 
removed under vacuum yielding the diasteromeric amines that were purified by gravity 
column chromatography (eluent: toluene-ethyl acetate, 1:1) to give the two 
diastereoisomers. 
 
 
(R)-2-(3,4-dimethoxyphenyl)-N-((S)-1-phenylethyl)propan-1-amine; (R,S)-59 
Clear oil; 0.53 mmol; 0.16 g; 31%. The free base was converted 
into the HCl salt: [α]20D = -34.9° (c=0.5; H2O); 1H NMR 
(CDCl3) δ 1.21 (d, J=7.2 Hz, 3H), 1.28 (d, J=6.8 Hz, 3H), 2.56-
2.66 (m, 2H), 2.80-2.89 (m, 1H), 3.70 (q, J=6.4 Hz, 1H), 3.87 (s, 6H), 6.73-6.84 (m, 
3H), 7.22-7.33 (m, 5H). 
 
 
(S)-2-(3,4-dimethoxyphenyl)-N-((S)-1-phenylethyl)propan-1-amine; (S,S)-59 
Clear oil; 0.43 mmol; 0.13 g; 25%. The free base was converted 
into the HCl salt: [α]20D = -20.7° (c=0.5; H2O).;1H NMR 
(CDCl3) δ 1.18 (d, J=7.2 Hz, 3H), 1.27 (d, J=6.8 Hz, 3H), 2.51-
2.65 (m, 1H), 2.65-2.69 (m, 1H), 2.84-2.91 (m, 1H), 3,73 (q, J=6.8 Hz, 1H), 3.84 (s, 
3H), 3.88 (s, 3H), 6.64-6.83 (m, 3H), 7.12-7.29 (m, 5H). 
 
 
(R)-2-(3,4-dimethoxyphenyl)propan-1-amine; (R)-33 
The Pearlman’s catalyst (10% p/p) was added to a solution of (R,S)-
59 (1.13 mmol; 0.34 g) in methanol (50 mL). The mixture was placed 
in a Parr apparatus at 60 Psi and allowed to react for 1 day at room 
temperature. The reaction was monitored by TLC (eluent: dichloromethane-methanol-
ammonia, 95:5:0.5). The catalyst was filtered off and the solvent removed under 
vacuum. The residue was then purified by flash chromatography (eluent: 
dichloromethane-methanol-ammonia, 90:10:0.5) yielding the free amine (R)-33 
obtained as a clear oil (0.82 mmol; 0.16 g; yield: 72%) that was converted into the HCl 
salt: [α]20D = +27.56° (c=0.5; H2O); 1H NMR (CDCl3) δ 1.24 (d, J=6.8 Hz, 3H), 2.66-
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2.75 (m, 1H), 2.77-2.84 (m, 2H), 3.86 (s, 3H), 3.88 (s, 3H), 6.72-6.76 (m, 2H), 6.81-
6.83 (m, 1H). 
 
 
(S)-2-(3,4-Dimethoxyphenyl)propan-1-amine; (S)-33 
It was obtained following the procedure described for (R)-33, starting 
from (S,S)-59 (0.73 mmol; 0.22 g). (S)-33 free base was obtained as a 
clear oil (0.66 mmol; 0.13 g; 91%) and converted into the HCl salt: [α]20D = -23.3° 
(c=0.5; H2O). The 1H NMR spectrum was identical to that of (R)-33. 
 
 
(R)-2-(3,4-Dimethoxyphenyl)-N-((S)-1-phenylethyl)propan-1-amine; (R,S)-60 
Formic acid (0.060 mol; 2.30 mL) and formaldehyde (37% in 
H2O; 0.018 mol; 1.43 mL) were added to a solution of (R,S)-59 
(0.004 mol; 1.05 g) in absolute ethanol (20 mL). The mixture was stirred at reflux for 6 
hours. The solvent was removed and the residue was dissolved in dichloromethane and 
washed twice with NaHCO3. The organic layers were collected, dried (Na2SO4) and 
evaporated under vacuum to give (R,S)-60 as a yellow oil (98%). The free base was 
converted into the HCl salt: [α]20D = -4.0° (c=1; CHCl3); 1H NMR (CDCl3) δ 1.27 (d, 
J=7.2 Hz, 3H), 1.33 (d, J=6.2 Hz, 3H), 2.20 (s, 3H), 2.37 (dd, J=11.6 Hz, J=6.4 Hz, 
1H), 2.43-2.48 (m, 1H), 2.77-2.94 (m, 1H), 3.60 (q, J=6.2 Hz, 1H), 3.81 (s, 3H), 3.89 
(s, 3H), 6.63 (s, 1H), 6.68 (d, J=8.0 Hz, 1H), 6.78 (dd, J=8.0 Hz, J=1.6 Hz, 1H), 7.21-
7.31 (m, 5H). 
 
 
(S)-2-(3,4-Dimethoxyphenyl)-N-((S)-1-phenylethyl)propan-1-amine; (S,S)-60 
It was synthesized following the procedure described for (R,S)-
60, starting from (S,S)-59 (0.003 mol; 0.81 g), formic acid 
(0.046 mol; 1.77 mL) and formaldehyde (37% in H2O; 0.014 
mol; 1.10 mL). (S,S)-60 was obtained as a yellow oil (98%). The free base was 
converted into the HCl salt: [α]20D = -6.3° (c=1; CHCl3); 1H NMR (CDCl3) δ 1.19 (d, 
J=6.8 Hz, 3H), 1.27 (d, J=5.6 Hz, 3H), 2.19 (s, 3H); 2.36 (dd, J=11.2 Hz, J=7.6 Hz, 
1H), 2.51 (dd, J=11.2 Hz, J=7.4 Hz, 1H), 2.78-2.91 (m, 1H), 3.56 (q, J=5.6 Hz, 1H), 
3.84 (s, 3H); 3.87 (s, 3H); 6.62 (s, 1H), 6.69 (d, J=8.3 Hz, 1H), 6.80 (dd, J=8.3 Hz, 
J=1.8 Hz, 1H), 7.15-7.31 (m, 5H). 
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(R)-2-(3,4-Dimethoxyphenyl)-N-methylpropan-1-amine; (R)-61 
Pd(OH2)/C (0.33 g) was added to a solution of (R,S)-60 (0.004 mol; 
1.13 g) in methanol (20 ml). The mixture was placed in a Parr 
apparatus at 65 Psi and allowed to react at room temperature for 1 day. The catalyst 
was filtered off and the solvent was removed to give (R)-61 as a gummy-yellow solid 
(80%). The free base was converted into the HCl salt: [α]20D = +19.4° (c=1; CHCl3). 1H 
NMR (CDCl3) δ 1.35 (d, J=6.8 Hz, 3H), 2.48 (s, 3H), 2.87 (dd, J=14.0 Hz, J=7.6 Hz, 
1H), 2.93 (dd, J=14.0 Hz, J=7.2 Hz, 1H), 3.10-3.19 (m, 1H), 3.83 (s, 3H), 3.87 (s, 3H), 
6.34 (bs, 1H), 6.77-6.82 (m, 3H). 
 
 
(S)-2-(3,4-Dimethoxyphenyl)-N-methylpropan-1-amine; (S)-61 
It was synthesized following the procedure described for (R)-61, 
staring from (S,S)-60 (0.003 mol; 0.83 g) and Pd(OH2)/C (0.25 g). (S)-
61 was obtained as a yellow oil (85%). The free base was converted 
into the HCl salt: [α]20D = -16.2° (c=1; CHCl3); 1H NMR (CDCl3) δ 1.27 (d, J=6.8 Hz, 
3H), 2.41 (s, 3H), 2.75 (dd, J=11.8 Hz, J=8.4 Hz, 1H), 2.79 (dd, J=11.8 Hz, J=6.4 Hz, 
1H), 2.90-3.04 (m, 1H), 3.84 (s, 3H); 3.87 (s, 3H), 3.94 (bs, 1H), 6.74-6.77 (m, 2H), 
6.80 (d, J=7.8 Hz, 1H). 
 
 
(E)-3-(4-Chlorobut-2-enyl)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one; trans-28 
(EC3) 
It was synthesized following the procedure described for cis-28, 
starting from 14 (0.018 mol; 4 g), potassium terbutoxyde (0.023 
mol; 2.5 g) and trans-1,4-dichlorobut-2-ene (0.023 mol; 3.3 mL). 26 was obtained as a 
yellow solid (60%; mp 83-86 0C). 1H NMR (CDCl3) δ 3.44 (s, 2H), 3.86 (s, 3H), 3.89 
(s, 3H), 3.97 (d, J=6.8 Hz, 2H), 4.17 (d, J=5.6 Hz, 2H), 5.58-5.65 (m, 1H), 5.68-5.74 
(m, 1H), 6.16 (d, J=9.0 Hz, 1H), 6.37 (d, J=9.0 Hz, 1H), 6.74 (s, 1H), 6.79 (s, 1H). 
 
 
(S,E)-3-(4-((1-(3,4-dimethoxyphenyl)propan-2-yl)(methyl)amino)but-2-enyl)-7,8-
dimethoxy-1H-benzo[d]azepin-2(3H)-one; (S)-62  
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Under nitrogen atmosphere, dry triethylamine (0.07 
mL; 0.0005 mol) and (S)-31 (0.10 g; 0.0005 mol) in 
dry CH3CN (4 mL) were added to a solution of 
trans-28 (0.15 g; 0.0005 mol) in dry CH3CN (3 mL). 
The reaction mixture was stirred for 24 hours at room temperature and monitored by 
TLC (eluent: dichloromethane-methanol-ammonia, 95:5:0.5). The solvent was removed 
under vacuum and the residue was dissolved in ethyl acetate and washed with aqueous 
NaHCO3 (saturated solution; 3 × 15 mL). The organic layers were collected, dried 
(Na2SO4) and evaporated under vacuum to give a residue that was purified by flash 
chromatography (eluent: dichloromethane-methanol-ammonia, 95:5:0.5). (S)-62 was 
obtained as a whitish solid: 0.08 g; 0.0002 mol; 36%; mp 85 °C; [α]20D = +2.2° (c=1; 
CHCl3); 1H NMR (CDCl3) δ 0.88 (d, J=6.4 Hz, 3H), 2.20 (s, 3H), 2.32 (dd, J=13.8 Hz; 
J=10.6 Hz, 1H), 2.80-2.89 (m, 2H), 3.00-3.10 (m, 2H), 3.44 (s, 2H), 3.84 (s, 3H), 3.84 
(s, 3H), 3.85 (s, 3H), 3.87 (s, 3H), 4.09-4.19 (m, 2H), 5.53 (dd, J=15.6Hz; J=5.0 Hz, 
1H), 5.59 (dd, J=15.6 Hz, J=5.6 Hz, 1H), 6.17 (d, J=9.2Hz, 1H), 6.31 (d, J= 9.2Hz, 
1H), 6.66-6.69 (m, 3H), 6.76-6.78 (m, 2H). 
 
 
(R,E)-3-(4-((1-(3,4-Dimethoxyphenyl)propan-2-yl)(methyl)amino)but-2-enyl)-7,8-
dimethoxy-1H-benzo[d]azepin-2(3H)-one; (R)-62  
It was synthesized following the procedure described 
for (S)-62, starting from (R)-31 (0.0005 mol; 0.10 g), 
trans-28 (0.15 g; 0.0005 mol), dry triethylamine 
(0.07 mL; 0.0005 mol) and dry CH3CN (7 mL). (R)-
62 was obtained as a whitish solid: 41%; mp 88 °C; [α]20D = -3.5° (c=1; CHCl3). The 
1H NMR spectrum was identical to that of (S)-62. 
 
 
(S,E)-3-(4-(((4,5-Dimethoxy-1,2-dihydrocyclobutabenzen-1-yl)methyl)(methyl) 
amino)but-2-enyl)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one; (S)-63 
Under nitrogen atmosphere, a solution of trans-28 
(0.15 g; 0.0005 mol), dry triethylamine (0.07 mL; 
0.0005 mol) and (S)-32 (0.10 g; 0.0005 mol) in dry 
CH3CN (4 mL) was stirred for 48 hours at room temperature. The solvent was removed 
under vacuum and the residue was dissolved in ethyl acetate and washed with aqueous 
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NaHCO3 (saturated solution; 3 × 15 mL). The organic layers were collected, dried 
(Na2SO4) and evaporated under vacuum. The residue was purified by flash 
chromatography (eluent: dichloromethane-methanol-ammonia, 95:5:0.5). (S)-63 was 
obtained as a yellow solid: 40%; mp 60-62 °C; [α]20D = +19.6° (c=1; CHCl3). 
e.e.=97.6% (determined by chiral HPLC); 1H NMR (CDCl3) δ 2.27 (s, 3H), 2.53 (dd, 
J=12.8 Hz, J=8.8 Hz, 1H), 2.68-2.75 (m, 2H), 3.00-3.09 (m, 2H), 3.25 (dd, J=12.8 Hz, 
J=5.2 Hz, 1H), 3.43 (s, 2H), 3.51-3.58 (m, 1H), 3.82 (s, 3H), 3.83 (s, 3H), 3.84 (s, 3H), 
3.87 (s, 3H), 4.14 (d, J=5.2 Hz, 2H), 5.52-5.65 (m, 2H), 6.14 (d, J=9.2 Hz, 1H), 6.29 (d, 
J=9.2 Hz, 1H), 6.68 (s, 2H), 6.70 (s, 1H), 6.77 (s, 1H); 13C NMR (CDCl3, APT) δ 
35.39, 40.77, 42.48, 43.25, 49.97, 56.07, 56.34, 56.42, 59.67, 61.35, 106.85, 107.53, 
109.55, 111.30, 117.20, 124.75, 126.49, 127.98, 128.46, 130.28, 135.06, 138.76, 
148.11, 149.43, 149.96, 167.60. 
 
 
(R,E)-3-(4-(((4,5-Dimethoxy-1,2-dihydrocyclobutabenzen-1-yl)methyl)(methyl) 
amino)but-2-enyl)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one; (R)-63 
It was synthesized following the procedure 
described for (S)-63, starting from trans-28 (0.08 g; 
0.0003 mol), dry triethylamine (0.04 mL; 0.0003 
mol) and (R)-32 (0.06 g; 0.0003 mol). (R)-63 was 
obtained as a pale yellow solid: 37%; mp 65-68 0C; [α]20D = -10.9° (c=0.34; CHCl3). 
e.e.=87.5% (determined by chiral HPLC). NMR spectra were identical to those of (S)-
63. 
 
 
(R,E)-3-(4-((2-(3,4-Dimethoxyphenyl)propyl)(methyl)amino)but-2-enyl)-7,8-dimethoxy-
1H-benzo[d]azepin-2(3H)-one; (R)-64 
It was synthesized following the procedure described 
for (S)-63, starting from trans-28 (0.32 g; 0.001 
mol), dry triethylamine (0.13 mL; 0.001 mol) and 
(R)-61 (0.20 g; 0.001 mol). (R)-64 was obtained as a 
pale yellow solid: 54%; mp 60-62 0C; [α]20D = -11.4° (c=1; CHCl3); 1H NMR (CDCl3) 
δ 1.14 (d, J=6.8 Hz, 3H), 2.11 (s, 3H), 2.28-2.40 (m, 2H), 2.74-2.96 (m, 3H), 3.39 (s, 
2H), 3.77 (s, 3H), 3.83 (s, 3H), 3.81 (s, 6H), 4.02-4.15 (m, 2H), 5.39-5.53 (m, 2H), 6.12 
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(d, J=9.2 Hz, 1H), 6.30 (d, J=9.2 Hz, 1H), 6.65-6.75 (m, 5H); 13C NMR (CDCl3, APT) 
δ 20.28, 37.43, 42.43, 43.02, 48.76, 55.76, 55.81, 56.00, 59.39, 64.43, 109.37, 110.50, 
111.08, 111.12, 116.89, 118.70, 124.51, 126.29, 127.61, 127.68, 130.42, 138.59, 
147.18, 147.87, 148.65, 149.71, 167.28. 
 
 
(S,E)-3-(4-((2-(3,4-Dimethoxyphenyl)propyl)(methyl)amino)but-2-enyl)-7,8-dimethoxy-
1H-benzo[d]azepin-2(3H)-one; (S)-64 
It was synthesized following the procedure described 
for (S)-63, starting from trans-28 (0.32 g; 0.001 
mol), dry triethylamine (0.13 mL; 0.001 mol) and 
(S)-61 (0.20 g; 0.001 mol). (S)-64 was obtained as a pale yellow solid: 9%; mp 59-61 
0C; [α]20D = +6.4° (c=1; CHCl3). NMR spectra were identical to those of (R)-64. 
 
 
3,3'-(2E,2'E)-4,4'-((R)-2-(3,4-Dimethoxyphenyl)propylazanediyl)bis(but-2-ene-4,1-
diyl)bis(7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one); (R)-65 
It was synthesized following the procedure 
described for (S)-63, starting from trans-28 
(0.445 g; 0.00145 mol) and (R)-33 (0.141 g; 
0.00072 mol). (R)-65 free base was obtained 
as a pale yellow solid: 7%; mp 89-93 0C; 
[α]20D = -14.7° (c=1; CHCl3). 
Due to the impossibility to purify the 
compound, the free base was converted into the HCl salt: [α]20D = +12.5° (c=1; 
CD3OD); 1H NMR (CDCl3) δ 1.13 (d, J=6.0 Hz, 3H), 2.87-3.10 (m, 3H), 3.19-3.49 (m, 
4H), 3.45 (s, 4H), 3.79 (s), 3.81 (s), 3.82 (s), 3.83 (s), 3.85 (s) (18H), 4.01-4.23 (m, 
4H), 5.08-5.26 (m, 2H); 5.51-5.61 (m, 1H), 5.66-5.74 (m, 1H), 6.24-6.29 (m, 2H), 
6.49-6.52 (m, 1H), 6.65 (d, J=8.0 Hz, 1H), 6.82-6.91 (m, 7H); 13C NMR (CD3OD, 
APT) δ 21.38, 36.65, 43.34, 49.96, 54.85, 56.57, 56.64, 56.78, 59.01, 111.51, 112.29, 
112.64, 113.70, 119.51, 119.59, 119.83, 120.49, 126.19, 127.86, 129.20, 135.45, 
138.79, 138.84, 149.81, 150.13, 151.15, 161.70, 169.48. 
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3,3'-(2E,2'E)-4,4'-((S)-2-(3,4-Dimethoxyphenyl)propylazanediyl)bis(but-2-ene-4,1-
diyl)bis(7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one); (S)-65 
It was synthesized following the procedure 
described for (S)-63, starting from trans-28 
(0.445 g; 0.00145 mol) and (S)-33 (0.141 g; 
0.00072 mol). (S)-65 was obtained as a pale 
yellow solid: 6%; mp 84-87 0C. NMR spectra 
were identical to those of (R)-65. Free base: 
[α]20D = +11.5° (c=1; CHCl3); HCl salt [α]20D = -13.1° (c=1; CD3OD). 
 
 
3,3'-(2Z,2'Z)-4,4'-(3,4-Dimethoxyphenethylazanediyl)bis(but-2-ene-4,1-diyl)bis(7,8-
dimethoxy-1H-benzo[d]azepin-2(3H)-one); 66 
Under nitrogen atmosphere, a solution of cis-
28 (0.17 g; 0.0006 mol), dry triethylamine 
(0.04 mL; 0.0003 mol) and homoveratrylamine 
(0.05 g; 0.0003 mol) in dry CH3CN (10 mL) 
was stirred at reflux for 16 hours. The solvent 
was removed under vacuum and the residue 
was taken up with dichloromethane and washed with 2M NaOH (3 × 15 mL). The 
organic layers were collected, dried (Na2SO4) and evaporated under vacuum. The 
residue was purified by flash chromatography (eluent: dichloromethane-methanol-
ammonia, 97:3:0.3). 66 was obtained as a pale yellow solid: mp 60-62 °C; 1H NMR 
(CDCl3) δ 2.69 (bs, 4H, CH2CH2); 3.22  (d, J=6.4 Hz, 4H, 2 x CH=CHCH2N); 3.42 (s, 
4H, 2 x CH2CO); 3.81 (s, 3H, OCH3); 3.83 (s, 6H, 2 x OCH3); 3.85 (s, 6H, 2 x OCH3); 
3.87 (s, 3H, OCH3); 4.22 (d, J=6.8 Hz, 4H, 2 x CH=CHCH2NCO); 5.42-5.48 (m, 2H, 2 
x NCH2CH=CHCH2NCO); 5.62-5.68 (m, 2H, 2 x NCH2CH=CHCH2NCO); 6.16 (d, 
J=9.2 Hz, 2H, 2 x ArCH=CHNCO); 6.31 (d, J=9.2 Hz, 2H, 2 x ArCH=CHNCO); 6.68-
6.78 (m, 7H, aromatics); 13C NMR (CDCl3, APT) δ 33.05, 43.08, 44.52, 50.55, 55.63, 
55.79, 55.83, 55.88, 109.50, 111.15, 111.19, 112.04, 117.18, 120.46, 124.56, 126.28, 
127.45, 127.55, 130.55, 132.79, 147.26, 147.97, 148.74, 149.84, 167.39. 
 
 
(R)-tert-Butyl 2-(3,4-dimethoxyphenyl)propylcarbamate; (R)-67 
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Under nitrogen atmosphere, di-tert-butyl-dicarbonate (0.15 g; 
0.0012 mol) in dry THF (5 mL) was added dropwise to a solution (0 
°C) of (R)-33 (0.15 g; 0.0007 mol) in dry THF (5 mL). The mixture 
was stirred for 15 hours at room temperature. Removal of the solvent afforded a residue 
that was taken up in dichloromethane and washed with brine. The organic layers were 
collected, dried (Na2SO4) and evaporated to give a crude that was purified by flash 
chromatography (eluent: dichloromethane-methanol, 98:2). (R)-67 was obtained as a 
pale yellow oil: 0.18 g; 0.0006 mol; 78%; [α]20D = +48.5° (c=1; CHCl3); 1H NMR 
(CDCl3) δ 1.23 (d, J=7.2 Hz, 3H), 1.41 (s, 9H), 2.83-2.88 (m, 1H), 3.10-3.17 (m, 1H), 
3.35-3.37 (m, 1H), 3.86 (s, 3H), 3.87 (s, 3H), 4.43 (bs, 1H), 6.71-6.75 (m, 2H), 6.82 (d, 
J=8.0 Hz, 1H). 
 
 
(R)-tert-Butyl allyl(2-(3,4-dimethoxyphenyl)propyl)carbamate; (R)-68 
Under anhydrous condition, sodium hydride (0.04 g; 0.0009 mol) 
and allyl bromide (0.08 ml; 0.0009 mol) were added to a solution (0 
°C) of (R)-67 (0.18 g; 0.0006 mol) in dry DMF (30 mL). After 
stirring for 90 minutes at 0 °C, the reaction mixture was stirred for 24 hours at room 
temperature. The reaction was then quenched with aqueous NH4Cl (saturated solution) 
and extracted with ethyl acetate. The organic layers were collected, dried (Na2SO4) and 
evaporated to give a residue that was purified by flash chromatography (eluent: 
cyclohexane-ethyl acetate, 4:1). (R)-68 was obtained as a clear oil: 0.082 g; 0.0002 
mol; 33%; [α]20D = +60.8° (c=1; CHCl3); 1H NMR (CDCl3) δ 1.31 (d, J=13.2Hz, 3H), 
1.43 (s, 9H), 3.00-3.15 (m, 2H), 3.23-3.39 (m, 1H), 3.42-3.57 (m, 1H), 3.66-3.87 (m, 
3H), 3.81 (s, 3H), 3.85 (s, 3H), 4.98-5.08 (m, 2H), 5.55-5.77 (m, 1H), 6.68-6.82 (m, 
3H). 
 
 
(R)-tert-Butyl benzyl(2-(3,4-dimethoxyphenyl)propyl)carbamate; (R)-69 
It was synthesized following the procedure described for (R)-68, 
starting from (R)-67 (0.22 g; 0.0007 mol), sodium hydride (0.05 g; 
0.0011 mol) and benzyl bromide (0.13 ml; 0.0011 mol). It was 
purified by flash chromatography (eluent: cyclohexane-ethyl 
acetate, 99:1). (R)-69 was obtained as a clear oil: 0.19 g; 0.0005 mol; 71%; [α]20D = 
+51.7° (c=1; CHCl3); 1H NMR (CDCl3) δ (2 rotamers: x and y) 1.21 (d, J=6.8Hz, 
  79 
3Hx+3Hy), 1.40 (s, 9Hy), 1.47 (s, 9Hx), 3.02-3.14 (m, 3H), 3.27-3.30 (m, 1H), 3.52-3.54 
(s, 1H), 3.83 (s, 3H), 3.84 (s, 3H), 3.84-3.87 (m, 1Hy), 4.00 (d, J=15.6 Hz, 1Hx), 4.37 
(d, J=16.0 Hz, 1Hy), 4.48 (d, J=15.6 Hz, 1Hx), 6.62-6.80 (m, 3H), 7.08-7.34 (m, 5H). 
 
 
(R)-tert-Butyl but-2-enyl(2-(3,4-dimethoxyphenyl)propyl)carbamate; (R)-70 (E+Z 
mixture) 
It was synthesized following the procedure described for (R)-68, 
starting from (R)-67 (0.18 g; 0.0006 mol), sodium hydride (0.05 g; 
0.0012 mol) and crotyl bromide (0.10 ml; 0.0012 mol). It was 
purified by flash chromatography (eluent: cyclohexane-ethyl acetate, 99:1). (R)-70 
(E+Z mixture) was obtained as a clear oil: 0.13 g; 0.0004 mol; 67%; [α]20D = +55.0° 
(c=1; CHCl3); 1H NMR (CDCl3) δ 1.19 (d, J=6.8 Hz, 3H), 1.41 (s, 9H), 1.62 (d, J=6.0 
Hz, 3H), 2.90-3.17 (m, 1H), 3.18-3.42 (m, 1H), 3.36-3.52 (m, 1H), 3.53-3.79 (m, 2H), 
3.82 (s, 3H), 3.84 (s, 3H), 5.27-5.60 (m, 2H), 6.66-6.79 (m, 3H). 
 
 
(R)-N-(2-(3,4-Dimethoxyphenyl)propyl)prop-2-en-1-amine; (R)-71 
Trifluoroacetic acid (0.40 mL) was slowly added to a solution of (R)-
68 (0.08 g; 0.00024 mol) in dichloromethane (1 mL) and. The mixture 
was stirred for 90 minutes at room temperature. Removal of the 
solvent  gave a residue that was taken up with aqueous NaHCO3 (saturated solution) 
and extracted with ethyl acetate. The organic layers were collected, dried (Na2SO4) and 
evaporated to afford (R)-71 as a yellow oil: 0.05 g; 0.00021 mol; 89%; [α]20D = +9.5° 
(c=1; CHCl3); 1H NMR (CDCl3) δ 1.24 (d, J=6.8 Hz, 3H), 1.90 (bs, 1H), 2.70-2.76 (m, 
2H), 2.78-2.92 (m, 1H), 3.18-3.25 (m, 2H), 3.85 (s, 3H), 3.87 (s, 3H), 5.04-5.14 (m, 
2H), 5.78-5.88 (m, 1H), 6.77-6.82 (m, 3H). 
 
 
(R)-N-benzyl-2-(3,4-dimethoxyphenyl)propan-1-amine; (R)-72  
It was synthesized following the procedure described for (R)-71, 
starting from (R)-69 (0.18 g; 0.00047 mol), dichloromethane (2.3 
mL) and trifluoroacetic acid (0.93 ml). (R)-72 was obtained as a 
clear oil: 0.12 g; 0.00042 mol; 90%; [α]20D = +13.4° (c=1; CHCl3); 1H NMR (CDCl3) δ 
1.25 (d, J=6.8 Hz, 3H), 2.36 (bs, 1H), 2.77-2.79 (m, 2H), 2.89-2.98 (m, 1H), 3.73 (d, 
  80 
J=13.2 Hz, 1H), 3.80 (d, J=13.2 Hz, 1H), 3.85 (s, 3H), 3.86 (s, 3H), 6.72 (d, J=1.6 Hz, 
1H), 6.76 (dd, J=8.0 Hz, J=1.6 Hz, 1H), 6.82 (d, J=8.0 Hz, 1H), 7.22-7.30 (m, 5H). 
 
 
(R)-N-(2-(3,4-Dimethoxyphenyl)propyl)but-2-en-1-amine; (R)-73 (E+Z mixture) 
It was synthesized following the procedure described for (R)-71, 
starting from (R)-70 (0.13 g; 0.00037 mol), dichloromethane (1.8 
mL) and trifluoroacetic acid (0.71 ml). (R)-73 (E+Z mixture) was 
obtained as a clear oil: 0.09 g; 0.00036 mol; 98%; [α]20D = +8.0° 
(c=1; CHCl3); 1H NMR (CDCl3) δ (ratio E/Z=2.7/1) 1.24 (d, J= 7.2 Hz, 3H), 1.59 (d, J= 
6.8 Hz, 3HZ), 1.64 (d, J= 6.0 Hz, 3HE), 2.76-2.80 (m, 2H), 2.89-2.96 (m, 1H), 3.16 (d, 
J= 6.4 Hz, 1HE), 3.27 (d, J= 6.8 Hz, 1HZ), 3.82 (s, 3H), 3.85 (s, 3H), 5.37-5.48 (m, 1H), 
5.54-5.62 (m, 1H), 6.72-6.80 (m, 3H). 
 
 
(R,Z)-3-(4-(Allyl(2-(3,4-dimethoxyphenyl)propyl)amino)but-2-enyl)-7,8-dimethoxy-1H-
benzo[d]azepin-2(3H)-one; (R)-74 
Under anhydrous condition, dry triethylamine 
(0.043 mL; 0.0003 mol) was added to a solution of 
(R)-71 (0.05 g; 0.0003 mol) in dry CH3CN (2 mL). 
The resulting mixture was poured into a solution of 
cis-28 (0.08 g; 0.0003 mol) in dry CH3CN (2 mL). The reaction mixture was stirred for 
24 hours at room temperature. Removal of the solvent gave a residue that was taken up 
with aqueous NaHCO3 (saturated solution) and extracted with dichloromethane. The 
organic layers were collected, dried (Na2SO4) and evaporated to afford a residue that 
was purified by flash chromatography (eluent: dichloromethane-methanol, 99:1). (R)-
74 was obtained as a grayish oil: 0.03 g; 0.00006 mol; 24%; [α]20D = +26.7° (c=1; 
CHCl3); 1H NMR (CDCl3) δ 1.22 (d, J=6.8Hz, 3H), 2.46 (dd, J=12.8Hz, J=7.6Hz, 1H), 
2.56 (dd, J=12.8 Hz, J=6.8 Hz, 1H), 2.82-2.90 (m, 1H), 3.02 (dd, J=14.2 Hz, J=6.6Hz, 
1H), 3.08-3.19 (m, 3H), 3.43 (s, 1H), 3.84 (s, 3H), 3.86 (s, 3H), 3.87 (s, 3H), 3.88 (s, 
3H), 4.11-4.23 (m, 2H), 5.10-5.16 (m, 2H), 5.37-5.43 (m, 1H), 5.63-5.71 (m, 1H), 5.75-
5.85 (m, 1H), 6.12 (d, J=9.2Hz, 1H), 6.30 (d, J=9.2Hz, 1H), 6.71-6.73 (m, 2H), 6.77-
6.80 (m, 3H); 13C NMR (CDCl3, APT) δ 20.86, 29.79, 37.17, 43.19, 44.62, 50.89, 
56.02, 56.09, 56.98, 60.66, 109.74, 110.83, 111.32, 111.46, 117.62, 119.07, 124.69, 
126.42, 127.66 129.02, 137.85, 147.73, 148.23, 149.08, 150.11, 167.62. 
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(R,Z)-3-(4-(Benzyl(2-(3,4-dimethoxyphenyl)propyl)amino)but-2-enyl)-7,8-dimethoxy-
1H-benzo[d]azepin-2(3H)-one; (R)-75 
It was synthesized following the procedure 
described for (R)-74, starting from (R)-72 (0.12 g; 
0.0007 mol), cis-28 (0.22 g; 0.0007 mol), dry 
triethylamine (0.10 ml; 0.0007 mol) and dry CH3CN (10 mL). (R)-75 was obtained as a 
white solid: 0.13 g; 0.0003 mol; 42%; mp 105 °C (HCl salt); [α]20D (free base)= -12.5° 
(c=1; CHCl3); 1H NMR (CDCl3) δ 1.21 (d, J=6.8 Hz, 3H), 2.45-2.50 (m, 1H), 2.56-2.59 
(m, 1H), 2.88-2.90 (m, 1H), 3.11-3.12 (m, 2H), 3.42 (s, 2H), 3.55-3.58 (m, 2H), 3.81 
(s, 3H), 3.86 (s, 3H), 3.88 (s, 3H), 3.89 (s, 3H), 4.00-4.18 (m, 2H), 5.39-5.42 (m, 1H), 
5.61-5.63 (m, 1H), 6.05-6.07 (m, 1H), 6.27-6.29 (m, 1H), 6.64-6.79 (m, 5H), 7.20-7.28 
(m, 5H); 13C NMR (CDCl3, APT) δ 20.28, 37.99, 43.27, 44.62, 50.84, 55.90, 56.01, 
58.96, 61.91, 109.65, 110.80, 111.20, 111.35, 117.20, 119.22, 124.67, 126.49, 126.90, 
127.18, 127.77, 128.20, 128.92, 131.42, 138.91, 139.75, 147.38, 148.14, 148.82, 
150.01, 167.55. 
 
 
3-((Z)-4-((E/Z)-But-2-enyl((R)-2-(3,4-dimethoxyphenyl)propyl)amino)but-2-enyl)-7,8-
dimethoxy-1H-benzo[d]azepin-2(3H)-one; (R)-76 
(E+Z mixture) 
It was synthesized following the procedure 
described for (R)-74, starting from (R)-73 (0.10 g; 
0.0008 mol), cis-28 (0.24 g; 0.0008 mol), dry triethylamine (0.10 ml; 0.0008 mol) and 
dry CH3CN (10 mL). (R)-76 (E+Z mixture) was obtained as a white solid: 0.13 g; 
0.0003 mol; 42%; mp 71 °C; [α]20D = +5.8° (c=1; CHCl3); 1H NMR (CDCl3) δ (ratio 
E/Z=2.7/1) 1.21 (d, J=6.8 Hz, 3HZ), 1.20 (d, J=6.8 Hz, 3HE), 1.61 (d, J=6.8 Hz, 3HZ), 
1.67 (d, J=6.4 Hz, 3HE), 2.40-2.46 (m, 1H), 2.51-2.55 (m, 1H), 2.80-2.88 (m, 1H), 
2.92-2.99 (m, 2H), 3.01-3.15 (m, 2H), 3.41 (s, 2H), 3.82 (s, 3H), 3.84 (s, 3H), 3.85 (s, 
3H), 3.86 (s, 3H), 4.10-4.22 (m, 2H), 5.35-5.44 (m, 2H), 5.49-5.63 (m, 2H), 6.10-6.12 
(d, J=9.2 Hz, 1H), 6.27-6.29 (d, J=9.2 Hz, 1H), 6.70-6.72 (m, 3H), 6.76-6.78 (m, 2H); 
13C NMR (CDCl3, APT) δ 13.19, 17.87, 20.42, 21.88, 37.78, 43.18, 44.52, 50.55, 
50.70, 50.94, 55.87, 55.90, 55.99, 56.37, 61.19, 61.49, 109.59, 110.70, 111.22, 111.27, 
117.13, 119.05, 124.69, 126.43, 127.00, 127.17, 127.25, 127.69, 127.82, 128.79, 
130.97, 131.06, 138.90, 147.33, 148.07, 148.80, 149.93, 167.52, 174.97. 
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3-(3-Chloropropyl)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one; (SB4) 
It was synthesized following the procedure described for cis-28, 
starting from 14 (0.019 mol; 4.1 g), potassium terbutoxyde (0.023 
mol; 2.5 g) and 1-bromo-3-chloropropane (0.023 mol; 2.2 mL). 
SB4 was obtained as a yellow-brown solid: 55%; mp 104-106 °C; 1H NMR (CDCl3) δ 
1.95-2.02 (m, 2H), 3.41-3.45 (m, 4H), 3.70 (t, J=6.4 Hz, 2H), 3.88 (s, 3H), 3.89 (s, 3H), 
6.23 (d, J=9.2 Hz, 1H), 6.35 (d, J=9.2 Hz, 1H), 6.73 (s, 1H), 6.78 (s, 1H). 
 
 
3-(3-Iodopropyl)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one; 77 
NaI (0.41 g; 0.003 mol) was added to a solution of SB4 (0.40 g; 
0.001 mol) in acetone (20 mL). The reaction mixture was stirred 
for 48 hours at reflux. After removal of the solvent, the residue 
was taken up with ethyl acetate and washed with brine. The organic layers were 
collected, dried (Na2SO4) and evaporated to afford 77 as a pale yellow solid: 76%; mp 
122-124 °C); 1H NMR (CDCl3) δ 2.00-2.07 (m, 2H), 3.04 (t, J=6.8 Hz, 2H), 3.43 (s, 
2H), 3.64 (t, J=6.4 Hz, 2H), 3.88 (s, 3H), 3.90 (s, 3H), 6.23 (d, J=9.2 Hz, 1H), 6.35 (d, 
J=9.2 Hz, 1H), 6.73 (s, 1H), 6.78 (s, 1H). 
 
 
(S)-3-(3-(((4,5-Dimethoxy-1,2-dihydrocyclobutabenzen-1-yl)methyl)(methyl)amino) 
propyl)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one; (S)-78 
It was synthesized following the procedure described 
for (S)-79, starting from 77 (0.001 mol; 0.39 g), 
Na2CO3 (0.16 g; 0.002 mol), (S)-32 (0.21 g; 0.001 
mol) dissolved in dry DMF (5 mL). (S)-78 was 
purified by flash chromatography (eluent: dichloromethane-methanol-ammonia, 
97:3:0.3) and obtained as a yellow solid: 42%; mp 48-50 °C; [α]20D = +7.0° (c=1; 
CHCl3); e.e.=93.8% (determined by chiral HPLC); 1H NMR (CDCl3) δ 1.64-1.71 (m, 
2H), 2.22 (s, 3H), 2.28 (t, J=6.8 Hz, 2H), 2.45 (dd, J=12.3 Hz, J=8.2 Hz, 1H), 2.61 (dd, 
J=12.3 Hz, J=6.8 Hz, 1H), 2.65 (dd, J=14.4 Hz, J=1.6 Hz, 1H), 3.16 (dd, J=14.4 Hz, 
J=5.0 Hz, 1H), 3.40 (s, 2H), 3.42-3.48 (m, 1H), 3.50-3.68 (m, 2H), 3.81 (s, 3H), 3.82 
(s, 6H), 3.85 (s, 3H), 6.18 (d, J=9.0 Hz, 1H), 6.27 (d, J=9.0 Hz, 1H), 6.66-6.67 (m, 3H), 
6.75 (s, 1H); 13C NMR (CDCl3, APT) δ 26.24, 35.13, 40.62, 42.42, 43.32, 46.21, 54.65, 
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55.98, 56.28, 56.36, 61.86, 106.79, 107.44, 109.39, 111.18, 117.04, 124.78, 126.41, 
128.72, 135.00, 139.02, 147.99, 149.29, 149.81, 167.63. 
 
 
(R)-3-(3-(((4,5-Dimethoxy-1,2-dihydrocyclobutabenzen-1-yl)methyl)(methyl)amino) 
propyl)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one; (R)-78 
It was synthesized following the procedure described 
for (S)-79, starting from 77 (0.001 mol; 0.37 g), 
Na2CO3 (0.14 g; 0.001 mol), (R)-32 (0.18 g; 0.001 
mol) dissolved in dry DMF (5 mL). (R)-78 was obtained as a yellow solid: 49%; mp 
55-60 °C; [α]20D = -6.0° (c=1; CHCl3). e.e.=97.9% (determined by chiral HPLC). The 
NMR were identical to those of (S)-78. 
 
 
(R)-3-(3-(((4,5-Dimethoxy-1,2-dihydrocyclobutabenzen-1-yl)methyl)(methyl)amino) 
propyl)-7,8-dimethoxy-4,5-dihydro-1H-benzo[d]azepin-2(3H)-one; 
(R)-80 (R-Ivabradine) 
Pd/C (10% p/p; 35 mg) was added to a solution of 
(R)-78 (0.07 g; 0.0002 mol) in acetic acid (15 mL). 
The mixture was placed in a Parr apparatus at 60 Psi 
and allowed to react for 24 hours at room temperature. The catalyst was filtered off and 
the filtrate was basified with 2.5M NaOH and extracted with dichloromethane. The 
organic layers were collected, dried (Na2SO4) and removed under vacuum to afford a 
residue, which was purified by flash chromatography (eluent: dichloromethane-
methanol-ammonia, 95:5:0.5). (R)-80 was obtained as a white solid: 24%; mp 55-58 
°C). [α]20D = -5.0° (c=1; CHCl3); 1H NMR (CDCl3) δ 1.74-1.81 (m, 2H), 2.31 (s, 3H), 
2.42 (t, J=6.4 Hz, 2H), 2.45 (dd, J=12.4 Hz, J=8.4 Hz, 1H), 2.69-2.73 (m, 2H), 3.03 (t, 
J=6.4 Hz, 2H), 3.22 (dd, J=13.6 Hz, J=4.8 Hz, 1H), 3.40-3.54 (m, 3H), 3.70 (t, J=6.4 
Hz, 2H), 3.79 (s, 2H), 3.80 (s, 3H), 3.82 (s, 3H), 3.83 (s, 3H), 3.84 (s, 3H), 6.54 (s, 1H), 
6.58 (s, 1H), 6.67 (s, 1H), 6.70 (s, 1H); 13C NMR (CDCl3, APT, δ): 26.38, 32.46, 
35.26, 40.68, 42.57, 42.78, 45.14, 46.69, 55.31, 55.97, 56.31, 56.43, 62.03, 106.87, 
107.50, 113.19, 114.03, 123.55, 127.50, 135.04, 138.95, 147.21, 147.91, 149.38, 
149.90, 172.15. 
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(S)-3-(3-((1-(3,4-Dimethoxyphenyl)propan-2-yl)(methyl)amino)propyl)-7,8-dimethoxy-
1H-benzo[d]azepin-2(3H)-one; (S)-79 
Under anhydrous condition, a solution of (S)-31 
(0.17 g; 0.0008 mol) in dry DMF (6 mL) was added 
to a solution of 77 (0.31 g; 0.0008 mol) and Na2CO3 
(0.13 g; 0.0012 mol) in dry DMF (3 mL). The mixture was stirred for 5 hours at 55 °C. 
Removal of the solvent gave a residue that was taken up with 1N HCl and extracted 
with ethyl acetate. The acidic aqueous phase was then basified with aqueous Na2CO3 
(saturated solution) and extracted with ethyl acetate. The organic layers were collected, 
dried (Na2SO4) and evaporated to afford a residue, which was purified by flash 
chromatography (eluent: absolute ethanol-ammonia-dichloromethane-petroleum ether, 
65:8:340:60). (S)-79 was obtained as a white solid: 0.13 g; 0.0003 mol; 34%; mp 81 
°C). [α]20D = +5.0° (c=1; CHCl3); 1H NMR (CDCl3) δ 0.82 (d, J=6.2 Hz, 3H), 1.65-
1.68 (m, 2H), 2.20 (s, 3H), 2.20-2.25 (m, 1H), 2.33 (t, J=6.6 Hz, 2H), 2.74-2.80 (m, 
2H), 3.39 (s, 2H), 3.52 (t, J=6.8 Hz, 2H), 3.80 (s, 3H), 3.82 (s, 3H), 3.84 (s, 3H), 3.85 
(s, 3H), 6.08 (d, J=9.2 Hz, 1H), 6.28 (d, J=9.2 Hz, 1H), 6.61-6.67 (m, 3H), 6.74-6.76 
(m, 2H). 
 
 
(R)-3-(3-((1-(3,4-Dimethoxyphenyl)propan-2-yl)(methyl)amino)propyl)-7,8-dimethoxy-
1H-benzo[d]azepin-2(3H)-one; (R)-79 
It was synthesized following the procedure described 
for (S)-79, starting from (R)-31 (0.0015 mol; 0.32 g), 
77 (0.59 g; 0.0015 mol), Na2CO3 (0.24 g; 0.0023 
mol) and dry DMF (6 mL). (R)-79 was purified by flash chromatography (eluent: 
absolute ethanol-ammonia-dichloromethane-diethyl ether-petroleum ether, 
180:9.9:360:360:900) and obtained as a white solid: 28%; mp 83 °C; [α]20D = -5.0° 
(c=1; CHCl3). The 1H NMR spectrum was identical to that of (S)-79. 13C NMR 
(CDCl3, APT) δ 13.27, 26.75, 36.20, 38.90, 43.08, 45.95, 50.06, 55.69, 55.74, 60.02, 
109.33, 110.02, 112.42, 116.57, 120.96, 124.63, 126.29, 128.65, 133.22, 147.03, 
147.83, 148.51, 149.65, 167.30. 
 
  85 
“..dove la Natura finisce di produrre le sue spezie, l’uomo quivi comincia con le cose 
naturali, con l’aiutoro di essa Natura, a creare infinite spezie..” 
Leonardo da Vinci 
 
 
 
 
 
 
 
 
 
 
5. RESULTS AND CONCLUSIONS 
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5.1 Biological results 
The compounds were tested on HEK293 cells stably expressing mouse HCN1, mouse 
HCN2, or human HCN4; their ability to block f-current was measured by means of 
patch clamp recording (whole-cell configuration). The experiments were made on the 
three isoforms as shown in figure 1 for 2 (EC32) on HCN1. If was recorded in control 
conditions (A) and in the presence of a 10 mM concentration of 2 (B). The activation 
curve under control conditions (black) and in the presence of 2 (gray) is shown in panel 
C; the midpoint of activation was not modified by the drug, thus suggesting that the 
biophysical property of the current did not change. In panel D the f-current amplitude 
elicited by steps to -120mV in presence of increasing doses (1-30µM) of 2 is shown: 
under these conditions the If amplitude is progressively reduced, showing that the effect 
is use-dependent. This has been demonstrated for all the tested compounds.  
The mean activation curves for compound 1 (EC4) and cis-3 (EC18), tested at the 
dose of 10 mM on the three isoforms are shown in figures 2 and 3. 1 (figure 2) reduces 
If in the three channel isoforms; the reduction at -120mV is more pronounced on HCN1 
(A, 70 %, CTR: 0.95±0.01 pS/pF, n=5; 1: 0.29±0.1 pS/pF, n=3) and HCN4 (B, 44%, 
CTR: 0.89±0.03 pS/pF, n=8; 1: 0.5±0.08 pS/pF, n=7) with respect to HCN2 (C, 34%, 
CTR: 0.83±0.03 pS/pF, n=8; 1: 0.55±0.07 pS/pF, n=8). cis-3 (figure 3) minimally 
reduces HCN1 If at -120mV (A, 7%, CTR 0.96±0.02 pS/pF, n=5; cis-3: 0.89 ±0.02 
pS/pF, n=4); on HCN2 the reduction is about 30% (B), while on HCN4 is much higher 
(C, 70%, CTR 0.92±0.05 pS/pF, n=4; cis-3: 0.3±0.06 ps/pF, n=4).  
For an easier evaluation of the potency of the compounds, the EC50 values for the If 
blocking activity of 1, 2 and cis-3 were determined from the dose-response curve, and 
compared with those of ivabradine, zatebradine and cilobradine, used as reference 
(table 1).  As expected177, ivabradine does not show selectivity for one of the three 
channel isoforms. Although cilobradine and zatebradine in our hands show slightly 
different potencies (cilobradine is more potent on HCN1, while zatebradine is 
equipotent on HCN2 and HCN4 but less potent on HCN1), the ratios between their 
EC50 values on the three isoforms are low (≤ 4); therefore, these compounds too cannot 
be considered isoform-selective.  
The results reported in table 1 show that structural modifications, such as the 
introduction of a double bond on the methylene chain, can change the pharmacological 
profile of zatebradine: in fact, 1, showing a trans butane moiety, is more active on 
HCN1 while 2 (the cis-butene analogue) is equipotent on HCN1 and HCN4 but less 
active on HCN2. A more marked effect is associated to the reduction of the 
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conformational flexibility: in fact cis-3, in which the three-methylene linker has been 
incorporated into a cyclohexane ring, is able to discriminate between HCN4 and 
HCN1. In this respect, it could be very interesting to test its enantiomers, and also its 
geometrical isomer trans-3: work is underway to obtain these molecules. 
Since the linear compounds are synthetically more accessible, we made some 
modifications on 2. First, we investigated the effect of reducing conformational 
flexibility on the basic part of the molecule, synthesizing 34 (MEL41) and 35 
(MEL47). We found that the incorporation of the phenylethylamino group into a 
tetrahydroisoquinoline ring reduced the potency, since 34 is four times less potent than 
2 on HCN1 and HCN4 and equipotent on HCN2. However, the 2-aminomethyl indane 
moiety gives a different result, since 35 is twice less potent than 2 on HCN1 and 
HCN4, but four times more potent on HCN2. 
As a second modification, we introduced a stereogenic center on the ethyl linker, 
while keeping free rotation on this part of the molecule. Therefore, the enantiomers of 
40 were prepared and studied. We found that the R-enantiomer is more active than the 
S-form on HCN1 and HCN2, where the eudismic ratio are 3 and 11, respectively, while 
there is lower potency and no enantioselectivity for the interaction with HCN4. While 
(S)-40 is not selective, the introduction of a methyl group in the R configuration on the 
benzylic position gives another compound [(R)-40] showing a preference for HCN2, 
since this compound is four times and ten times more potent on this isoform than on 
HCN1 and HCN4, respectively.  
Third, we investigated the effect of increasing the size of the molecule by 
introducing a second (7,8-dimethoxybenzazepin-3-yl)butenyl group on the basic 
nitrogen, preparing 66 and the enantiomers of 39. (R)-39 shows an unexpected 
pharmacological profile, with high selectivity for HCN1. As shown in figure 4A, this 
compound markedly reduces If on this isoform, and its activity is significantly lower on 
the other two isoforms. On HCN1 at -120mV If reduction caused by (R)-39 at 10mM is 
about 80% (A, CTR 0.94±0.02 pS/pF, n=5; (R)-39 0.2±0.1pS/pF, n=3), being 40% on 
HCN2 (CTR 0.82±0.05 pS/pF, n=4; 10mM 0.6±0.1pS/pF, n=4) and only 7% on HCN4 
(CTR 0.92±0.09 pS/pF, n=6; (R)-39 0.86±0.1pS/pF, n=5). 66 is much less active than 2 
or (R)-39 on the three isoforms, its potency being similar to that of (S)-39. The 
interaction of 39 with the HCN1 channel is enantioselective (ER = 26), the eutomer 
being once again the R enantiomer; on HCN2 the eudismic ratio is much lower (4) 
while the interaction with HCN4 is not enantioselective.  
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The results of enantioselectivity are somehow puzzling. In fact, in 40 and 39 the 
stereogenic center is located at the same position as in ivabradine, which has the S 
configuration: this enantiomer has been developed as drug due to its higher specificity 
for HCN channels with respect to its R-isomer [(R)-80], which interacts also with K+ 
channels121,178,179. Ivabradine and its R enantiomer show the same potency on cardiac 
HCN channels, but the activity of (R)-80 on homomeric channels has not been reported 
in the literature.  
These reasonings prompted us to make on zatebradine the following structural 
modifications:  
A) The structure of 1 and 2 were hybridized with that of ivabradine, synthesizing 
compounds (S)-63, (S)-37 and their R enantiomers (S)-63 and (S)-37. Moreover, we 
prepared also (R)-80 and its dihydrobenzazepinone analogue(R)-78, and to extend the 
comparison, also the S-form of the latter [(S)-78].  
B) The chiral center was shifted from the benzylic position to the carbon atom alfa 
to the basic nitrogen, to give compounds (R)/(S)-62, (R)/(S)-36 and (R)/(S)-79. 
C) The trans analogues of compounds 40 and 39 (compounds 64 and 65) were 
prepared, in order to study the effect of cis/trans isomerism. 
D) Since (R)-39 has not good drug-like properties (high molecular weight, low 
water solubility of the hydrochloride salt) one of the (7,8-dimethoxybenzazepin-3-
yl)butenyl groups on the basic nitrogen has been replaced by a smaller unsaturated 
moiety, such as allyl, benzyl and crotyl, obtaining compounds (R)-74, (R)-75 and (R)-
76. 
Since the determination of EC50 is time-consuming, in order to have a preliminary 
indication of the activity of the compounds, we decided to speed-up the experiments by 
measuring the percentage of If blockade by the compounds at a fixed dose (5 mM) on 
HCN1 and HCN4 channels, the two most interesting isoforms. By this way, we could 
select the most interesting substances on which a better characterization should be 
performed. Unfortunately, only few of the synthesized compounds have been tested so 
far, and for this reason we can derive only limited structure-activity relationships. 
The results of the tested compounds are reported in table 2, in comparison with their 
close analogues. The trans derivatives are always less active than their cis analogues as 
we can see comparing (R)-64 with (R)-40, (R)-65 with (R)-39 and (S)-65 with (S)-39, 
and (S)-63 with (S)-37. When enantiomeric couples have been tested [(R)-65 and (S)-
65], also in the trans series the eutomer is the R isomer. (S)-37, the hybrid between 2 
and ivabradine, shows high potency (the If is reduced by > 40%) but it is not selective 
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for HCN1 or HCN4, while (S)-63, its trans analogue, reduces If on HCN1 (19 %) but 
does not show activity on HCN4. 
We calculated the ratio between the EC50 values as a measure of the selectivity of 
the compounds for one isoform over the others. We arbitrary select the value 5 as 
threshold for selectivity, considering isoform-selective a compound showing a ratio 
higher than 5. The selectivity ratios are reported in figure 5. According to this criterion, 
cis-3, (R)-40, (R)-39 and 1 can be considered isoform-selective. cis-3 is more active on 
HCN4, the selectivity ratios being 17 and 6 for, respectively, HCN4 vs HCN2 and 
HCN4 vs HCN1. (R)-40 shows selectivity for HCN2 over HCN4, with a ratio of 11, 
but it does not discriminate between HCN1 and HCN2. 1 is more potent on HCN1 than 
on HCN2 (ratio = 7.5) but it does not discriminate between HCN1 and HCN4. (R)-39 is 
the most potent and selective compounds among those tested so far, since its activity is 
170-fold and 30-fold higher on HCN1 than, respectively, on HCN4 and HCN2.  
Selective compounds may be useful as drugs, providing they have high specificity 
for HCN with respect to other ion channels: for instance, a HCN1 selective blocker 
may be useful for the treatment of neuropathic pain33, a HCN4 selective inhibitor can 
be useful to control sinus node rhythm and ventricular arrhythmia69, a HCN2 selective 
compound may be useful to study the role of If in pathologies where HCN2 channels 
are overexpressed (i.e. cardiac hypertrophy). Moreover, they may be important tools to 
study the stoichiometry of the channels in native tissues (as reported in the 
introduction, there is evidence that in vivo the channels may be heteromeric, but the 
exact composition is not known), providing that they are specific for HCN channels 
and do not modulate other ion currents, especially at the cardiac level. Therefore, it is 
important to determine the effect of our compounds on other ion currents; these 
experiments are carried out at present in the laboratory of Prof. Andras Varro at the 
University of Szeged (Hungary) 
 
 
5.2 Conclusions 
Our data show that, by manipulating the chemical structure of phenylalkylamines 
related to zatebradine, it is possible to achieve selectivity, at least on the homomeric 
channels. The compounds reported in this work represent analogues with different 
steric and conformational characteristics, and some of them show a different preference 
for the homomeric HCN channel isoforms. Selectivity may be related to the ability of 
these compounds to adopt different conformations, to the presence of specific 
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interactions due to the introduction of additional moieties, or to the different shape or 
volume of the molecules. Work is underway to derive sound structure activity 
relationships in this class of compounds in order to optimize their potency and 
selectivity. 
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“..quegli che pigliavano per altore altro che la Natura, maestra de’ maestri, 
s’affaticavano invano..” 
Leonardo da Vinci 
 
 
 
 
 
 
 
 
 
 
6. BIOLOGICAL METHODS 
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These experiments were carried out at the department of Preclinical and Clinical 
Pharmacology by the group of Prof. Alessandro Mugelli and Prof. Elisabetta Cerbai. 
 
Materials and Methods: 
6.1 Cell culture and isolation 
Human embryonic kidney cells, transfected with mHCN1, mHCN2 and hHCN4 cDNA 
were cultured in DMEM medium (Gibco, DMEM + GlutaMaxTM-I x1) supplemented 
with 10% fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin, 200 
µg/ml G418 (Gibco) in T25 flasks and incubated at 37 °C with 5% CO2. When 
confluent (3-5 days after plating), cells were detached using an enzymatic dissociation 
with trypsin-EDTA. Digestion was stopped by adding medium, and the sedimented 
cells were either re-plated or used for electrophysiological measurements.  
Electrophysiological Recordings 
Prior to electrophysiological recordings, HEK293 cells were incubated in normal 
Tyrode’s solution for 2-3 hours at room temperature. Measurement of f-current was 
performed by patch-clamp technique in the whole-cell configuration. The experimental 
set-up for patch-clamp (whole-cell) recording and data acquisition was similar to that 
described previously. Patch-clamp pipette had a resistance of 4.5-6.5 MΩ when filled 
with the internal solution. The patch-clamped cell was superfused by means of a 
temperature-controlled microsuperfusor, allowing rapid changes of the solution bathing 
the cell. Temperature was maintained in the range of 36 ± 0.5 °C. Cell membrane 
capacitance (Cm) was measured by applying a ± 20mV pulse from holding potential of 
-40mV. The f-current was evoked from a holding potential of -20mV to more negative 
voltages in a range of -40 to -150, in 10mV increments. Cells were superfused with a 
modified Tyrode’s solution. After recording If properties in control conditions, the cells 
were superfused with solutions containing one of the test compounds. If amplitude was 
measured as the difference between the steady-state current and the peak current, 
measured at the end and the beginning of the hyperpolarizing step, respectively and 
normalized to Cm. Dose-effect curves were fitted by using the Hill equation: y= 
Emax[xn/( kn+xn)] where Emax is the maximum effect, k corresponded to EC50, 
concentration at which 50% Emax is obtained, x the drug’s concentration and n the 
coefficient of Hill. All the results were expressed like mean ± s.e. 
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6.2 Solutions 
The composition of solutions used was the following (in mmol):  Tyrode’s solution: D-
(+)-glucose 10, NaCl 140, KCl 5.4, MgCl2 1.2, CaCl2 1.8, HEPES-NaOH 5.0, (pH 7.3); 
modified Tyrode’s solution:  Tyrode’s solution containing 25mM KCl in order  to 
amplify If. Pipette solution: K-aspartate 130; Na2-ATP 5, MgCl2 2, CaCl2 5, EGTA 11, 
HEPES-KOH 10 (pH 7.2; pCa 7.0). Drug solutions were obtained from stock solutions 
(10-2M) in water and diluted in the different modified Tyrode’s solution to reach the 
final concentration (range 1 -30 µM). 
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6.3 Figures and Charts 
 
Figure 1. Effect of 2 (EC32) on HCN1. A: Current recordings at -120mV in control condition (A) and 
superfusing with 2 10µM (B). C: Activation curve of If current in absence (black line) and in presence of 
2 10µM (grey line). D: f-current amplitude elicited by steps to -120mV in presence of increasing doses 
(1-30µM) of 2. 
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Figure 2. Effect of 1 (EC4) 10µM on HEK293 cells expressing HCN1 (A), HCN2 (B) and HCN4 (C).  
 
 
 
 
 
Figure 3. Effect of cis-3 (EC18) 10µM on HEK293 cells expressing HCN1 (A), HCN2 (B) and HCN4 
(C).  
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Figure 4. Effect of (R)-39 (MEL57A) 10µM on HEK293 cells expressing HCN1 (A), HCN2 (B) and 
HCN4 (C).  
 
 
 
 
 
 
Figure 5. Selectivity ratios of selected compounds on the three channel isoforms. Blue: HCN1/HCN2. 
Red: HCN4/HCN1. Green: HCN4/HCN2 
 
 
 
 
 
 
 
     1       2 cis-3      34      35 (R)-40 (R)-39 cilo iva zat
e 
173 
  97 
Table 1. If-blocking potency of selected compounds in comparison with ivabradine, cilobradine and 
zatebradine. 
 
a Mouse HCN channel expressed in HEK 293 cells. b Eudismic Ratio: ratio between the activity of the 
two enantiomers. c Human HCN channel expressed in HEK 293 cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
compound 
EC50 (µM) 
mHCN1a 
ERb 
EC50 (µM) 
mHCN2a 
ERb 
EC50 (µM) 
hHCN4c 
ERc 
1 (EC4) 2.31 ± 0.37 - 17.22 ± 1.74 - 7.23 ± 2.60 - 
2 (EC32) 5.60 ± 0.26 - 24.58 ± 4.89 - 6.81 ± 0.37 - 
cis-3 (EC18) 30.82 ± 0.95 - 87.15 ± 25.61 - 5.19 ± 0.63 - 
34 (MEL41) 25.5 ± 3.22 - 19.2 ± 9.20 - 27.68 ± 7.40 - 
35 (MEL47) 12.34 ± 0.20 - 5.78 ± 4.30 - 13.63 ± 2.00 - 
R40 (MEL55A) 9.41 ± 0.25 2.3 ± 0.60 24.94 ± 0.10 
S40 (MEL55B) 31.27 ± 6.69 
3 
25.47 ± 3.70 
11 
31.59 ± 3.49 
1 
66 (PK1) 106.9 ± 49.9 - 147.4 ± 0.62 - 70.67 ± 23.80 - 
R39 (MEL57A) 0.60 ± 0.07 18.3 ± 0.14 103.78 ± 29.80 
S39 (MEL57B) 17.94 ± 0.48 
26 
50.11 ± 11.9 
4 
135.73 ± 74.70 
1 
Ivabradine 4.50 ± 0.44 - 4.52 ± 2.82 - 4.28 ± 0.40 - 
Zatebradine 16.78 ± 0.9 - 5.45 ± 1.04 - 8.57 ±1.85 - 
Ciloradine 4.66 ± 1.44 - 20.47 ± 4.77 - 12.01 ± 3.78 - 
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Table 2. Blockade of If at 5 mM, in comparison with ivabradine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Mouse HCN channel expressed in HEK 293 cells. c Human HCN channel expressed in HEK 293 cells.  
 
 
 
 
 
 
 
 
 
compound 
mHCN1a 
(%) 
hHCN4c 
(%) 
1 (EC4) 64.9 43.7 
2 (EC32) 47.4 41.0 
S63 (PK8) 19.0 0 
S37 (PK9) 45.3 42.7 
R64 (PK10) 13.2 24.2 
S64 (PK11) / / 
R40 (MEL55A) 37.5 17.1 
S40 (MEL55B) 9.2 10 
66 18.5 24 
R65 (PK12) 37.5 23.2 
S65 (PK13) 3 0 
R39 (MEL57A) 73.0 5.8 
S39 (MEL57B) 27.8 5.3 
Ivabradine 52.8 51.4 
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1. INTRODUCTION 
 
1. 1 Small molecule: the missing piece in the “central dogma” 
Recently1, the crucial role of small molecules in biological systems has been 
highlighted including them in the “central dogma” of biology (Figure 1). According to 
this principle the information into cells flows through macromolecules, from DNA to 
RNA to proteins. Nowadays Chemical Biology provides the missing piece in the 
central dogma, which is small molecules.  
In fact they are key players in a range of topics at the heart of the life sciences such as 
memory, cognition, sensing, signaling and treatment of diseases. Moreover connections 
exist between the three family of macromolecules and small molecules in both 
directions.  
Small molecules can bind and modulate DNA, RNA or proteins functions and these 
macromolecules have been used as templates for design and synthesis of small 
molecules.  
 
Figure 1. Central Dogma (as viewed by a chemical biologist). 
 
 
1. 2 The Role of Organic Chemistry 
Given the powerful role of small molecules both as probes for understanding cell states 
and circuits and as pharmacological agents for promoting and restoring health, the new 
intriguing challenge for synthetic organic chemistry2 is to become the tool to gain 
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access to collections of compounds in highly efficient way. In other words, the key for 
synthetic organic chemistry is to set itself on a course which allows it to tackle any 
problem in biology, from the dissection of a pathway to the understanding of complex 
networks, and eventually even to global biology or molecular physiology. For organic 
chemistry to play an initiating role in biological investigation, it is important that the 
organic chemist is able to direct effectively synthetic chemistry efforts toward a set of 
probes of two sorts.  
In the first case, a chemist might want to prepare small molecules having overall 
properties never seen before. In technical terms this means that such molecules address 
a currently poorly populated region of chemical space, which in that way can be 
interrogated.  
In the second case, a chemist might want to prepare small molecules capable of 
targeting a region of chemical space known to be optimal for modulating an area of 
biological interest. In this case it will be possible to study and understand the 
relationship of chemical space to biological space.  
Generally chemical or biological space is defined as n-dimensional space described by 
n descriptors, which can be of chemical or biological nature and are either computed or 
measured (Figure 2).  
 
Figure 2. Chemical or biological space representation. 
 
 
In order to gain access to small molecules, synthetic organic chemistry uses three main 
approaches:  
 
- Target-oriented synthesis (TOS) 
- Targeted Library Synthesis 
- Diversity-oriented synthesis (DOS) 
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1.2.1 Target-Oriented Synthesis (TOS) 
This approach2-4 has a long history in organic chemistry and relies on Nature to 
discover small molecules endowed with interesting macromolecule-perturbing 
properties. Natural compounds with an already known or just hypothesized biological 
activity can be identified in screens of extract mixtures, isolated and then structurally 
characterized using a variety of spectroscopic techniques.  
Once such a structure has been identified, it often becomes the target for chemical 
synthesis. In terms of chemical space, targeted-oriented synthesis aims at gaining 
access to a precise region of chemistry space, most often defined by a complex natural 
product known to have a useful biological function (Figure 3). 
 
 
Figure 3. The aim of TOS is to synthesize a single target molecule, which addresses a precise region of 
chemical space (black sphere).  
 
Target-oriented synthesis of these small molecules can be efficiently planned with 
retrosynthetic analysis3, 4. This strategy considers the target molecule as a reaction 
product for which a substrate and proper reaction conditions have to be sought in order 
to generate the complex target. For this purpose retrosynthetic analysis is based on the 
recognition of key structural elements in reaction product that code for synthetic 
transformations. Repetitive application of this process allows the synthetic chemist to 
start with a structurally complex target and find structurally simpler retrons that can be 
used to start the synthesis 
As for chemical reactions, two classes are of considerable value and widely used in 
TOS; the first one is represented by the so-called “fragment coupling reactions” which 
join together two different building blocks and the second one corresponds to all the 
family of reactions that generate complexity in stereoselective way (i.e. Oxi-Cope 
Rearrangement and Diels-Alder Reactions). 
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1.2.2 Targeted Library Synthesis 
The second approach4 aims to address a dense region of chemical space in proximity to 
a precise region defined by a molecule known to have useful properties (Figure 4). The 
source of lead compounds can be represented by a bioactive natural product, a known 
drug or a rationally designed molecule. 
 
 
Figure 4. The goal in medicinal and combinatorial chemistry is to synthesize a collection of analogs 
(blue sphere) of a bioactive target. These compounds populate a dense region of chemical space. 
 
As for planning strategy, collections of compounds analogs to an identified lead 
(targeted libraries) can still be effectively designed through retrosynthetic analysis.  
 
1.2.3 Diversity-Oriented Synthesis (DOS) 
The two previous approaches have led to major advances in the chemical and life 
sciences, but none of them is able to answer the following question: Are the regions of 
chemistry space defined by natural products and known drugs, which have been so 
intensely scrutinized to date, the best or most fertile regions for discovering small 
molecules that modulate macromolecular function in useful ways? 
One of the goals of the third general synthetic chemistry-based approach, diversity-
oriented synthesis (DOS)2-7, is to meet this challenge.       
In DOS, the synthesis effort aims at creating broad representations of compounds in 
chemistry space, including currently poorly populated (or even vacuous) space (Figure 
5).  
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Figure 5. The aim in DOS is to populate chemistry space broadly with collections of diverse and 
complex small molecules having unknown properties.  
 
 
The first step toward achieving this goal is to recognize that the problem of accessing 
broad regions of chemistry space is different from the problem of accessing precise or 
dense regions and because of this diversity these problems present distinct challenges 
and require distinct solutions.  
DOS, as it has been evolving in the last years, entails the development of synthetic 
pathways leading to the efficient synthesis of collections of small molecules having 
structurally complexity, rich skeletal and stereochemical diversity and the potential to 
attach appendages. Complexity and diversity intuitively favors a greater variation of 
assay outcomes than would be obtained with a collection of more similar compounds. 
DOS libraries in fact are not directed toward a single biological target, but their utility 
is based on their ability to provide selective probes for multiple different biological 
targets.   
 
In contrast to TOS, diversity-oriented synthesis is not aimed at one particular target and 
thus, retrosynthetic analysis cannot be applied. However the foundations of 
retrosynthetic analysis have been used to develop a complementary strategy to facilitate 
synthetic planning in DOS, named forward-synthetic analysis3,4. 
Beginning with a simple building block, this strategy provides a synthetic pathway 
leading to a large collection of structurally complex and diverse compounds. 
In order to achieve compounds with these characteristics, synthetic pathways are 
branched and divergent and they are planned in the forward-synthetic direction, moving 
from simple and similar to complex and diverse. 
Therefore in forward-synthetic analysis a key element is the transformation of a 
collection of substrates into a collection of products by performing a number of 
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chemical reactions in the forward-synthetic direction. To plan an efficient DOS 
synthesis, it is crucial to identify products-equals-substrates relationships, such that the 
products of one process could have some common inherent chemical reactivity that 
makes them all potential substrates for the subsequent reaction. 
 
Skeletal Complexity  
The structures and functions of natural products suggest that structural complexity3,4,8 
may be positively correlated with macromolecule-perturbing function and specificity of 
action. Besides, complexity is important since the increase of the size and number of 
rigidifying elements in small molecules is essential for these compounds to bind tightly 
to sites of protein-protein interaction, which tend to be flat in comparison to the 
concave topography characteristic of enzymes active sites. It is known that many 
biological processes are critically dependent on protein-protein interactions and many 
small molecules able to disrupt these interactions are complex natural products. 
Therefore one of the goals of DOS is to access small molecules with complex 
molecular skeletons and forward synthetic analysis proceeds in the direction simple → 
complex.  
For this purpose it is crucial to identify and to implement complexity-generating 
reactions that rapidly assemble complex molecular scaffolds. Moreover the 
identification in the forward direction of pairwise relationships, where the product of 
one complexity-generating reaction is the substrate for a second one, can lead to high 
levels of complexity in a very efficient manner. 
 
Skeletal Diversity 
Small molecule diversity2-4 is a critical feature to gain access to broad regions of 
chemical space. Moreover a collection of diverse compounds is essential in chemical 
genetics assays where there is no one particular target in cell-based or organism-based 
screens and potentially any one of the entire cell’s or organism’s macromolecule could 
be an eventual target. 
 
1.3 How a DOS library should be prepared? 
The best, but most difficult, strategy is to make compounds in a way that anticipates 
problems at each step of the drug-discovery process in which organic synthesis is 
involved9. Usually this process requires three main steps: 
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1) Find a molecule that modulates a disease: synthesize thousands of structurally 
diverse compounds. 
2) Optimize the biological properties: synthesize analogues of the compounds 
ideally modifying every atom of the compound. 
3) Synthesize the optimal compound 
 
Usually pharmaceutical industry has dealt with each of these steps in a serial fashion 
and the associated problems have been addressed independently. Each step is 
challenging and can create bottlenecks in the overall process. DOS aims to address, if 
not overcome, all of these challenges before the first compounds have even been 
screened9. 
For doing that, the DOS synthetic route has to follow some particular features as: ‐ Modularity. Many modifications can in principle be made to each skeleton 
simply by using different variants of the reactant at the first step. This is ideal 
for the optimization stage of drug discovery. ‐ Small number of steps. ‐ Purification.  
The products obtained in this way differ from the compounds found in most small-
molecule screening collections. Typically purchased from commercial vendors, the 
compounds in such collections frequently lack chirality and are structurally simple so 
they can bind to only a small number of biological targets. Moreover these compounds 
are structurally similar, where their diversity is limited to variations in appendages 
attached to a small number of common skeletons9. 
 
1.3.1 Planning DOS with the build/couple/pair strategy. 
The build/couple/pair strategy10 is aiming at flexible, modular and short constructions 
of transformative screening collections of small molecules, poised for optimization and 
modifications in follow-up studies. 
This is a very useful approach to plan new DOS libraries in very few steps (ideally 
from 3 to 5) to rapidly achieve high stereochemical and skeletal diversity. The process 
is shown in figure 6. 
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Figure 6. Generation of stereochemical and skeletal diversity with the build/couple/pair strategy. 
 
In the build phase, building blocks are synthesized. Usually asymmetric synthesis of 
chiral building blocks containing orthogonal sets of functionality suitable for 
subsequent coupling and pairing steps are performed. This process when combined 
with the couple phase provides the basis for stereochemical diversity. 
In the couple phase, intermolecular coupling reactions are performed to join the 
building block previously synthesized. To achieve the full matrix of all possible 
stereoisomeric products, coupling reactions are used that either generate no new 
stereogenic elements or that can provide every possible stereoisomeric outcome. 
In the pair phase, intramolecular coupling reactions are performed that join 
strategically placed appendages in the building blocks and result in compounds with 
diverse skeletons. This process provides the basis for skeletal diversity that could be 
afforded by a chemoselective and intramolecular joining of strategically polar and non-
polar functional groups. 
 
 
1.4 ChemBank v. 2.0 
All compounds generated by DOS chemistry are then used to probe a broad swath of 
biological space; in fact they are tested in a wide variety of biological assays (termed 
high-throughput screening). The results of these works are then reported to the 
international research community through a web-based database and analysis 
environment named ChemBank11. 
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1.4.1 ChemBank’s history 
Since12 1997 the National Cancer Institute (NCI) has been interested in Chemical 
Genetics and some of the successes of this approach has reinforced the belief that it 
could be a powerful way to accelerate the discovery of potential drugs. To expand this 
approach the NCI created the Initiative in Chemical Genetics (ICG) and, after a 
national competition Harvard’s Institute of Chemistry and Chemical Biology (ICCB) 
was chosen as the first recipient of ICG funding. 
One of the goals of this collaboration is to create a proper tool to make chemical 
genetics approach available to the whole scientific community. 
For this purpose at ICCB Schreiber and co-workers, who are making a pioneering work 
in this field both from a chemical and a biological point of view, have been developing 
a freely available collection of data about small molecules and resources for studying 
their properties, especially their effects on biology. This powerful tool (ChemBank), is 
in continuous evolution and since 2006 it is accessible online the renewed, more 
complete and efficient version 2.011. 
ChemBank is a suite of informatics tools and databases aimed at promoting the 
development and use of Chemical Genetics by scientists worldwide. It aims at assisting 
chemists designing novel compounds or libraries, biologists who wish to identify small 
molecules that can be used to perturb a particular biological system and serves as a 
source of data for cheminformatic analyses. The ICCB is populating ChemBank’s 
databases with baseline information generated by biologist’s and chemist’s work with 
the additional aim to incorporate the large body of data produced outside ICCB. In fact 
the growing community of academic and industrial scientists interested in data 
exchange is encouraged to submit information on the structures and activities of their 
small molecules.  
Analysis and study of biological and chemical knowledge deposited in ChemBank will 
provide a critical link from genomic discovery to drug development. 
As more biological data and small molecule collections are added to this database, 
more ChemBank should become increasingly powerful. 
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2. AIM OF THE WORK 
 
During my 10-month training period at Harvard University, I was involved in a project 
called CMLD (Chemical Methodology and Library Development). The development of 
new methodologies useful to set up new DOS libraries was the target I was aiming at. 
With this idea stacked in my mind, I have tried to expand the potential of enyne ring-
closing metathesis (enyne RCM)13a-b, an extraordinary reaction in the context of DOS14.  
The remarkable functional group tolerance combined with the ability to form rings of 
varied sizes gives this class of reactions a degree of generality not often realized by the 
vast majority of reactions.  Even still, the enyne metathesis products are not well poised 
for diverse modifications since they are simple 1,3-butadienes (see figure 7). 
 
 
Figure 7. Enyne RCM. The limitation of this extraordinary reaction is that the product obtained is not 
well poised for diverse modification; in fact, it can undergo only Diels-Alder reaction. 
 
 
I have therefore turned my attention to the development of metathesis-based methods 
that rely on alternative substrates, which can be modified post-metathesis to give 
diverse structures. 
The idea was to modify the diene moiety into a dienophile one because of the different 
reactivity of the two functional groups (see figure 8). 
 
 
Figure 8. Post-metathesis transformation: from diene to enone for higher skeletal diversity. 
 
 
Why do I have chosen the enone? The enone has unique features as for its structure. In 
fact, all the four carbon atoms are very different one from the other in reactivity (figure 
9), and this peculiarity can allow us to address diverse synthesis manipulating one 
single atom in order to achieve high skeletal diversification. 
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Figure 9. Reactivity of enone. 
 
 
So, from one single scaffold we can obtain many different structures for higher skeletal 
diversity as shown in picture 10. 
 
 
Figure 10. Planning a DOS-library: from one scaffold to many others. 
 
 
Specifically, I have focused on the chemistry of siloxy and silyl alkynes (R1 group). 
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3. CHEMISTRY 
 
3.1 Siloxy alkyne’s methodology 
I have explored the potential of siloxy alkynes to form substituted dienes poised for 
protodesilylation to deliver the corresponding enone. 
In 200115, Kozmin et al. showed the utility of triisopropylsiloxane (-OTIPS) in enyne 
RCM. They proved that the -OTIPS group did not interfere with the ruthenium of the 
Hoveyda-Grubbs 2nd generation catalyst (HG-II) during the catalytic cycle of the 
metathesis reaction, and it means that it is possible to get the formation of the cyclic 
compound in good yield. 
This point is crucial, because usually the presence of the oxygen atom directly bonded 
on terminal position of the alkyne does interfere with ruthenium due to the formation of 
a stable complex. As consequence of that, the catalytic cycle of metathesis is stopped 
and the catalyst goes under degradation without closure of the compound. 
For this reason I have decided to use the –OTIPS group as the ideal siloxane to use in 
the development of a new methodology for setting up a new DOS library. 
 
The formation of the siloxy alkyne (4) was the crucial step of the whole synthesis due 
to the instability of the compound. Many different procedures16a-d were followed but 
only the procedure adapted from the Kozmin’s paper15 was the successful one. 
The synthesis (figure 11) started with the 1,4-Michael addition of allyl amine to methyl 
acrilate followed by the protection of the secondary amine as tosylate (2)17. Then, 
dibromomethane was deprotonated by lithium tetramethylpiperidine (LiTMP) and the 
formed anion reacted with the ester to afford the dibromoketone (3)16c,18. The acidic 
proton between the two bromine atoms and the carbonyl group was deprotonated by 
LHMDS and then 2 equivalents of n-butyl lithium were added to give the formation of 
the ynolate that was finally quenched with triisopropylsilyl trifluoromethanesulfonate 
(TIPS-OTf) to yield the siloxy alkyne (4). 
In order for the last reaction to work, the atom in β to the carbonyl has not to be an 
heteroatom but a methylene moiety, because the α protons have to be not acid enough 
to react with LHMDS and n-butyl lithium; in this case in fact, the reaction stops and the 
product goes under decomposition. 
Moreover, given the instability of siloxy alkyne, I have set up a one-pot ynol 
formation-silylation-enyne metathesis to get the cyclic diene. Once the siloxy alkyne 
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was formed, the solvent was removed then the crude was immediately dissolved in 
benzene and HG-II (10% mol) was added to yield 5. 
Finally, protodesilylation occurred treating the compound with TBAF at 0 C giving 6. 
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Figure 11. a) methyl acrilate 1eq, allylamine 1.03eq, MeOH 0.1M, 40 C, 4 h. b) 1 1eq, Ts-Cl 1.2eq, 
NEt3 1.2eq, DMAP 0.1eq, DCM 0.2M, rt, 14 h. c) 2 1eq, CH2Br2 2.2eq, n-BuLi 2.2eq, 2,2,6,6-
tetramethylpiperidine 2.4eq, dryTHF 0.065M, -78 C, 20 min. d) n-BuLi 1.05eq, HMDS 1.2eq, 3 1eq, n-
BuLi 2.2eq, TIPS-OTf 1.1eq, dryTHF 0.1M, -78 to 0 C, 10 min. e) 4 1eq, HG-II 0.05eq, benzene 0.05M, 
50 C, 30 min. f) 5 1eq, TBAF 1.1eq, dryTHF 0.1M, 0 C, 10 min. 
 
 
To expand the potential of the developed methodology, it is possible to form diverse 
heterocyclic scaffolds poised for further skeletal diversification as shown in figure 12, 
changing the heteroatom and the length of the chain. The synthesis of these scaffolds is 
still undergoing. 
 
 
Figure 12. Different heterocyclic scaffolds poised for further skeletal diversification. 
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Moreover, it is also possible to change the allylamine with chiral homo allylamines in 
order to achieve stereochemical diversity (figure 13). 
 
 
Figure 13. Introducing stereochemical diversity. 
 
To do that, different chiral homo allyl amines with different protecting groups were 
synthesized.  
Boc-protected compound (R)-10 was synthesized (figure 14) starting from 
commercially available protected Serine 7. The carboxylic acid was first activated by 
DCC, and then was treated with methanol to give the ester that was finally reduced to 
alcohol (R)-8 with lithium aluminum hydride. Treating compound (R)-8 with tosyl 
chloride under basic condition has afforded the aziridine (R)-9, which was then opened 
with vinyl magnesium bromide to yield the desired compound. 
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   Et2O, reflux NH
(R)
OBn
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VinylMgBr, CuCN
Et2O/THF 1:1.5
 -78 C          0Boc
Boc Boc Boc
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Figure 14. Synthesis of Boc-protected chiral homo allylamine. 
 
The synthesis (figure 15) of Ts-protected homo chiral allyl amines (R)-14 and (S)-14 is 
slightly different from the previous one. In this case, the commercially available 
enantiopure Serine 11 is not protected on the aminic function. First, the carboxylic acid 
was reduced to alcohol 12 then a one-pot procedure afforded both aziridine and 
tosylated amine 13. The desired compounds were obtained opening the aziridine in 
presence of vinyl magnesium bromide. 
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 -78 C          0
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Figure 15. Synthesis of Ts-protected chiral homo allylamine. Both (R)-11 and (S)-11 are commercially 
available. 
a ee was determined by SFC using Chiralcel® AS-H column, mobile phase 20% MeOH/ 80% CO2. 
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In conclusion, starting from an old methodology I have developed a new method to get 
substrates containing high skeletal diversifications. The principal features are: 
– Versatility and generality of the method for ring size variation. 
– Possibility to form a dense stereochemical matrix. 
– Formation of diverse heterocyclic scaffolds poised for further skeletal 
diversification. 
Unfortunately, this methodology requires some particular conditions to work, as for 
example the presence of an ester not directly bonded to atoms bearing acidic protons as 
described before, and this is a limitation for its generality in other field of organic 
synthesis. 
To overcome to this problem, I have decided to set up a new methodology that can be 
more powerful and more general than the previous one. So I have focused my attention 
on the chemistry of silane utilizing as a key reaction the Fleming-Tamao oxidation. 
 
3.2 Toward a new methodology: the Fleming-Tamao oxidation of Silane 
The Fleming-Tamao oxidation constitutes a powerful method for the conversion of 
silanes into alcohols19 (figure 16). In fact the silyl group masks the hydroxyl group, 
and this particular behavior is very useful in organic synthesis because silanes are more 
stable and less reactive than alcohols under different reaction conditions.  
 
 
Figure 16. Fleming-Tamao oxidation: the conversion of silanes into alcohols. 
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Also for this new methodology, the goal was to get properly substituted compounds, 
which can be modified post-metathesis reaction to give the enone. 
I have set up a new method that generates enone from substituted diene through enyne 
RCM in only three steps: silylation, metathesis reaction and Fleming-Tamao oxidation. 
The first step was the silylation of the terminal alkyne of N-allyl-4-methyl-N-(prop-2-
ynyl)benzenesulfonamide20, used as testing compound. Then, the silylated product 
reacted with alkene and underwent efficient enyne RCM to provide a cyclic substituted 
diene (figure 17). Many different silyl groups were screened (table 1) in order to find 
the best one over the two steps.  
 
 
Figure 17. General scheme of silylation and enyne RCM. 
 
 
In the silylation step, the terminal alkyne portion of the substrate was first deprotonated 
by n-butyl lithium to form the lithium salt that was then quenched with an excess of the 
silyl group. From the results summarized in table 1, it seemed clear that the silyl group 
(R group) required an halogen (-X) as leaving group to react with the substrate. In fact 
entries 2 and 3, which have respectively a -methoxy or -etoxy leaving group, did not 
give the silylated compound. 
All the other compounds (entries 1, 4-8) were screened in enyne RCM step, utilizing 
different procedure and conditions as for catalyst21a-c (Grubbs 1st gen., Grubbs 2nd gen., 
InCl3 and Hoveyda-Grubbs 2nd gen.), atmosphere22 (argon or ethylene gas), solvent 
(toluene, benzene and dichloromethane) and temperature (from room temperature to 50 
C). 
SiClMe2
SiMe2OMe
SiPh2OtBu
SiMe2H
SiPhMe2
1
2
3
4
5
6
7
80%
NO
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32%
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NO
-
NO
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Entry R group Silylationyield%
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-Cl
-Cl
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-Cl
-Cl
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-Cl
cpd.
15
16
-
-
cpd.
-
-
-
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-
 
Table 1.  
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Silylated compounds bearing other leaving groups (entries 1 and 4) or mobile proton 
(entry 6) did not give the cyclic products under any condition. 
The best results were obtained with entries 5, 7 and 8 that were utilized in the next and 
final step. 
Regarding on entry 5, compound 21 did not undergo Fleming-Tamao oxidition 
protocol (scheme 18); many procedures23a-b,19d and attempts were followed under 
different condition without any result. 
 
N
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21 25
Ph
tBuO
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Figure 18. Unsuccessful application of Fleming-Tamao oxidation protocol to diene 21. 
 
 
If the R group was the phenyldimethylsilane (entry 7), the resulting metathesis product 
was subjected to a two-steps Fleming-Tamao protocol to yield the enone 25. According 
to literature23b,19d, the first step was the formation of the fluorosilane 24 (not isolated) 
followed by the oxidation with m-CPBA (figure 19). 
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Figure 19. Application of Fleming-Tamao oxidation to properly substituted diene. 
a) BF3.2AcOH or HBF4.OEt2, DCM. b) m-CPBA, KF, DMF. 
 
 
When the R group was instead the trimethylsilane (entry 8), a different procedure was 
pursued (figure 20). In fact, the TMS group cannot undergo Fleming-Tamao oxidation 
due to the impossibility to form the hetero silane. To get the enone 25, an alternative 
route was followed: the post-metathesis product 23 treated with m-CPBA gave first the 
epoxide24 26, which was then opened25 to deliver the corresponding α,β-unsatured 
ketone. 
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Figure 20. Alternative route to the enone. To notice that the two epoxides formed (26, 27) after the first 
step were easily separated by column chromatography in a ratio 5 to 1. 
a) m-CPBA, NaHCO3, DCM. b) H2SO4/MeOH. 
 
 
In conclusion, the new developed methodology is much more powerful respect of the 
previous one. In fact, the formation of substituted diene and its conversion into the 
corresponding enone is achieved in few steps with high yields. Moreover, this new 
method is also more general because, theoretically, it can be applied at any point of the 
synthesis and over different scaffolds. 
The principal features are: 
– Appropriate silane groups can be easily introduced in diverse molecular 
scaffolds bearing a terminal alkyne. 
– The silyl-functionalized enyne efficiently undergoes metathesis reaction. 
– The silyl-substituted diene is poised for post-metathesis modification leading to 
the α,β-unsatured ketone. 
 
 
3.3 Conclusion 
I have carried out new methodological studies on the synthesis of siloxy- and silane-
substituted alkynes to expand the potential of enyne metathesis chemistry. 
The developed methodologies opened new avenues to rapidly achieve skeletal diversity 
in a library setting from efficient synthetic manipulations of properly functionalized 
1,3-dienes. 
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4. EXPERIMENTAL SECTION 
 
Material and Methods: 
Dry solvents were dispensed from a solvent purification system that passes solvents 
through packed columns (THF and CH2Cl2: dry neutral alumina; toluene: dry neutral 
alumina and Q5 reactant). Unless otherwise stated, all reagents were obtained from 
commercial sources and used without further purification. Infrared spectra were 
recorded on a Nicolet IR100 FTIR from Thermo Scientific. 1H NMR spectra were 
recorded on Varian Unity/Inova I500 (500MHz) spectrometer. 1H data are reported as 
follows: chemical shift in parts per million relative to residual protonated solvent 
(CHCl3: d 7.26, C6H6: d 7.15), multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; 
m, multiplet; br, broadened), coupling constant (Hz), and integration. 13C magnetic 
resonance spectra were recorded on Varian Unity/Inova I500 and I600 (126MHz) 
spectrometer. 13C chemical shifts are reported in parts per million relative to solvent 
(CHCl3: d 77.0). All 13C spectra were determined with broadband decoupling. 
Microwave heating was performed using Explorer®-48 positions, CEM. High-
resolution mass spectra were obtained through the Harvard University mass 
spectrometry facility. All reactions were magnetically stirred and monitored by thin-
layer chromatography (TLC) using E. Merck silica gel 60 F254 precoated plates (0.25 
mm). Flash chromatography was performed either on EM Science silica gel 60 (230–
400 mesh) or using a CombiFlash companion system (Teledyne ISCO, Inc.) with pre-
packed FLASH silica gel columns (Biotage, Inc.). Optical rotations were obtained 
using digital polarimeter Autopol IV (Rudolph research Analytical) with a 1 mL cell 
and a 1 dm path length. SFC/MS chromatography was performed with a Berger 
analytic SFC (Waters ZQ Mass Spectrometer) using CO2 and MeOH or MeOH/i-PrOH 
as the mobile phase and using a Chiralcel® OD-H column, or a Chiralpak® AD-H 
column purchased from Chiral Technology Inc. (column length: 4.6x250mm, pore size: 
5um). 
 
4.1 Siloxane’s methodology 
 
Methyl 3-(allylamino)propanoate (1) 
A solution of allyl amine (0.899 mL, 11.96 mmol) and methyl 
acrylate (1.053 mL, 11.62 mmol) in MeOH (116 mL, 0.1 M) was 
N
H
OCH3
O
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stirred at 40 C for 4 hours. The reaction was controlled by TLC in dichloromethane-
methanol (9-1).      
The solvent was removed under reduced pressure and the crude was purified by flash 
chromatography. The desired product 1 was obtained (1.12 g, 7.82 mmol, 67.3 % yield) 
as a colorless-yellowish oil.  
 
1H NMR (CDCl3, δ): 2.50 (t, J=13 Hz, 3H), 2.86 (t, J=13 Hz, 3H), 3.23 (d, J=5.5 Hz, 
3H), 3.66 (s, 3H), 5.06-5.17 (m, 2H), 5.82-5.89 (m, 1H). 
 
 
Methyl 3-(N-allyl-4-methylphenylsulfonamido)propanoate (2) 
In a 100 mL pear flask, 1 (0.56 g, 3.91 mmol) was dissolved in 
dichloromethane (19.56 mL, 0.2 M) and triethylamine (0.651 mL, 
4.69 mmol) and DMAP (0.048 g, 0.391 mmol) were added. Then, a solution of tosyl 
chloride (0.895 g, 4.69 mmol) in dichloromethane was added dropwise at 0 C. The 
reaction mixture was allowed to reach RT and stirred for additional 14 hours.        
After addition of t-BuOMe, the organic layer was washed consecutively with 1% 
aqueous solution of HCl, a saturated aqueous solution of NaHCO3, brine and finally 
was dried over Na2SO4. Removal of the solvent under reduced pressure followed by 
flash chromatography (hexane-ethyl acetate 8-2) gave the desired compound 2 (0.92 g, 
3.09 mmol, 79 % yield) as a colorless oil. 
 
1H NMR (CDCl3, δ): 2.42 (s, 3H), 2.63 (t, J=15 Hz, 3H), 3.39 (t, J=15 Hz, 3H), 3.65 
(s, 3H), 3.79 (d, J=6.5 Hz, 3H), 5.14-5.20 (m, 2H), 5.60-5.67 (m, 1H), 7.30 (d, J=8 Hz, 
2H), 7.69 (d, J=8 Hz, 2H). 
 
 
N-allyl-N-(4,4-dibromo-3-oxobutyl)-4-methylbenzenesulfonamide (3) 
A solution of dibromomethane (0.207 mL, 2.96 mmol) in THF (10 
mL) was cooled to -78 C. In a separate flask, a solution of 2,2,6,6-
tetramethylpiperidine (0.548 mL, 3.23 mmol) in THF (5 mL) was cooled to 0 C and 
treated with n-butyl lithium (2.5 M in hexane, 1.184 mL, 2.96 mmol), and this yellow 
LiTMP solution was immediatly added dropwise via an addition funnel to the 
dibromomethane solution. After 5 min 2 (0.400 g, 1.345 mmol) dissolved in THF (5 
mL) was added dropwise (-78 C). 
N OCH3
O
Ts
N
O
Ts
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Br
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After 10 minutes, the reaction was quenched by slow addition to a 1.2 M aqueous 
solution of HCl, extracted with ethyl acetate, washed with water, dried over Na2SO4, 
filtered and concentrated. The crude was purified by flash chromatography (hexane-
ethyl acetate 8-2) to give 3 (0.35 g, 0.797 mmol, 59.2 % yield) as a colorless-yellowish 
solid. 
 
1H NMR (CDCl3, δ): 2.43 (s, 3H), 3.27 (t, J=7.5 Hz, 2H), 3.40 (t, J=7.5 Hz, 2H), 3.80 
(d, J=6.5 Hz, 2H), 5.17-5.22 (m, 2H), 5.61-5.69 (m, 1H), 5.79 (s, 1H), 7.30 (d, J=8 Hz, 
2H), 7.69 (d, J=8 Hz, 2H). 
 
 
1-tosyl-4-(1-(triisopropylsilyloxy)vinyl)-1,2,3,6-tetrahydropyridine (5) 
A flame-dried round bottom flask under argon atmosphere was charged 
with 3 (0.205 g, 0.467 mmol), THF (2.4 mL), and cooled to -78 °C. In a 
separate flame-dried flask, a solution of HMDS (0.117 mL, 0.560 
mmol) was diluted with THF (2.3 mL), cooled to 0 °C and subsequently treated with n-
butyl lithium (0.196 mL, 0.490 mmol). This colorless LHMDS solution was 
immediately added to the dibromoketone solution via canula over 5 minutes. After 5 
minutes of stirring, n-butyl lithium (0.411 mL, 1.027 mmol) was added over a 5 
minutes period to the reaction mixture. TLC showed no starting material remaining. 
TIPS-OTf (0.139 mL, 0.513 mmol) was then added to quench the formed ynolate. The 
reaction mixture was stirred for 10 minutes and brought to 0 °C, after which time TLC 
showed predominately one spot corresponding to the siloxyalkyne. The reaction was 
quenched into 20 mL hexanes via canula; water (0.1 mL) was added, the solution was 
allowed to stir for 10 minutes, and then dried with anhydrous Na2SO4. The solution 
was filtered through a glass frit (fine porosity) and concentrated. The residue was 
diluted with a small portion of benzene, filtered, and concentrated to afford crude 
siloxyalkyne (4) that was used in the next step without purification due to its instability 
both on silica gel and on solution. 
4 was dissolved in benzene (9.32 mL, 0.05 M) and 10%mol (0.029 g, 0.047 mmol) of 
Hoveyda-Grubbs 2nd generation catalyst were added. The reaction was left stirring at 
50 C for 1 hour and a variation of color from green to brown was observed. The TLC 
showed a new product and no starting material remaining, so the solvent was removed 
under vacuum and the residue was purified via flash chromatography (hexane – ethyl 
N
TIPSO
Ts
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acetate 10-1) to afford the desired cyclic compound 5 (0.073 g, 0.168 mmol). The yield 
over the two steps was 36%. 
 
13C NMR (CDCl3, δ): 12.70, 18.05, 21.51, 25.25, 42.79, 45.10, 90.13, 119.33, 127.74, 
127.79, 129.62, 143.54 
 
 
1-(1-tosyl-1,2,3,6-tetrahydropyridin-4-yl)ethanone (6) 
5 (0.020 g, 0.046 mmol) was dissolved in THF (0.459 mL, 0.1 M) and 
TBAF (0.050 mL, 0.050 mmol) was slowly added at 0 C. The reaction 
was left stirring at 0 C and controlled by TLC in hexane-ethyl acetate 1-1. 
After 10 minutes the mixture was quenched with saturated aqueous solution of NH4Cl 
and extracted with ethyl acetate. The organic layer was dried on Na2SO4, filtered and 
concentrated. The crude material was purified by prep-TLC (0.5 mm plate) to give 6 
(0.007 g, 0.025 mmol, 54.6% yield).  
 
 
Synthesis of chiral homoallyl amines: 
(R)-tert-butyl 1-(benzyloxy)-3-hydroxypropan-2-ylcarbamate (R)-8 
(R)-8 was synthesized starting from commercially available (S)-O-Benzyl-
N-BOC-serine (R)-7 by intermediate conversion to methyl ester.26 
 
 
(R)-2-amino-3-(benzyloxy)propan-1-ol (R)-12 
(R)-12 was synthesized starting from commercially available O-benzyl-L-
serine (R)-11.27  
 
General procedure to synthesize N-protected-Aziridines 
(R)-tert-butyl 2-(benzyloxymethyl)aziridine-1-carboxylate (R)-9 
To a solution of (R)-8 (48 mg, 0.17 mmol) and TsCl (39 mg, 0.20 mmol) in 
diethyl ether (3.4 mL) was added freshly powdered KOH (38 mg, 0.68 mmol) 
at room temperature. The stirred mixture was refluxed until TLC indicates 
disappearance of the reactants. The mixture was poured into a separatory funnel filled 
with crushed ice. The organic phase was separated, washed with brine, dried over 
Na2SO4 and the solvent was removed under reduced pressure. The crude was purified 
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by flash chromatography (20% of ethyl acetate in hexanes) to give the desired aziridine 
in 60% of yield. 
 
1H NMR (CDCl3, δ): 1.45 (s, 9H), 2.09 (d, J=3.5 Hz., 1H), 2.29 (d, J=6 Hz., 1H), 2.65-
2.67 (m, 1H), 3.57-3.59 (m, 2H), 4.61 (ddd, J=37 Hz., J=9 Hz., J=2 Hz., 2H), 7.24-7.35 
(m, 5H). 
13C NMR (CDCl3, δ): 28.10, 29.20, 36.70, 70.10, 72.90, 81.30, 127.80, 127.90, 
128.60, 138.20, 162.10 
UPLC–MS: m/z 263.8 [M + 1]+.  
[α]20D = +62.85° (c=0.14; CHCl3). 
 
(R)-2-(benzyloxymethyl)-1-tosylaziridine (R)-13 
1H NMR (CDCl3, δ): 2.20 (d, J=4.4 Hz., 1H), 2.41 (s, 3H), 2.67 (d, J=7.2 Hz., 
1H), 3.00-3.04 (m, 1H), 3.40-3.44 (m, 1H), 3.60-3.63 (d, J=11.2 Hz., 1H), 4.43 
(s, 2H), 7.20 (d, J=7 Hz., 2H), 7.27-7.32 (m, 5H), 7.85 (d, J=8.5 Hz., 2H). 
13C NMR (CDCl3, δ): 21.80, 30.90, 39.20, 69.30, 73.10, 127.80, 127.90, 128.30, 
128.60, 130.00, 135.10, 138.00, 144.90 
UPLC–MS: m/z = 318.28 [M + H]+.  
[α]20D = +46.43° (c=0.14; CHCl3). 
 
General procedure to synthesize homo-allylamines 
(R)-tert-butyl 1-(benzyloxy)pent-4-en-2-ylcarbamate (R)-10 
Vinylmagnesium bromide (17.09 mL, 17.09 mmol, solution 1M in THF) 
was added to a -78 °C slurry of copper(I) cyanide (0.286 g, 3.19 mmol) in 
diethyl ether (18.99 mL). After stirring for 20 min, a solution of  (R)-9 (1.5 g, 5.70 
mmol) in THF (28.5 mL) was added. After the addition, the reaction mixture was 
allowed slowly to warm to 0 °C for about 2 h. The mixture was quenched with a 
solution composed of 10% conc. NH4OH/ 90% sat. aq. NH4Cl solution. The mixture 
was diluted with Et2O and stirred at room temperature until all solids were dissolved 
(ca 4h). The layers were separated and the organic layer was washed with brine, dried 
over Na2SO4, filtered, concentrated and purified by flash chromatography (15% ethyl 
acetate in hexanes) to give the desired (R)-10 in 60% of yield. 
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1H NMR (CDCl3, δ): 1.45 (s, 9H), 2.32-2.40 (m, 2H), 3.47-3.49 (m, 2H), 3.82 (bs, 
1H), 4.51 (dd, J=25 Hz., J=15 Hz., 2H), 4.82 (bs, 1H), 5.05-5.10 (m, 2H), 5.75-5.81 (m, 
1H), 7.26-7.37 (m, 5H). 
13C NMR (CDCl3, δ): 28.60, 36.70, 50.10, 71.40, 73.40, 79.30, 117.90, 127.80, 
127.90, 128.00, 128.60, 134.80, 138.40, 155.70 
UPLC–MS: m/z 314.4 [M + Na]+.  
[α]20D = +12.94° (c=0.17; CHCl3). 
 
 
(R)-N-(1-(benzyloxy)pent-4-en-2-yl)-4-methylbenzenesulfonamide (R)-14 
1H NMR (CDCl3, δ): 2.29-2.30 (m, 2H), 2.42 (s , 3H), 3.40-3.43 (m, 2H), 
4.39 (s, 2H), 5.00 (bs, 1H), 5.03-5.06 (m, 2H), 5.56-5.61 (m, 1H), 7.24-
7.26 (m, 2H), 7.30-7.36 (m, 5H), 7.75 (d, J=8.5 Hz., 2H). 
13C NMR (CDCl3, δ): 21.80, 37.00, 53.20, 71.00, 73.40, 118.70, 127.40, 127.90, 
128.00, 128.60, 129.80, 133.80, 138.00, 138.10, 143.50 
UPLC–MS: m/z 345.9 [M + H]+.  
[α]20D = +27.37° (c=0.095; CHCl3). 
 
 
4.2 Silane’s methodology 
N-allyl-N-(3-(chlorodimethylsilyl)prop-2-ynyl)-4-methylbenzenesulfonamide (15) 
In a 25 mL dried-pear flask under Argon atmosphere, N-allyl-4-methyl-N-
(prop-2-ynyl)benzenesulfonamide (0.1 g, 0.401 mmol) was dissolved in dry 
THF (4.01 mL, 0.1 M) to give a colorless solution, then n-butyl lithium (2.5M 
in hexane; 0.160 mL, 0.401 mmol) was carefully added  at -78C. The solution 
changed color and became pale yellow. After 1 hour the dichlorodimethylsilane (0.483 
mL, 4.01 mmol) was added. The reaction was controlled by TLC in hexane-ethyl 
acetate (9-1). 
After 1 hour at -78C, the mixture was quenched with saturated aqueous solution of 
NH4Cl and extracted with dichloromethane (3 × 15 mL). The organic layers were 
washed once with water and once with brine and then collected, dried on Na2SO4 and 
evaporated under vacuum. The residue was finally purified via flash chromatography 
and the desired product was obtained as a clear oil in 80% yield (0.11 g, 0.322 mmol). 
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1H NMR (CDCl3, δ): 0.00-0.14 (m, 6H), 2.42 (s, 3H), 3.81-3.82 (m, 2H), 4.10 (s, 2H), 
5.21-5.27 (m, 2H), 5.67-5.75 (m, 1H), 7.28 (d, J=8.5 Hz, 2H), 7.71 (d, J=8.5 Hz, 2H). 
 
 
N-allyl-N-(3-(methoxydimethylsilyl)prop-2-ynyl)-4-methylbenzenesulfonamide (16) 
In a 50 mL dried-pear flask under Argon atmosphere, N-allyl-4-methyl-N-
(prop-2-ynyl)benzenesulfonamide (0.300 g, 1.203 mmol) was dissolved in 
dry THF (12.03 mL, 0.1 M) to give a colorless solution, then n-butyl 
lithium (2.5M in hexane; 0.481 mL, 1.203 mmol) was carefully added  at -
78C. The solution changed color and became pale yellow. After 1 hour the 
chloro(methoxy)dimethylsilane (0.750 mL, 6.02 mmol) was added. The reaction was 
controlled by TLC in hexane-ethyl acetate (9-1). 
After 2 hours at -78C, the mixture was quenched with saturated aqueous solution of 
NH4Cl and extracted with dichloromethane (3 × 15 mL). The organic layers were 
washed once with water and once with brine and then collected, dried on Na2SO4 and 
evaporated under vacuum. The residue was finally purified via flash chromatography 
and the desired product was obtained as a clear oil in 32% yield (0.13 g, 0.385 mmol). 
 
1H NMR (CDCl3, δ): 0.08 (s, 6H), 2.39 (s, 3H), 3.70-3.73 (m, 2H), 3.79-3.80 (m, 3H), 
4.07 (s, 2H), 5.20-5.28 (m, 2H), 5.67-5.75 (m, 1H), 7.28 (d, J=8.5 Hz, 2H), 7.71 (d, 
J=8.5 Hz, 2H).  
 
 
N-allyl-N-(3-(tert-butoxydiphenylsilyl)prop-2-ynyl)-4-methylbenzenesulfonamide (17) 
 In a 50 mL dried-pear flask under Argon atmosphere, N-allyl-4-methyl-N-
(prop-2-ynyl)benzenesulfonamide (0.300 g, 1.203 mmol) was dissolved in 
dry THF (12.03 mL, 0.1 M) to give a colorless solution, then n-butyl lithium 
(2.5M in hexane; 0.481 mL, 1.203 mmol) was carefully added  at -78C. The 
solution changed color and became pale yellow. After 1 hour the tert-
butoxychlorodiphenylsilane (1.626 mL, 6.02 mmol) was added. The reaction was 
controlled by TLC in hexane-ethyl acetate (9-1). 
After 2 hours at -78C, the mixture was quenched with saturated aqueous solution of 
NH4Cl and extracted with dichloromethane (3 × 15 mL). The organic layers were 
washed once with water and once with brine and then collected, dried on Na2SO4 and 
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evaporated under vacuum. The residue was finally purified via flash chromatography 
and the desired product was obtained as a clear oil in 99% yield (0.60 g, 1.191 mmol). 
 
 
N-allyl-N-(3-(dimethylsilyl)prop-2-ynyl)-4-methylbenzenesulfonamide (18) 
In a 250 mL dried-pear flask under Argon atmosphere, N-allyl-4-methyl-N-
(prop-2-ynyl)benzenesulfonamide (1.60 g, 6.42 mmol) was dissolved in dry 
THF (64.2 mL, 0.1 M) to give a colorless solution, then n-butyl lithium 
(2.5M in hexane; 2.57 mL, 6.42 mmol) was carefully added  at -78C. The 
solution changed color and became pale yellow. After 1 hour the chlorodimethylsilane 
(6.97 mL, 64.2 mmol) was added. The reaction was controlled by TLC in hexane-ethyl 
acetate (9-1). 
After 30 minutes at -78C, the mixture was quenched with saturated aqueous solution of 
NH4Cl and extracted with dichloromethane (3 × 20 mL). The organic layers were 
washed once with water and once with brine and then collected, dried on Na2SO4 and 
evaporated under vacuum. The residue was finally purified via flash chromatography 
and the desired product was obtained as a clear oil in 76% yield (1.50 g, 4.88 mmol). 
 
1H NMR (CDCl3, δ): 0.05-0.06 (m, 6H), 2.42 (s, 3H), 3.81-3.82 (m, 2H), 3.87-3.90 
(m, 1H), 4.10 (s, 2H), 5.23-5.30 (m, 2H), 5.71-5.78 (m, 1H), 7.29 (d, J=8.5 Hz, 2H), 
7.73 (d, J=8.5 Hz, 2H). 
 
 
N-allyl-N-(3-(dimethyl(phenyl)silyl)prop-2-ynyl)-4-methylbenzenesulfonamide (19) 
In a 100 mL dried-pear flask under Argon atmosphere, N-allyl-4-methyl-N-
(prop-2-ynyl)benzenesulfonamide (0.500 g, 2.005 mmol) was dissolved in 
dry THF (20.05 mL, 0.1 M) to give a colorless solution, then n-butyl lithium 
(2.5M in hexane; 0.802 mL, 2.005 mmol) was carefully added  at -78C. The 
solution changed color and became pale yellow. After 1 hour the 
chlorodimethyl(phenyl)silane (1.67 mL, 10.03 mmol) was added. The reaction was 
controlled by TLC in hexane-ethyl acetate (9-1). 
After 2 hours at -78C, the mixture was quenched with saturated aqueous solution of 
NH4Cl and extracted with dichloromethane (3 × 15 mL). The organic layers were 
washed once with water and once with brine and then collected, dried on Na2SO4 and 
evaporated under vacuum. The residue was finally purified via flash chromatography 
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and the desired product was obtained as a clear oil in 81% yield (0.625 g, 1.629 mmol). 
 
1H NMR (CDCl3, δ): 0.24 (s, 6H), 2.33 (s, 3H), 3.82-3.84 (m, 2H), 4.18 (s, 2H), 5.22-
5.28 (m, 2H), 5.71-5.79 (m, 1H), 7.17 (d, J=8.5 Hz, 2H), 7.33-7.45 (m, 5H), 7.72 (d, 
J=8.5 Hz, 2H).  
 
N-allyl-4-methyl-N-(3-(trimethylsilyl)prop-2-ynyl)benzenesulfonamide (20) 
In a 100 mL dried-pear flask under Argon atmosphere, N-allyl-4-methyl-N-
(prop-2-ynyl)benzenesulfonamide (0.500 g, 2.005 mmol) was dissolved in 
dry THF (20.05 mL, 0.1 M) to give a colorless solution, then n-butyl 
lithium (2.5M in hexane; 0.802 mL, 2.005 mmol) was carefully added  at -
78C. The solution changed color and became pale yellow. After 1 hour the 
chlorotrimethylsilane (2.54 mL, 20.05 mmol) was added. The reaction was controlled 
by TLC in hexane-ethyl acetate (9-1). 
After 1 hour at -78C, the mixture was quenched with saturated aqueous solution of 
NH4Cl and extracted with dichloromethane (3 × 15 mL). The organic layers were 
washed once with water and once with brine and then collected, dried on Na2SO4 and 
evaporated under vacuum. The residue was finally purified via flash chromatography 
and the desired product was obtained as a clear oil in 91% yield (0.585 g, 1.820 mmol). 
 
1H NMR (CDCl3, δ): 0.00 (s, 9H), 2.42 (s, 3H), 3.81-3.82 (m, 2H), 4.10 (s, 2H), 5.23-
5.30 (m, 2H), 5.71-5.78 (m, 1H), 7.29 (d, J=8.0 Hz, 2H), 7.73 (d, J=8.0 Hz, 2H).  
 
 
3-(1-(tert-butoxydiphenylsilyl)vinyl)-1-tosyl-2,5-dihydro-1H-pyrrole (21) 
In a 15 mL dried-pear flask, 17 (0.101 g, 0.201 mmol) was dissolved in 
Toluene (4.01 mL, 0.05 M) to give a colorless solution. Then, under 
ethylene atmosphere at room temperature, Hoveyda-Grubbs 2nd generation 
catalyst (0.013 g, 0.020 mmol) was added. After the addition of the catalyst the 
solution became green and after 20 minutes it became dark green-brown. 
The reaction was controlled by TLC in hexane - ethyl acetate (9-1). 
The solvent was removed under vacuum and the residue was purified by flash 
chromatography. The NMR spectrum showed that the product isolated was 21 (0.062 g, 
0.123 mmol, 61.4% yield). 
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1H NMR (CDCl3, δ): 1.17 (s, 9H), 2.43 (s, 3H), 4.08-4.09 (m, 2H), 4.26-4.27 (m, 2H), 
5.67-5.68 (m, 1H), 5.75-5.78 (m, 2H), 7.29-7.35 (m, 6H), 7.39-7.42 (m, 2H), 7.58-7.60 
(m, 4H), 7.69-7.71 (m, 2H). 
 
 
3-(1-(dimethyl(phenyl)silyl)vinyl)-1-tosyl-2,5-dihydro-1H-pyrrole (22) 
In a 250 mL dried-pear flask, 19 (0.87 g, 2.268 mmol) was dissolved in 
Toluene (45.4 mL, 0.05 M) to give a colorless solution. Then Hoveyda-
Grubbs 2nd generation catalyst (0.071 g, 0.113 mmol) was added at room 
temperature under ethylene gas and the solution became green. After the addition of the 
catalyst the solution became green and after 20 minutes it became dark green-brown. 
The reaction was controlled by TLC in hexanes-ethyl acetate (4-1). After 1 hour, the 
solvent was removed under vacuum and the residue was purified by flash 
chromatography. 22 was obtained in 93% yield (0.81 g, 2.112 mmol). 
 
1H NMR (CDCl3, δ): 0.38 (s, 6H), 2.43 (s, 3H), 4.08-4.09 (m, 2H), 4.23-4.24 (m, 2H), 
5.38-5.39 (m, 1H), 5.55-5.56 (m, 1H), 5.66-5.70 (m, 1H), 7.31-7.34 (m, 5H), 7.43 (d, 
J=8.5 Hz, 2H), 7.71 (d, J=8.5 Hz, 2H). 
 
 
- Fleming-Tamao oxidation: procedure A 
 
1-(1-tosyl-2,5-dihydro-1H-pyrrol-3-yl)ethanone (25) 
To a solution of 22 (0.089 g, 0.232 mmol) in DCM (2.320 mL, 0.05 M) was 
slowly added tetrafluoroboric acid-diethylether complex (0.086 mL, 1.160 
mmol) at 0 C. The reaction mixture was left stirring at RT for 1 day. The 
reaction was quenched with saturated aqueous solution of NaHCO3 at 0 C and 
extracted with Et2O (3 × 10 mL). The organic layers were collected, washed with brine, 
dried, filtered and concentrated to give the crude fluorosilane (24) that was used in the 
next step without any purification. 
24 was dissolved in DMF (2.320 mL, 0.05 M) and then KF (0.027 g, 0.464 mmol) and 
m-CPBA (0.120 g, 0.696 mmol) were added at 0 C. The reaction was left stirring at 
room temperature overnight. 
The reaction mixture was diluted with dichloromethane and washed with saturated 
aqueous solution of sodium thiosulfate, saturated aqueous solution of Na2CO3 and 
brine.  The organic layer was dried on Na2SO4, filtered and concentrated under 
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vacuum. The residue was finally purified via flash chromatography yielding the desired 
product 25 (0.036 g, 0.136 mmol, 59% yield). 
 
- Fleming-Tamao oxidation: procedure B 
22 (0.036 g, 0.093 mmol) was dissolved in DCM (1.867 mL, 0.05 M) and then BF3-
acetic acid complex (0.185 mL, 0.467 mmol) was slowly added at 0 C. The reaction 
was left stirring overnight at room temperature.      
The reaction was quenched with K2CO3 (0.064 g, 0.467 mmol) in water (saturated 
solution). The mixture was dried on Na2SO4, filtered and the solvent was evaporated 
under vacuum. 
The crude fluorosilane 24 (0.026 g, 0.080 mmol, 86 % yield) was dissolved in DMF (3 
mL, 0.05 M) and then KF (10.84 mg, 0.187 mmol) and m-CPBA (0.064 g, 0.280 
mmol) were added at 0 C. The reaction was left stirring at room temperature overnight.      
The TLC showed a new product and no starting material remaining, so the mixture was 
diluted with dichloromethane and washed with aqueous solution of sodium thiosulfate, 
aqueous solution of Na2CO3 and brine. The organic layer was dried on Na2SO4, filtered 
and concentrated. The residue was finally purified via flash chromatography (hexane – 
ethyl acetate 1-1) yielding the desired product 25 (0.014 g, 0.053 mmol, 56.5% yield). 
 
1H NMR (CDCl3, δ): 2.26 (s, 3H), 2.42 (s, 3H), 4.23-4.25 (m, 2H), 4.34-4.36 (m, 2H), 
6.48-6.49 (m, 1H), 7.32 (d, J=8.5 Hz, 2H), 7.72 (d, J=8.5 Hz, 2H). 
13C NMR (CDCl3, δ): 21.50, 26.29, 53.28, 55.76, 127.45, 129.88, 133.61, 135.52, 
140.41, 143.82, 193.66. 
 
-Alternative route to the enone: 
 
1-tosyl-3-(1-(trimethylsilyl)vinyl)-2,5-dihydro-1H-pyrrole (23) 
In a 10 mL dried-pear flask, 20 (0.087 g, 0.271 mmol) was dissolved in 
Toluene (5.41 mL, 0.05 M) to give a yellow solution. Then, under 
ethylene atmosphere at room temperature, Hoveyda-Grubbs 2nd generation 
catalyst (0.017 g, 0.027 mmol) was added.  
After the addition of the catalyst the solution became green and after 20 minutes it 
became dark green-brown. The reaction was controlled by TLC in hexanes-ethyl 
acetate (9-1). The solvent was evaporated under vacuum and the residue was purified 
via flash chromatography to give the desired product 23 as a white solid in 77% yield 
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(0.067 mg, 0.208 mmol). 
 
1H NMR (CDCl3, δ): 0.12 (s, 9H), 2.42 (s, 3H), 4.20-4.24 (m, 4H), 5.47-5.52 (m, 2H), 
5.59-5.60 (m, 1H), 7.32 (d, J=8.5 Hz, 2H), 7.73 (d, J=8.5 Hz, 2H). 
 
 
1-tosyl-3-(2-(trimethylsilyl)oxiran-2-yl)-2,5-dihydro-1H-pyrrole (26) 
In a 25 mL pear flask, 23 (0.11 g, 0.342 mmol) and NaHCO3 (0.043 g, 0.513 mmol) 
were dissolved in dichloromethane (6.84 mL, 0.05M) to give a colorless solution. Then 
m-CPBA (0.079 g, 0.342 mmol) dissolved in 1 mL of dichloromethane was added 
dropwise over a period of 2 hours at 0 C. 
The reaction was left stirring at room temperature for one day and was controlled by 
TLC in dichloromethane. The TLC showed two new products so the reaction was 
quenched with NaHSO3 at 0 C. The organic layer was separated and was washed twice 
with saturated aqueous solution of NaHCO3 and brine. The solvent was dried over 
Na2SO4, filtered and concentrated. 
The crude material was purified by column chromatography (the column was 
equilibrated with hexanes) and was eluted with dichloromethane. The first spot (less 
polar) eluted was 27 (0.013 g, 0.039 mmol, 11.3% yield) whereas the second one (more 
polar) was the desired product 26 (0.058 g, 0.172 mmol, 50.2% yield). 
 
(26) 1H NMR (CDCl3, δ): 0.02 (s, 9H), 2.43 (s, 3H), 2.65 (d, J=5.5 Hz, 1H), 2.73 (d, 
J=5.5 Hz, 1H), 4.01-4.03 (m, 2H), 4.12-4.13 (m, 2H), 5.49-5.50 (m, 1H), 
7.32 (d, J=8.5 Hz, 2H), 7.70 (d, J=8.5 Hz, 2H). 
 
 
(27) 1H NMR (CDCl3, δ): 0.07 (s, 9H), 2.43 (s, 3H), 3.37 (s, 1H), 3.43 (dd, J=12 Hz, 
J=1 Hz, 1H), 3.53 (d, J=12.5 Hz, 1H), 3.59 (d, J=12 Hz, 1H), 3.70 (d, 
J=12.5 Hz, 1H), 5.56 (d, J=2.5 Hz, 1H), 5.88 (d, J=2.5 Hz, 1H), 7.31 (d, 
J=8.5 Hz, 2H), 7.68 (d, J=8.5 Hz, 2H). 
 
 
1-(1-tosyl-2,5-dihydro-1H-pyrrol-3-yl)ethanone (25) 
In a 15 mL pear flask, 26 (0.009 g, 0.027 mmol) was dissolved in a solution of sulfuric 
acid (0.2 mL) in methanol (2 ml) at 0 C. The reaction was left stirring at room 
temperature for 2 hours and was controlled by TLC in hexane-ethyl acetate (6-4). 
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The mixture was diluted with ethyl acetate and was washed twice with saturated 
aqueous solution of NaHCO3 and brine. The organic layer was dried over Na2SO4, 
filtered and concentrated. Purification of the crude material by flash chromatography 
using ethyl acetate-hexane (1-1) afforded compound 25 in good yield (0.004 g, 0.015 
mmol, y. 56%). 
 
 
 
  141 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